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Abstract 
Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB), is the leading cause of 
death and disease by a bacterial pathogen worldwide. The growing incidence of drug 
resistant TB, especially multi-drug resistant TB highlights the need for new drugs with novel 
modes of action. Current treatment of TB involves a multi-drug regimen of four drugs 
including isoniazid and rifampicin, both of which were discovered over 40 years ago. 
Bedaquiline is one of the first novel TB drugs to enter clinical trials since the discovery of 
rifampicin, and has shown excellent activity against drug resistant TB. Although isoniazid and 
rifampicin are well established anti-TB drugs, significant gaps in knowledge regarding their 
modes of action exist. Furthermore, little information on the mode of action of the novel 
drug bedaquiline is known beyond its primary target. Characterisation of drug mode of 
action facilitates rational modifications of drugs to improve the treatment of TB. 
The aim of this study was to identify novel aspects of the modes of action of isoniazid, 
rifampicin, and bedaquiline by characterising drug hypersensitive mutants of M. smegmatis 
mc2155. A sub-saturated M. smegmatis mc2155 transposon mutant collection with 1.1-fold 
genome coverage (7680 mutants) was constructed, with this collection estimated to contain 
mutations in 73.2% of all genes capable of maintaining a transposon insertion (non-essential 
genes). A high-throughput assay was developed for screening the collection, and mutants 
related to known drug mode of action were identified for isoniazid (ahpC and eccCa1) and 
bedaquiline (atpB). Additionally, known mechanisms of drug inactivation were identified for 
isoniazid (nudC), rifampicin (arr and lspA), and bedaquiline (mmpL5). The finding that 
transposon mutants of nudC are hypersensitive to isoniazid independently validated the 
recent discovery of the role of NudC in basal isoniazid resistance by Wang et al. (2011). The 
remaining genes identified in this thesis represent potentially novel aspects of the modes of 
action or resistance mechanisms of these drugs. 
Cross-sensitivity to other drugs indicated that the mechanism of sensitivity was drug specific 
for the mutants examined. Differential-sensitivity testing against drug analogues revealed 
that Arr is involved in resistance to the rifampicin analogue rifapentine as well, indicating 
that Arr can detoxify rifapentine similar to rifampicin. The nudC mutant showed increased 
sensitivity to a range of isoniazid analogues, indicating that it can detoxify these analogues 
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similar to the parent compound. Interestingly six analogues were found to be less active 
against the nudC mutant than expected. A number of overexpression strains were tested 
against these six analogues; a nudC overexpression strain, and a strain overexpressing inhA, 
the primary target for isoniazid. Overexpression of nudC as well inhA increased the 
resistance of WT to isoniazid, but failed to increase resistance to three of the analogues, 
NSC27607, NSC33759, and NSC40350. Isoniazid is a prodrug and is activated by the 
peroxidase/catalase enzyme KatG. Overexpression of katG resulted in increased isoniazid 
sensitivity, as well as increased sensitivity to NSC27607, NSC33759, and NSC40350. Together 
these results suggest that NSC27607, NSC33759, and NSC40350 are activated by KatG, but 
that InhA is not the primary target. Additionally the inability of NudC overexpression to 
confer resistance suggests these analogues are not acting via a NAD adduct, the mechanism 
by which isoniazid inhibits InhA. These results suggest that there are other toxic metabolites 
being produced by KatG activation of these three analogues.  
In conclusion, characterisation of mutants identified in a high-throughput assay for drug 
hypersensitivity identified genes involved in the modes of action or resistance mechanisms 
for isoniazid, rifampicin, and bedaquiline. Additionally, a number of novel genes were 
identified that have no known connections to the known modes of action or resistance 
mechanisms for these drugs. Further testing of a nudC mutant revealed three isoniazid 
analogues that appear to inhibit growth of M. smegmatis mc2155 independent of InhA, the 
primary target of isoniazid. This study has successfully demonstrated that screening for drug 
hypersensitivity can generate novel information on drug mode of action and resistance 
mechanisms. This information can ultimately be used to help drive the development of new 
drugs, and improve treatment of TB.  
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1. General Introduction 
1.1. Tuberculosis 
TB is a disease primarily caused by Mycobacterium tuberculosis, and is the first equal cause 
of mortality by a single pathogen along with the human immunodeficiency virus / acquired 
immune deficiency syndrome (HIV/AIDS) (WHO, 2014). The incidence of TB is worst amongst 
the poor due to factors such as inadequate health care, overcrowding and malnutrition 
(Bucher et al., 1999; Marais et al., 2013). As such, improvements in social economic 
conditions have been shown to improve TB control (Stop TB Partnership, 2006). Other 
significant risk factors for TB include substance abuse, smoking, chronic lung disease, and 
the presence of co-morbidities such as HIV and diabetes (Marais et al., 2013). These risk 
factors either compromise the immune system or lung integrity, increasing the rate of 
developing active disease, and often affecting treatment outcomes. It is estimated that one 
third of the world’s population is infected with the etiological agent of TB, M. tuberculosis 
(Dye et al., 1999). Susceptibility to TB varies with age, with high rates in young children, 
lower rates in older children, and higher rates again after adolescence (Dubos and Dubos, 
1952). M. tuberculosis can be divided into six lineages based upon genetic polymorphisms, 
with the different lineages  varying in terms of geographic distribution, virulence, and drug 
resistance (Click et al., 2012; Gagneux and Small, 2007; Gagneux et al., 2006; Parwati et al., 
2010; Reed et al., 2009). 
In 2013 there were an estimated 9 million new cases of TB in the world, and 1.5 million 
deaths (WHO, 2014). Of the 9 million new cases, approximately 56% of cases occurred in 
South-East Asia and the Western Pacific region, with China accounting for 11% and India 24% 
of cases (Figure 1.1). A further 25% of all new cases were from Africa, which had the highest 
incidence rate along with the highest mortality rate of any region.  
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Figure 1.1: Estimated global tuberculosis incidence rates for 2013. Image reproduced from the 
Global tuberculosis report 2014 with permission (WHO, 2014). 
Resistance to anti-TB drugs is widespread with drug resistant cases reported in all countries 
surveyed by the World Health Organisation (WHO) (Figure 1.2). Multi-drug resistant TB 
(MDR-TB), defined as resistant to at least the two front line TB drugs isoniazid and 
rifampicin, is of significant clinical importance as it has an associated lower cure rate (48% 
globally in 2011) and higher mortality rate. The incidence of new cases of MDR-TB globally 
was around 3.5% in 2013 (480,000); however, in some Asian and Eastern European counties 
the incidence was as high as 35% for new cases, and 75% for previously treated cases. 
Combined, India, China, and the Russian Federation account for over 50% of all MDR-TB 
cases. Approximately 9% of MDR-TB cases in 2013 were extensively drug resistant (XDR-TB), 
which displays additional resistances to fluoroquinolone and a second-line injectable agent. 
XDR-TB has a much lower cure rate (22% in 2011) and has now been detected in over 100 
countries, with several cases of totally drug resistant XDR-TB reported (Udwadia et al., 2012; 
WHO, 2014). 
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Figure 1.2: Estimated number of global multi-drug resistant tuberculosis cases for 2013. Image 
reproduced from the Global tuberculosis report 2014 with permission (WHO, 2014). 
In the 1980’s TB was thought to largely be under control but by the 1990’s the HIV pandemic 
was driving a resurgence of M. tuberculosis infection (Murray et al., 1990). This was 
particularly true in sub-Saharan Africa where HIV/AIDS was becoming a leading cause of 
morbidity and mortality. HIV infection is associated with increased susceptibility to TB due to 
the immune-compromising effects of the HIV virus (Hopewell, 1992). HIV co-infection 
increases the reactivation risk of TB from a 5-10% lifetime risk to a 10% risk per year (Shenoi 
and Friedland, 2009; Suthar et al., 2012). HIV co-infection also shows a significant association 
with TB drug resistance, including MDR-TB and XDR-TB (Shenoi and Friedland, 2009). 
M. tuberculosis infection in HIV positive cases represents over 10% of total cases annually, of 
which 80% occur in Africa, with TB responsible for 25% of deaths in HIV positive individuals 
(WHO, 2014). A major obstacle in treating HIV/TB co-infected individuals is that the front 
line TB drug rifampicin activates the cytochrome p450 system that metabolises common 
anti-retroviral drugs used to treat HIV, thereby reducing their efficacy (L’homme et al., 2009; 
Niemi et al., 2003). Diabetes is another significant comorbidity for TB, with diabetics three 
times more likely to develop active TB, primarily due to a defective host immune response 
(Lönnroth et al., 2014). Additionally, treatment of TB is less effective in diabetics, resulting in 
lower cure rates and higher mortality (Baker et al., 2011). In 2013, 15% of all adult cases of 
TB were associated with diabetes. The rates of diabetes in those countries most at risk to TB 
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has increased over the past decade and is proposed to be in part responsible for the lower 
than expected reduction in the number of cases of TB in these regions during that time 
frame. 
 
1.1.1. Tuberculosis in New Zealand 
The incidence rate for TB in New Zealand (NZ) is 6.6 cases per 100,000 with a total of 279 
new cases in 2012 (Lim and Heffernan, 2013). The majority of these cases (75%) occurred in 
individuals born outside of NZ, indicating that place of origin is a significant risk factor for TB 
in NZ. There were four cases of MDR-TB in 2012 in NZ and a total of 32 cases of MDR-TB over 
the previous 10 years. Of the cases of MDR-TB in NZ only two out of the 32 were NZ born, 
and it is assumed the other 30 were infected with MDR-TB outside of NZ (Lim and Heffernan, 
2013). To date there has only been a single case of XDR-TB, which occurred during 2010. The 
predominant TB lineage in NZ cases is lineage four (Euro-American), followed by lineages 
one (Indo-Oceanic), two (East Asian), and three (East African Indian) (Yen et al., 2013). NZ 
and Pacific Island born patients were predominantly lineage four; whereas, individuals born 
outside of NZ predominately had lineages common to their place of origin. 
 
1.2. Pathogenesis 
M. tuberculosis is an obligate pathogen for which humans are the primary host (Saviola and 
Bishai, 2006). Unlike other infectious mycobacteria such as M. bovis, that routinely causes 
disease in a large number of mammals (including humans); M. tuberculosis does not have 
any significant environmental reservoirs. Disease caused by M. tuberculosis most commonly 
manifests as a pulmonary infection, with 70% of TB cases occurring in the lungs (Harisinghani 
et al., 2000; Young et al., 2008). Extra-pulmonary TB will occur in 10 – 42% of patients, 
dependent on additional factors such as age, ethnicity, additional underlying disease, 
specific M. tuberculosis strain, and host immune state (Caws et al., 2008). During HIV 
co-infection, extra-pulmonary disease can be more common than pulmonary, with little or 
no lung involvement, and is often diagnosed as another disease and only identified as TB 
upon autopsy (Mudenda et al., 2012; von Reyn et al., 2011). The characteristic symptoms of 
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pulmonary TB include a chronic cough, production of sputum, haemoptysis, a loss of 
appetite, weight loss, and night sweats (Lawn and Zumla, 2011). Infection spreads by 
inhalation of bacteria-containing droplets expelled from infected individual’s lungs. The 
number of bacteria required to start a new infection has previously been reported to be as 
few as 1—3 bacilli (Riley, 1957); however, the number required for a successful infection in 
humans may be significantly higher (Orme, 2014). Once inhaled, the bacilli enter the alveoli 
of the lungs where they are phagocytosed by resident alveolar macrophages (Clark-Curtiss 
and Haydel, 2003; Mehta et al., 1996; Saunders and Cooper, 2000). The macrophages are 
then activated by T cells, stimulating the formation of the acidified phagolysosome, killing 
the phagocytosed bacteria (Clark-Curtiss and Haydel, 2003). However, M. tuberculosis can 
live within host macrophage phagosomes by preventing their fusion with lysosomes and 
therefore their acidification (Brown et al., 1969; Mwandumba et al., 2004). The immune 
system’s response to M. tuberculosis infection is to wall off the site of infection, forming a 
granuloma or ‘tubercule’ within which the tissue undergoes the caseous necrosis 
characteristic of TB (Saunders and Cooper, 2000).  
 In 10% of cases, acute disease will continue as the bacilli spread throughout the lung and 
later into other organ systems including the kidneys, liver, and brain (Caws et al., 2008). In 
the remaining 90% of cases the infection is either successfully cleared or enters a latent 
disease state within which the bacteria are believed to be in a dormant growth phase, 
possibly similar to the sporulation phase exhibited by other bacterial species (Bentrup and 
Russell, 2001; Parrish et al., 1998). Evidence, however, is mounting that M. tuberculosis 
continues to replicate, albeit at a reduced rate, within the host during chronic infection (Gill 
et al., 2009). Individuals with latent TB have a 10% lifetime reactivation risk, although this 
rate becomes much higher if the patient is immunocompromised (Girardi et al., 1999; 
Selwyn et al., 1989). For example, HIV-positive individuals are 37 times more likely to 
develop active TB than HIV negative individuals (WHO, 2010), with HIV co-infection 
increasing reactivation to a 10% per year risk (Shenoi and Friedland, 2009; Suthar et al., 
2012). Additionally, individuals with diabetes also have a three-fold higher risk of developing 
active disease (Dye and Williams, 2010). 
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1.3. Mycobacteria 
Mycobacteria belong to the family Mycobacteriaceae within the order Actinomycetales and 
are characteristically acid fast, have a mycolic-acid rich cell wall, and a high GC genome 
content (61-71%) (Pitulle et al., 1992; Shinnick and Good, 1994). Mycobacteria are 
commonly divided into two groups, the fast growing and the slow growing mycobacteria, 
whereby the slow growing mycobacteria are classified as those that take longer than seven 
days for colonies to appear on solid media; whereas, the colonies of the fast growing species 
appear in less than seven days (Pitulle et al., 1992; Shinnick and Good, 1994).  
The slow growing mycobacteria include those belonging to the M. tuberculosis complex that 
consists of the bacterial species M. tuberculosis, M. bovis, M. africanum, M. microti, M. 
orygis, M. pinnipedi, and M. canetti (Pitulle et al., 1992; Shinnick and Good, 1994). Each 
member of the M. tuberculosis complex has a preferred host, but is capable of causing 
disease in other mammals (Smith et al., 2006). This is in part due to their very similar genetic 
makeup, sharing more than 99.9% genetic identity (Fleischmann et al., 2002; Gutacker et al., 
2002; Huard et al., 2006). Evidence suggests M. tuberculosis-like bacteria have existed for 
around three million years, evolving in Africa alongside humans (Galagan, 2014). The fast 
growing mycobacteria, of which approximately 40 species have been identified, are primarily 
saprophytic and can inhabit a wide variety of habitats in the environment (Saviola and 
Bishai, 2006; Shinnick and Good, 1994). It was thought for a long time that the fast growers 
were simply environmental bacteria; however, more species are now demonstrating their 
ability to cause disease as opportunistic pathogens (Howard and Byrd, 2000).  
 
1.3.1. Physiology 
Mycobacteria are aflagellate, irregular rod shaped bacilli of approximately 0.3 - 0.5 µm in 
diameter with variable length (Figure 1.3)(Martinez et al., 1999; Shinnick and Good, 1994). 
Mycobacteria are often referred to as gram-positive; however, they have a structurally 
different cell wall from most gram-positive bacteria and are better defined as acid-fast, as 
determined by Ziehl-Neelsen staining (Figure 1.3).  
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Figure 1.3: Ziehl-Neelsen-stained M. smegmatis. The lipid rich mycobacterial cell wall resists 
decolourisation during Zeihl-Neelsen staining; therefore, mycobacteria retain the red colour of the 
primary stain carbol fuchin. Non acid-fast bacteria lose the primary stain and show up blue from the 
counterstain methylene blue. Characteristic clumping of the mycobacteria can be observed in this 
image. 
The cell wall of mycobacteria is composed of two segments: an inner segment, consisting of 
the peptidoglycan layer and the arabinogalactan layer with bound mycolic acids, and an 
outer segment that consists of free lipids (Figure 1.4)(Brennan, 2003). The free lipids in the 
outer segment along with the mycolic acids in the inner segment form an asymmetric lipid 
bilayer that gives mycobacteria their characteristic acid fastness. This outer lipid layer also 
contributes to the innate drug resistance of mycobacteria by limiting drug permeability 
(Jarlier and Nikaido, 1994). 
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Figure 1.4: Structure of the mycobacterial cell wall. Working outwards, the mycobacterial envelope 
consists of the plasma membrane, a peptidoglycan (PG) layer, an arabinogalactan (AG) layer, a 
mycolic acid (MA) layer covalently bound to the arabinogalactan layer, and an outer segment 
consisting of free lipids (FL). The free lipids include phosphatidylinositol mannoses, 
dimycolytrehalose, phthiocerol dimycocerosate, and sulfolipids. The cell wall also contains 
lipoarabinomannas (LAM) that span the double-layered membrane, and various porins and cell wall 
proteins.  
 
1.3.2. Mycobacterium tuberculosis 
TB was first identified as a contagious disease in 1868 when it was shown to be transmitted 
from humans to rabbits (Saviola and Bishai, 2006), although it wasn’t until 1882 that Robert 
Koch first directly observed the bacilli of M. tuberculosis responsible for the disease (Adler 
and Rose, 1996).  M. tuberculosis belongs to the M. tuberculosis complex and is therefore a 
slow growing mycobacterium, with a doubling time of approximately 24 hours (Shinnick and 
Good, 1994). The M. tuberculosis genome encodes approximately 4000 genes. The genome 
of the common laboratory strain H37Rv was first sequenced in 1998 (Cole et al., 1998). As 
M. tuberculosis is an airborne pathogen, its handling requires specific safety precautions 
(Alderton and Smith, 2001), and as not all laboratories are equipped to handle virulent 
M. tuberculosis, surrogate strains are often used instead, including the attenuated H37Ra 
strain, M. bovis Bacillus Calmette–Guérin (BCG), or the low virulence environmental 
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mycobacterium M. smegmatis (Altaf et al., 2010; Chaturvedi et al., 2007; Steenken et al., 
1934).  
 
1.3.3. Mycobacterium smegmatis 
M. smegmatis is a soil dwelling saprophyte with a doubling time of approximately four 
hours, taking around three days for visible colonies to form on rich solid media (Shiloh and 
DiGiuseppe Champion, 2010). The fast doubling time of M. smegmatis makes it a useful 
surrogate for M. tuberculosis in high-throughput drug screening and large scale genetic 
based assays. Genetic studies of M. smegmatis were greatly facilitated by the discovery of a 
transformation efficient mutant, mc2155, that has a 10 - 100,000 increase in efficiency 
(Snapper et al., 1990). Interestingly, M. smegmatis mc2155 contains a genomic duplication of 
approximately 56 kilobases (Kb) not present in the parental strain (Wang et al., 2008). This 
duplication contains the alcohol dehydrogenase gene adhC, a gene previously predicted to 
be duplicated in the M. smegmatis mc2155 geneome (Galamba et al., 2001). The gene 
encoding the β subunit of the F1 domain of the adenosine triphosphate (ATP) synthase, 
atpD, is also predicted to be duplicated in the genome of M. smegmatis mc2155 (Tran and 
Cook, 2005). However, atpD does not appear to be duplicated in the genome sequence. This 
suggests there may be more regions of the genome of M. smegmatis that are duplicated 
other than the characterised 56 Kb region. The original M. smegmatis reference genome 
sequence (NCBI Accession CP000480) had 6947 predicted genes, based mostly on homology 
to other known gene sequences. More recently, efforts to improve the accuracy of 
M. smegmatis mc2155’s genome annotations led to a newer updated genome sequence 
(NCBI Accession CP001663). Confirmation of gene sequences with protein sequence data led 
to refinement of the M. smegmatis mc2155 genome, and this new reference sequence 
encodes only 6752 genes (Deshayes et al., 2007; Gallien et al., 2009; Perrodou et al., 2006).  
Significant genetic differences exist between M. smegmatis and M. tuberculosis, whereby 
approximately half of the M. smegmatis genome contains genes that do not have 
homologues in M. tuberculosis (Altaf et al., 2010). This translates into phenotypic differences 
including different sensitivities to various compounds. However, M. smegmatis has a 
demonstrated ability to identify growth-inhibitory compounds that are active against 
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M. tuberculosis in high-throughput assays (Altaf et al., 2010). Although the number of false 
positives are higher than when using the closer biological model M. bovis BCG, the majority 
of compounds active against M. tuberculosis can be identified using M. smegmatis. On 
balance, the benefits provided by the fast doubling time of M. smegmatis outweigh the 
disadvantages arising from genetic differences to M. tuberculosis. Any findings in 
M. smegmatis can ultimately be confirmed in lower throughput validation assays with 
M. tuberculosis. 
 
1.4. Treatment of tuberculosis 
Directly observed therapy, short course (DOTS) was a strategy developed to help control TB, 
encompassing policies around funding, case detection, treatment, logistics of drug supply, 
and monitoring (WHO, 2010). The Stop TB Strategy was developed as the successor to DOTS 
with the goal “to dramatically reduce the global burden of TB by 2015 in line with the 
Millennium Development Goals and the Stop TB Partnership targets” (Uplekar et al., 2006). 
Specifically, the WHO’s Millennium Development Goals are to reverse the incidence of TB by 
2015 (WHO, 2010); while, the Stop TB partnership has the additional goals of halving the 
mortality rates by 2015 compared to 1990 levels, and eliminating TB by 2050 (WHO, 2010). 
Currently, treatment of drug-susceptible TB consists of a two-month course of isoniazid, 
rifampicin,  pyrazinamide, and ethambutol, followed by a further four months of isoniazid 
and rifampicin alone (WHO, 2014). Treatment of drug-resistant TB requires the use of 
alternative second-line drugs that are generally more expensive, less effective, have higher 
associated toxicities, and lower cure rates. Treatment of drug-sensitive TB has a cure rate of 
over 90%; while, the cure rate for MDR-TB is lower at only 50-70% (WHO, 2010). Treatment 
of MDR-TB takes on average two years, while in extreme cases of XDR-TB there is no 
successful treatment. It is a commonly held belief that the current tools for the treatment 
and prevention of TB are ineffective, with a great need for drugs that can both reduce the 
treatment time and effectively treat drug-resistant TB, especially MDR-TB and XDR-TB  
(Duncan, 2003; O’Brien and Nunn, 2001; WHO, 2010; Young et al., 2008). 
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1.4.1. Anti-tuberculosis Drugs 
Prior to the advent of the first antibiotic, treatment of TB involved travelling to a sanatorium, 
where it was believed rest and a healthy diet would help to cure patients (Davis, 1996). 
Streptomycin, discovered in 1945, was the first antibiotic that was successful in treating TB 
infections (Pyle, 1947). Para-aminosalicylic acid was discovered almost simultaneously and 
was found to be effective for treating TB, especially in combination with streptomycin 
(Lienhardt et al., 2012). Isoniazid was discovered in 1951, demonstrating even greater 
activity against M. tuberculosis than either para-aminosalicylic acid or streptomycin and 
enabling the first three-drug treatment of TB (Pansy et al., 1952). By the mid-1980’s, 
ethambutol and pyrazinamide had replaced para-aminosalicylic acid and streptomycin, and 
rifampicin had been introduced as well, giving the core first-line multidrug treatment for TB 
still used today.  In cases of drug resistance, second-line drugs are utilised, including the 
aminoglycosides (including streptomycin), fluoroquinolones (e.g. ciprofloxacin), 
capreomycin, and the macrolides.   
The current anti-TB drugs target a limited range of cellular processes, namely cell wall 
biosynthesis, DNA replication, transcription, translation, and folate biosynthesis (Table 1.1).  
Discovery of drugs that can inhibit novel targets is crucial for improving the current 
treatment regimens of TB, particularly drug-resistant TB (Duncan, 2003; O’Brien and Nunn, 
2001; Young et al., 2008).  
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Table 1.1: Modes of action of current anti-tuberculosis drugs. 
Drug Mode of Action References 
Rifamycins 
(including 
rifampacin) 
Binds to the β Subunit of RNA polymerase, inhibiting 
transcription 
(Wehrli et al., 
1968) 
Isoniazid Inhibits mycolic acid biosynthesis 
(Banerjee et al., 
1994) 
Ethionamide Inhibits mycolic acid biosynthesis 
(Banerjee et al., 
1994) 
Ethambutol Inhibits arabinogalactan layer biosynthesis 
(Deng et al., 
1995) 
D-Cycloserine 
Prevents D-serine insertion into peptidoglycan, inhibiting 
cell wall synthesis 
(Prosser and de 
Carvalho, 2013) 
Fluoroquinolones Inhibits DNA gyrase, inhibiting DNA synthesis 
(Fernandes, 
1988) 
Capreomycin Interferes with the ribosome inhibiting protein synthesis 
(Maus et al., 
2005) 
Macrolides Binds the 50s ribosomal subunit, inhibiting translation 
(Chopra and 
Brennan, 1998) 
P-aminosalicylic acid 
Inhibits dihydropteroate synthetase, inhibiting folate 
biosynthesis 
(Chakraborty et 
al., 2013) 
Aminoglycosides Binds the 30s ribosomal subunit, inhibiting translation 
(Moazed and 
Noller, 1987) 
Pyrazinamide Inhibits trans-translation (Shi et al., 2011) 
 
For 40 years after the discovery of rifampicin in the 1950s no new drug classes were 
developed for the treatment of TB. Research into anti-TB drugs has only become more active 
in the last decade. There are currently 10 drugs in the various phases of clinical trials, and a 
further nine in preclinical development (WHO, 2014). Of the 10 drugs currently in clinical 
trials, four have novel modes of action and are active against MDR-TB: Delamanid, PA-824, 
bedaquiline, and SQ109. Delamanid, previously known as OPC 67683, is a nitroimidazole that 
targets mycolic acid biosynthesis, and is similar to another recently discovered 
nitroimidazole PA-824 (Matsumoto et al., 2006; Singh et al., 2008; Stover et al., 2000). 
Delamanid is currently undergoing phase III clinical trials, while PA-824 is undergoing phase II 
clinical trials. Bedaquiline, previously known as TMC207, is a diarylquinoline, a novel class of 
anti-TB drug that targets the C subunit of the ATP synthase F0 domain. The two drugs, 
bedaquiline and delamanid, have been approved for use in treating restricted cases of 
MDR-TB (Villemagne et al., 2012). The only other anti-TB drug with a novel mode of action 
currently in clinical trials is SQ109, which is currently in phase II clinical trials. SQ109 inhibits 
integration of mycolic acid into the cell wall by inhibition of the transporter MmpL3, which 
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appears to be involved in translocating mycolic acids to outside the cell (Protopopova et al., 
2005; Tahlan et al., 2012). 
 
1.4.2. Drug resistance 
Clinical resistance has been reported for all of the drugs used to treat TB, with the first cases 
identified shortly after the initial use of streptomycin. Spontaneous drug resistance, in the 
clinical setting or in a laboratory environment, most often occurs from point mutations in 
the gene encoding the drug’s target, reducing the affinity of the drug for its target. For 
example, mutations in the target of rifampicin, rpoB, led to rifampicin resistance 
(Ramaswamy and Musser, 1998), whereas mutations in the fluoroquinolone targets, the 
DNA gyrase encoding genes gyrA and gyrB, led to fluoroquinolone resistance (Kocagöz et al., 
1996). Alternatively, if the drug is a prodrug, resistance often occurs from mutations in the 
prodrug activating enzyme, e.g. mutations in katG which encodes the catalase peroxidase 
enzyme KatG responsible for activating isoniazid lead to isoniazid resistance.  
The long treatment time for TB (i.e. 6 months or longer) has been shown to play a significant 
role in the generation of drug resistance due to treatment non-compliance (Chao and Rubin, 
2010; Claxton et al., 2001). This non-compliance selects for drug-resistant populations and 
has been demonstrated by Saunders et al. (2011) who sequenced serial isolates from a 
patient who was not adhering to the treatment regimen. Over the course of treatment the 
isolates developed sequential isoniazid then rifampicin resistance, with only two single 
nucleotide changes identified in the genome, one in katG and one in rpoB.  
 
1.4.3. Modes of action of the anti-tuberculosis drugs to be examined in this 
study 
Isoniazid is an inhibitor of mycolic acid biosynthesis, an important substrate of the 
mycobacterial cell wall. Specifically, isoniazid inhibits the fatty acid synthase II (FASII) 
enoyl-acyl carrier protein reductase (InhA). Isoniazid was first shown to have anti-TB activity 
in 1952, and was far superior to any agents in use at the time (Bernstein et al., 1952; Pansy 
et al., 1952). Despite its long history of use, little was known about the mode of action of 
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isoniazid until recently. Loss of catalase activity was long known to accompany isoniazid 
resistance in mycobacteria, but it was not until the advent of genetic techniques that 
mutations in the catalase/peroxidase katG were identified as the cause of both isoniazid 
resistance and catalase negative phenotypes (Zhang et al., 1992). InhA was first identified in 
the isoniazid mode of action when a catalase positive mutant resistant to isoniazid was 
identified carrying mutations in inhA (Banerjee et al., 1994). Subsequent studies have shown 
that isoniazid is a pro-drug that is activated by KatG into a reactive species that reacts with 
nicotinamide adenine dinucleotide (NAD) to form the isoniazid-NAD (INH-NAD) adduct 
responsible for inhibition of InhA (Johnsson and Schultz, 1994; Rozwarski et al., 1998; 
Wilming and Johnsson, 1999). Other targets have been suggested for isoniazid since, 
including ketoacyl synthase A (KasA) (Mdluli et al., 1998) and dihydrofolate reductase (DhfR) 
(Argyrou et al., 2006), although the lack of correlation between overexpression of these 
proteins and increased isoniazid resistance has helped support the hypothesis that InhA is 
the drug’s primary target (Larsen et al., 2002; Wang et al., 2010). However, multiple isoniazid 
radicals have been demonstrated (Wengenack and Rusnak, 2001), as well as a range of 
secondary radicals (Ito et al., 1992; Timmins et al., 2004; Timperio et al., 2005; Van Zyl and 
Van Der Walt, 1994) whose activity within the mycobacterial cell supports the idea that the 
mode of action of isoniazid is broader than just inhibition of InhA. 
Rifampicin is a transcriptional inhibitor which binds to, and inhibits the β subunit of the DNA 
dependent RNA polymerase enzyme (RpoB) in bacteria (Wehrli et al., 1968), including 
mycobacteria (Levin and Hatfull, 1993). Rifampicin is a semi-synthetic drug derived from the 
natural product rifamycin (Maggi et al., 1966). This derivative was found to have improved 
activity against gram-negative bacteria and the actinobacteria including mycobacteria. 
Clinical resistance to rifampicin is almost entirely due to mutations in rpoB, with 96% of 
mutations in rifampicin-resistant clinical isolates occurring within an 81 base pair (bp) 
sequence of the gene (Ramaswamy and Musser, 1998). 
Bedaquiline is a diarylquinoline, the first novel class of anti-mycobacterials to be discovered 
in 40 years (Andries et al., 2005). The primary target for bedaquiline is the C subunit of the F0 
ATP synthase domain encoded by atpE (Andries et al., 2005; Koul et al., 2007). Due to its 
recent discovery, limited work has been done investigating the mode of action of 
bedaquiline beyond the primary ATP synthase target.  
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1.5. Drug Discovery 
The TB drug development pipeline involves identification of compounds that are 
bacteriostatic or bactericidal against M. tuberculosis, development of lead compounds 
including identification of drug modes of action, and finally progression into clinical trials 
(Duncan, 2003). These anti-TB compounds are identified from high-throughput screening of 
chemical libraries against mycobacteria (whole-cell screening), or from screening of isolated 
enzyme targets (Balganesh et al., 2008). Whole-cell screening has been the most successful 
approach to drug discovery as it simultaneously assesses all factors related to a drug’s 
efficacy (Lechartier et al., 2014; Payne et al., 2007). Numerous variations on whole cell 
screening exist using a number of different model systems including macrophage infection, 
nutrient starvation, non-replicating, latent systems, and incorporating various different 
animal models. While these approaches have the potential to identify compounds that will 
be active in the clinic, care needs to be taken as each model makes an assumption about 
M. tuberculosis infection that can lead to misinterpretation of results (Miller et al., 2009; 
Pethe et al., 2010).  
A disadvantage to whole-cell based screening for anti-mycobacterial compounds is that no 
information on the mode of action of the drug is generated. The absence of any target 
information from whole-cell screening prevents the rational design of structural 
modifications to improve drug activity without further investigation of the drug’s mode of 
action (Koul et al., 2011). However, whole-cell screening remains an effective way to identify 
new anti-TB drugs, including those with new modes of action. Whole-cell screening was used 
to identify bedaquiline, delamanid, PA-824, and SQ109, (Lechartier et al., 2014). 
Screening of isolated enzyme targets has been largely unsuccessful in identifying anti-TB 
compounds due to difficulty with translating good target inhibition in biochemical assays 
into good bactericidal or bacteriostatic activity against whole cells (Ioerger et al., 2013). This 
difficulty largely stems from an incomplete understanding of what makes an enzyme a good 
drug target. An alternative approach is target-based whole-cell screening, whereby target 
information is incorporated into the whole-cell screen (Abrahams et al., 2012; Ioerger et al., 
2013; Nisa et al., 2010). A common strategy in this type of screen is the conditional 
repression of a gene of interest with a system such as the tetracycline inducer and repressor 
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system (Ehrt et al., 2005; Williams et al., 2010). By reducing the levels of the target protein 
the cells become more sensitive to compounds that inhibit that protein, with specific 
inhibitors demonstrating differential activity between the conditional mutant and wild-type 
(WT). This approach has been used to find inhibitors of an enzyme essential for cell division 
(ParA) (Nisa et al., 2010), an enzyme involved in vitamin B5 biosynthesis (PanC) (Abrahams et 
al., 2012), and the malate synthase enzyme (Krieger et al., 2012). 
 
1.5.1. Mode of action identification 
Mode of action identification studies are essential during development of novel anti-TB 
drugs, generating information on the primary drug target, secondary off target effects, and 
mechanisms of drug resistance (Azad and Wright, 2012; Lechartier et al., 2014). Drugs are 
pleiotropic by nature, and determining the primary and secondary targets provides 
information on whether drug-drug interactions are likely to occur when the novel drug is 
used in combination with current drugs, a consideration important in the multi-drug 
treatment of TB (Ginsberg and Spigelman, 2007). Additionally, identification of the primary 
and secondary targets enables a rational approach to chemical modifications to drugs to 
improve their efficacy against both the primary and secondary drug targets (Balganesh et al., 
2008; Campbell et al., 2001; Ioerger et al., 2013).  
There are three commonly used genetic techniques to investigate the mode of action of a 
drug: a) identification of genes involved in drug resistance, b) identification of genes whose 
transcription is altered upon drug treatment, and c) identification of genes involved in drug 
hypersensitivity. These three different genetic approaches complement each other well, and 
utilising all of them, combined with biochemical data, gives the most information on drug 
mode of action. Past studies have focused on the identification of resistance inducing 
mutations, and altered transcription upon gene treatment. To the best of my knowledge, 
only two previous studies have examined drug sensitising mutations in mycobacteria, one 
study by Alexander et al. (2003) looking for rifampicin hypersensitive mutants, and another 
by Daugherty et al. (2011) looking for mutants hypersensitive to a ubiquitin derived peptide. 
Therefore, the study of sensitising mutations for current anti-TB drugs has the potential to 
generate novel information on drug mode of action.  
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1.5.1.1. Resistance inducing mutations 
The majority of primary targets that have been identified for the current anti-mycobacterial 
drugs were found by studying genes involved in drug resistance (Andries et al., 2005; 
Banerjee et al., 1994; Belanger et al., 1996). Resistance to most TB drugs occurs through 
point mutations in the gene encoding the primary target. Alternatively, resistance can occur 
due to mutations in genes that are functionally interacting with the drug target. Therefore, 
identification of point mutations in drug resistant mutants has facilitated target 
identification. This approach can also identify enzymes responsible for activating pro-drugs 
when the primary resistance mechanism is loss of pro drug activation (Lechartier et al., 
2014). Transposon mutagenesis has been used in a similar manner, although this type of 
mutation typically causes loss of function and consequently is not useful for determination 
of the primary targets (Billman-Jacobe et al., 2006). Drug resistance studies have a very 
narrow focus, singling out individual genes that directly interact with the compound, such as 
the primary drug target, pro-drug activating enzymes, or enzymes responsible for drug 
detoxification. 
 
1.5.1.2. Altered transcription with drug treatment 
Investigation into which genes are up/down-regulated in response to drug treatment 
provides a broader picture of drug mode of action. Transcriptional analysis is useful for 
identifying pathways that are inhibited by a drug, including both the primary and secondary 
target pathways. Transcriptional analysis can be performed on a small scale, using 
quantitative polymerase chain reaction (PCR) to measure changes in messenger RNA (mRNA) 
expression levels of individual genes, or on a larger scale, using micro-arrays to measure 
changes in mRNA expression levels of large sets of genes, or even the whole transcriptome 
(Boshoff, 2004). Large scale transcriptional analysis is useful for grouping compounds with 
similar modes of actions in mycobacteria. For example, Boshoff et al. (2004) measured the 
transcriptional response of M. tuberculosis to a range of growth inhibitory conditions, 
including drug treatment, and clustered the transcriptional profiles for each condition. This 
approach was able to group conditions with similar modes of action, e.g. isoniazid and 
ethionamide clustered together along with thiolactomycin, three drugs that all inhibit 
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components of the FASII machinery. More recently, transcriptional profiling identified the 
mode of action of the novel anti-TB drug PA-824 as involving both inhibition of mycolic acid 
biosynthesis and nitric oxide induced (NO) respiratory poisoning (Manjunatha et al., 2009).  
A limitation of the transcriptional analysis approach is that while affected pathways are 
determined, the specific gene target cannot be directly identified. Additionally, this 
approach is only as strong as the size of the gene set against which each new drug is tested. 
Finally, transcriptional analysis  gives an incomplete description of a drug’s mode of action 
(Sassetti et al., 2001). For example, transcriptional analysis does not provide information on 
constitutively expressed genes, or genes that are post-transcriptionally regulated.  
 
1.5.1.3. Hypersensitivity inducing mutations 
Analysis of mutations that cause drug hypersensitivity provides information on genes that 
are conditionally essential to maintaining WT drug sensitivity. Similar to transcriptional 
studies, this approach yields information on which pathways are inhibited by the drug 
(primary and secondary target pathways), as opposed to the specific molecular target. This 
approach is routinely used in the budding yeast Saccharomyces cerevisiae to study drug 
mode of action where it is termed chemical genetics (Parsons et al., 2004, 2006). A viable 
loss of function mutation within a pathway targeted by the drug will sensitise the organism 
to the drug, thereby identifying that pathway as being involved in the drug’s mode of action. 
This approach also identifies specific proteins responsible for maintaining basal drug 
resistance, i.e. drug detoxification mechanisms (Alexander et al., 2003).  It is necessary to 
isolate mutants and assay them individually for increased drug-sensitivity as the mutations 
of interest produce a recessive phenotype. Therefore, a common limitation of this technique 
is a poor genomic coverage for the collection of mutants being studied. This is especially 
pertinent when using a mutagenesis approach such as random transposon mutagenesis 
which is unable to create mutations in essential genes (Griffin et al., 2011; Sassetti et al., 
2001, 2003). Despite this limitation, random transposon mutagenesis is routinely used to 
generate collections of random mutants for phenotypic screening, including screening for 
drug hypersensitivity, because of the ease of identifying the site of insertion, and the 
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consistent nature of the mutation (loss of function) (Alexander et al., 2003; Daugherty et al., 
2011; Gutacker et al., 2002). 
1.6. Random transposon mutagenesis of M. smegmatis 
Assaying for drug hypersensitivity requires the prior construction of a collection of viable 
mutants. This collection should be randomly generated, with good genome coverage and 
minimal overlap. Insertional mutagenesis using transposons is favoured for the generation of 
random bacterial mutants due to the inherent labelling of the site of mutation with the 
transposon DNA, which facilitates the identification of the genetic basis for the mutant 
phenotype (Billman-Jacobe et al., 2006; Prod’hom et al., 1998; Sassetti et al., 2001). A 
transposon insertion into a gene leads to a loss of function of the gene product, which has 
the important implication that only genes not essential for the organism’s survival can 
harbour a transposon insertion (Sassetti et al., 2001). As such, transposon mutant libraries 
will only contain those genes that are non-essential for survival in the conditions used. This 
characteristic has been utilised for determining the varying set of essential genes under a 
range of conditions, including in vitro in various media, intra-macrophage survival, in vivo 
mouse models, and under different drug treatment conditions (Alexander et al., 2003; 
Billman-Jacobe et al., 2006; Daugherty et al., 2011; McAdam et al., 2002; Rengarajan et al., 
2005; Sassetti et al., 2001, 2003). 
Two different delivery systems exist for transposon mutagenesis in mycobacteria: phage 
based, such as φMycoMarT7, which delivers the Himar1 transposon (Sassetti et al., 2001), or 
plasmid based systems such as pCG79, which delivers the Tn611 transposon (Guilhot et al., 
1994). Transposon mutagenesis systems often use delivery vectors which are temperature 
sensitive for replication in mycobacteria, which allows the process of transfection or 
transformation to be separated from the process of transposition. Transposition is a 
relatively rare event, but appropriate selection techniques can improve the yield of mutants 
obtained (Bardarov et al., 1997). Transformed/transfected cells can be plated out at a 
non-permissive temperature for plasmid/phage replication and only successful transposition 
events will grow. These strains can then be stored individually for later study. 
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1.7. Aims of this thesis 
The aim of this thesis was to generate information on drug mode of action by identifying the 
genetic basis of drug hypersensitivity in mutants of M. smegmatis mc2155. To the best of my 
knowledge, only two previous studies have investigated the mode of action of anti-TB 
compounds through studying drug hypersensitive mutants, one published after this present 
study had begun (Alexander et al., 2003; Daugherty et al., 2011). To enable the identification 
of drug hypersensitive mutants of M. smegmatis mc2155 we also aimed to develop a 
high-throughput assay for drug hypersensitivity. M. smegmatis mc2155 was selected as a 
model for M. tuberculosis in this study as it was able to be used in the physical containment 
2 (PC2) laboratories available, and as it provided time advantages over the slow growing 
models. Transposon mutagenesis was selected for generating the mutants of M. smegmatis 
mc2155 due to the reported consistent nature of the mutations, and the ease of identifying 
the site of the genetic lesion responsible for the hypersensitivity phenotype. 
The front line TB drugs isoniazid and rifampicin were selected for this study as the known 
aspects of their modes of action would enable validation of our methodology. Bedaquiline, 
which has recently been approved for limited treatment of MDR-TB, was also included in this 
study as little is known about its mode of action other than the primary target. Due to the 
absence of prior studies of this nature, there was a large potential to identify novel aspects 
of the modes of action of these three anti-TB drugs. A better understanding of the modes of 
action of these drugs would enable rational modifications of the drugs to improve treatment 
of TB. To this end the following specific aims were addressed: 
1. Identification of isoniazid, rifampicin, and bedaquiline hypersensitive transposon 
mutants of M. smegmatis mc2155. To achieve this aim the following sub aims were 
addressed: Construction of a transposon mutant collection in M. smegmatis mc2155, 
and development of a high-throughput assay for drug hypersensitivity. 
2. Identification and validation of the genotypic basis for the observed drug 
hypersensitivity to generate information about each drug’s mode of action. 
3. Characterisation of drug sensitivity phenotypes, including cross-sensitivities and 
differential-sensitivities to other anti-TB drugs and drug analogues, respectively. 
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2. Materials and Methods 
2.1. Bacterial strains 
Strains used in this study are listed in Table 2.1 along with the relevant genotypic and 
phenotypic properties. Stocks of all strains were stored at -80 °C in 20% (v/v) glycerol. 
Table 2.1: Bacterial strains used in this study. 
Strain Genotype and/or phenotype Reference 
E. coli DH5α 
F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 
endA1 hsdR17(rk-, mk+) phoA supE44 thi-1 
gyrA96relA1 λ- 
Invitrogen™ 
M. smegmatis 
mc2155 
High plasmid transformation efficiency strain of 
M. smegmatis 
(Snapper et al., 1990) 
M. tuberculosis 
H37Rv 
Virulent laboratory reference strain of 
M. tuberculosis 
(Oatway Jr. and 
Steenken Jr., 1936; 
Steenken et al., 1934) 
 
2.2. Plasmids 
Plasmids used in this study are listed in Table 2.2 along with the relevant properties. 
Table 2.2: Plasmids used in this study. 
Plasmid Properties Reference 
pCG79 
OriM (ts pAL5000), KanR, Strep/SpecR, Tn611 
transposon 
(Guilhot et al., 1994) 
pNIT-1 
Mycobacterial conditional expression vector, OriE, 
OriM, KanR, NIT operon, MCS 
(Pandey et al., 2009) 
pRC10 Derivative of pNIT-1 with NIT operon removed This study 
pLL192_hsp60 OriE, OriM, KanR, hsp60 driven GFP expression 
(Srivastava et al., 
2007) 
pKW08_Lx 
Mycobacterial conditional expression vector, OriE, 
OriM, HygR, inducible PTet, MCS, luxAB 
(Williams et al., 2010) 
pRC20 
Derivative of pKW08_Lx with luxAB replaced with 
GFP 
This study 
 
2.3. Chemicals and reagents 
Unless otherwise specified all general reagents and chemicals were obtained from 
Sigma-Aldrich. HyperLadder™ 1 Kb DNA ladder and DNA loading dye were obtained from 
Bioline (Auckland, NZ). 
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2.4. Enzymes 
All restriction endonuclease enzymes were purchased from New England Biolabs (Auckland, 
NZ), as were Antarctic phosphatase, T4 DNA polymerase, and T4 polynucleotide kinase. The 
PCR enzyme master mixes BioMix™ Red and AccuSure™ were obtained from Bioline 
(Auckland, NZ). T4 DNA ligase, Proteinase K and lysozyme were obtained from Invitrogen. 
Phusion® polymerase was obtained from Thermo-Fisher Scientific. 
 
2.5. Growth media 
All media were made up in sterile distilled and deionised H2O (ddH2O) according to the 
manufacturer’s instructions and sterilised by autoclaving at 121 °C for 30 minutes, unless 
stated otherwise. 
Luria Broth  
All Luria Broth (LB) and LB agar (LA) low salt powders (Duchefa Biochemie) were purchased 
from Total Lab Systems (Auckland, NZ). All agar plates, and liquid media containing 
antibiotics, were stored at 4 °C; liquid media without antibiotics were stored at room 
temperature. 
7H9 
Difco™ Middlebrook 7H9 broth was ordered from Becton Dickson. 7H9 broth was made up 
according to the manufacturer’s instructions in ddH2O, containing 0.05% Tween™80 (v/v), 
0.05% glycerol (v/v) and 10% oleic acid, albumin, dextrose, catalase (OADC) supplement, and 
stored at 4 °C. 
 
2.5.1. Media supplements 
Tween™ 80 
Tween™ 80 was made up as a 20% (v/v) stock solution using ddH2O and sterilised by 
autoclaving at 121 °C for 30 minutes. Tween™ 80 stocks were stored at room temperature. 
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D-arabinose 
D-arabinose was made up as a 100 mg∙mL-1 stock solution in ddH2O and filter sterilised 
through a 0.22 µM nylon syringe filter unit. D-arabinose stocks were stored at 4°C. 
Oleic acid, albumin, dextrose, catalase enrichment (OADC) 
OADC was purchased from Fort Richard Laboratories and was stored at 4 °C 
Glycerol 
Glycerol was made up as a 10% (v/v) stock and sterilised by autoclaving at 121 °C for 30 
minutes. Glycerol stocks were stored at 4 °C. 
Antibiotics 
All antibiotics used to select for or maintain plasmids/transposons were made up in ddH2O 
and filter sterilised through a 0.22 µM nylon syringe filter before storage at -20 °C, with the 
exception of hygromycin B, which was purchased as a 52.5 mg∙mL-1 aqueous solution and 
stored at 4 °C. Antibiotic concentrations used for different bacterial strains are listed in Table 
2.3. 
Table 2.3: Antibiotic concentrations used for marker selection.  
 Strain 
Antibiotic E. coli 
M. smegmatis 
Tn611 Mutants Other 
Ampicillin (Amp) 200 µg∙mL-1 n/a n/a 
Apramycin (Apr) 50 µg∙mL-1 25 µg∙mL-1 25 µg∙mL-1 
Hygromycin B (Hyg) 200 µg∙mL-1 20 µg∙mL-1 50 µg∙mL-1 
Kanamycin (Kan) 50 µg∙mL-1 20 µg∙mL-1 50 µg∙mL-1 
 
2.5.2. E. coli growth conditions 
Escherichia coli (E. coli) was routinely grown in LB or on LA (section 2.5) at 37 °C. Liquid 
cultures were aerated with shaking at 200 rpm unless otherwise stated. All E. coli strains 
generated were stored as freezer stocks in 20% glycerol (v/v) at -80 °C. Cultures of E. coli 
were prepared from freezer stocks by streaking out an inoculating loop of cells from the 
frozen stock onto appropriately supplemented LA plates. Plates were incubated overnight, 
with single colonies used to inoculate 5 mL of LB broth the next day. These 5 mL starter 
cultures were grown for a further 24 hours before being diluted 100-fold in fresh LB medium 
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and grown for a further 24 hours. These cultures were used for generating chemically 
competent E. coli, or for plasmid preparation. 
 
2.5.3. Mycobacteria growth conditions 
2.5.3.1. M. smegmatis mc2155 
M. smegmatis mc2155 was routinely grown in LB broth or on LA (section 2.5) at 37 °C. Liquid 
cultures were aerated with shaking at 200 rpm unless otherwise stated. Tn611 transposon 
mutants of M. smegmatis mc2155 were grown at 41 °C with shaking at 150 rpm. Liquid 
cultures of M. smegmatis mc2155 were supplemented with 0.05% (v/v) Tween™ 80 and 
100 µg∙mL-1 D-arabinose (section 2.5.1) to minimise cell clumping (Allen, 1998; Anton et al., 
1996). All M. smegmatis strains generated, except the transposon mutant collection, were 
stored as freezer stocks in 20% glycerol (v/v) at -80 °C. The description of storage of the 
transposon mutant collection is described in section 2.7. Cultures of M. smegmatis mc2155 
were prepared from freezer stocks by streaking out an inoculating loop of cells from the 
frozen stock onto appropriately supplemented LA plates. Plates were incubated for 3 – 5 
days until colonies appeared. An individual colony was inoculated into 1 mL of appropriately 
supplemented LB broth and grown for 72 hours. The 1 mL starter cultures were then diluted 
100-fold in fresh LB broth and grown for a further 24 hours. These cultures of M. smegmatis 
mc2155 were used for the generation of electrocompetant cells, or in assays. 
 
2.5.3.2. M. tuberculosis H37Rv 
Growth and assaying of M. tuberculosis H37Rv was performed at University College Dublin, in 
Dublin Ireland, in the physical containment 3 (PC3) laboratory of Professor Stephen Gordon. 
M. tuberculosis H37Rv was routinely grown in 7H9 broth at 37 °C, with liquid cultures aerated 
with shaking at 200 rpm unless otherwise stated. M. tuberculosis H37Rv stocks were 
maintained by continuous culture in roller bottles as described by Bacon and Hatch (2009). 
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2.6. Molecular biology 
2.6.1. DNA isolation and purification 
2.6.1.1. CTAB genomic DNA isolation 
Genomic DNA (gDNA) was isolated from bacterial strains using cetyltrimethylammonium 
bromide (CTAB) as described by Bull et al. (2000). Briefly, 10 mL overnight liquid cultures of 
M. smegmatis mc2155 (section 2.5.3.1) were spun down at 2700 xg for 20 minutes to pellet 
cells, then re-suspended in 400 µL of 1x TE buffer (Appendix section 8.1) and transferred to 
1.5 mL micro-centrifuge tubes. Cells were heat killed for 20 minutes at 80 °C in a heat block, 
then left in a rack to cool to room temperature. Cells were then incubated at 37 °C for one 
hour with 0.5 mg lysozyme. To the cells 0.15 volumes of 10% SDS (w/v) and 0.01 volumes of 
10 mg∙mL-1 proteinase K (Appendix section 8.1) were added before being briefly vortexed 
then incubated at 65 °C for 10 minutes. Following this, 0.2 volumes of 5 M NaCl and 0.2 
volumes of a prewarmed (65 °C) CTAB/NaCl (Appendix section 8.1) solution were added. The 
cells were vortexed until the solution turned white. The cells were then incubated at 65 °C 
for 10 minutes. To purify the DNA, 1 volume chloroform was added to the cells followed by 
brief vortexing then spinning in a micro centrifuge for 8 minutes at 12,000 xg. The aqueous 
phase was removed and 0.6 volumes of isopropanol was added before a further spin for 15 
minutes at 12,000 xg. The supernatant was removed and the DNA pellet washed with 1 mL 
cold 70% (v/v) ethanol before a final spin for 5 minutes at 12,000 xg. The ethanol was 
removed and the pellet left to air dry before suspension of the DNA in 50 µL ddH2O and 
storage at -20 °C. 
 
2.6.1.2. Plasmid mini-preparation 
Small scale extraction of plasmid DNA from bacterial cells was performed using either the 
Zymo Research Zyppy™ Plasmid Mini-Prep kit or the Qiagen QIAprep Spin Miniprep kit 
according to the relevant manufacturer’s instructions. Plasmid DNA was extracted from 3 – 5 
mL of an overnight culture of E. coli (section 2.5.2), eluted in 50 µL ddH2O and stored 
at -20 °C. 
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2.6.1.3. Plasmid midi-preparation 
Medium scale extraction of plasmid DNA from bacterial cells was performed using the 
Invitrogen™ PureLink™ HighPure Plasmid DNA Midi-Prep kit according to the manufacturer’s 
instructions. Plasmid DNA was extracted from 50 – 100 mL of an overnight culture of E. coli 
(section 2.5.2), eluted in 50 µL ddH2O and stored at -20 °C. 
 
2.6.1.4. Agarose gel electrophoresis 
DNA samples were run on 1% agarose (w/v) gels in 1x Tris acetate-EDTA (TAE) buffer 
(Appendix section 8.1). Samples were run with 1x DNA loading buffer and alongside the 
HyperLadder™ 1 Kb DNA ladder. Samples were electrophoresed using constant voltage at 
120 V for 25 – 40 minutes until suitable band separation was achieved. 
 
2.6.1.5. Agarose gel DNA extraction 
DNA bands were extracted from agarose gels following electrophoresis using the 
Zymoclean™ Gel DNA Recovery Kit (Zymo Research) according to the manufacturer’s 
instructions. DNA was eluted in 12 µL ddH2O and stored at -20 °C. 
 
2.6.1.6. DNA purification 
DNA in solution was purified using the DNA Clean & Concentrator™-5 kit (Zymo Research) 
according to the manufacturer’s instructions. DNA was eluted in 12µL ddH2O and stored 
at -20 °C. 
 
2.6.1.7. DNA quantification 
DNA was quantified using a NanoDrop® ND-100 Spectrophotometer (NanoDrop 
Technologies, Auckland, NZ) and the NanoDrop® 3.1.0 software using the DNA setting. A 
1 µL aliquot of ddH2O was used to initialise the NanoDrop®. A 1 µL aliquot of ddH2O was 
used to generate a blank reading before DNA concentrations were read at 230 nm using 1 µL 
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of sample. The ratio of the reading at 260 nm and 280 nm was recorded to assess sample 
purity. 
 
2.6.2. DNA sequencing 
DNA sequencing was performed by Macrogen Inc. (South Korea), using their standard 
sequencing service. A minimum of 200 ng PCR or plasmid DNA was sent for sequencing in a 
minimum volume of 10 µL. Primers were sent at 10 µM concentrations or synthesised by 
Macrogen Inc. using their primer synthesis service. 
 
2.6.3. Genetic manipulations 
2.6.3.1. Primers 
Primers were designed using the Geneious 5.5.6 bioinformatics software and ordered from 
IDT. Primers were designed to include 15-25 nucleotides of the ends of the DNA sequence to 
be amplified, a restriction site if applicable, and a 5’ CTAG motif. Primers were reconstituted 
in ddH2O to a concentration of 100 µM and working stocks of 10 µM were made up in ddH2O 
and stored at -20 °C. Primers used in this study are listed in Table 2.4. 
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Table 2.4: Primer sequences used in this study.  
Product Primer Name Sequence (5’ - 3’) 
Tm 
(°C) 
GFP 
GFP_RBS_F 
CTAGGGATCCTTTAAGAAGGAGATATACATATGAGT
AAAGGAGAA 
60.8 
GFP_R CTAGGGATCCTTATTATTTGTATAGTTCATCCATGCC 57.6 
pRC20 MCS 
primers 
TetRO_int GCCGACCTCTGCGGTTTGCT 63.2 
GFP_int AAGGACAGGGCCATCGCCAA 62.0 
nudC 
(MSMEI_1904) 
pRC20_1904_F CTAGGGATCCATGAGCGAACACCGCACGTTCGG 68.3 
pRC20_1904_R CTAGGGATCCTCAGTCGAGTGCGGCCCAGGATT 68.7 
MSMEI_1905 
pRC20_1905_F 
CTAGGGATCCATGACTACTGCTTCCAGCGAACTCAT
CATG 
65.7 
pRC20_1905_R CTAGGGATCCTCAGCCGAGCTTGGCCTTGACCT 68.9 
1905_BamHInull
_59mer 
TCAGCCGAGCTTGGCCTTGACCTGCTTGATGGTCGG
GTTGGTCAGCGTGGATCCGTCGG 
75.2 
MSMEI_4267 
pRC20_4267_F CTAGGGATCCATGAAACTCCAGGTCACACA 61.0 
pRC20_4267_R CTAGGGATCCCTATAGATCGAGTGTTAATTTCGCG 61.1 
MSMEI_6092 
pRC20_6092_F CTAGGGATCCGTGACCACAGTGCAT 62.2 
pRC20_6092_R CTAGGGATCCCTAGATGGTGCTGCT 61.5 
inhA 
(MSMEI_3070) 
pRC20_3070_F CTAGGGATCCATGACAGGCCTACTCGAAGG 62.5 
pRC20_3070_R CTAGGGATCCTCACAACAGCTGCGTGCTGG 65.5 
arr 
(MSMEI_1186) 
pRC20_1186_F CTAGGGATCCGTGGCGAATCCGCCG 66.8 
pRC20_1186_R CTAGGGATCCCTAGTCATAGATGACCGCCA 63.0 
MSMEI_3093 
pRC20_3093_F CTAGGGATCCGTGGACACCCGGTCGAT 66.4 
pRC20_3093_R CTAGGGATCCTCACAGTGCGTGCCGG 66.2 
katG 
(MSMEI_6216) 
pRC20_6216_F CTAGGGATCCTTGCCTGAGGATCGCC 61.9 
pRC20_6216_R CTAGGGATCCTCAGGCGACGTCGAA 61.8 
6216_int_F CAACGGCAATCCGGACCCGCAGGCCTCGGC 73.6 
6216_int_R TCCGGATTGCCGTTGGGGCCTTCGGGGTTG 71.7 
ligation-
mediated PCR 
Salpt TCGAGCTCGTGC 47.0 
Salgd TAGCTTATTCCTCAAGGCACGAGC 58.8 
IS6100 primers 
3053 GAACCGCTTCGCTGCCTTG 45.0 
3054 AACCACCATTTCGCAGCAGC 44.0 
OligoF AAGAATTCATCGTTCCGTCCGTCCAATCTCC 62.9 
OligoG GAGCGACAGCCTACCTCTGACT 60.4 
Sequences of primers used to amplify genes, or used for sequencing, along with their melting 
temperatures (Tm). Underlined bases represent restriction endonuclease recognition sites introduced 
into the primer. Bases in bold in primer GFP_RBS_F represent a shine-delgano ribosomal binding site 
sequence introduced into the primer. Italicised bases in sequences salgd and salpt represent 
homologous regions of these two oligonucleotides used to generate a linker during ligation-mediated 
PCR. 
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2.6.3.2. Polymerase chain reaction 
PCR was run using the conditions as listed in Table 2.5. All PCR mixes were prepared 
according to the manufacturer’s instructions. AccuSure™ mix or Phusion® polymerase was 
used for reactions requiring high fidelity such as amplification of genes for downstream 
cloning into expression vectors. AccuSure™ was also used for all touchdown PCR and 
ligation-mediated PCR reactions. Biomix™ Red was used for inverse PCR and the overlap PCR 
of katG. Specific PCR reaction protocols used are listed in Table 2.6 – Table 2.9. All reactions 
used 100 – 200 ng of template; plasmid pll192_hsp60 was used as the template for GFP 
amplification; M. smegmatis mc2155 gDNA (section 2.6.1.1) was used as the template for 
amplification of M. smegmatis genes; the left and right amplified fragments of katG were 
used as templates for the katG overlap PCR reaction; generation of the template for inverse 
PCR and ligation-mediated PCR are described in detail in sections 2.6.4 and 2.6.5 
respectively. 
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Table 2.5: PCR conditions for product amplification.  
Product Primer pair Protocol Enzyme 
Annealing 
Temp. (°C) a 
Extension 
time 
(minutes) 
GFP GFP_RBS_F/GFP_R Touchdown AccuSure™ 68(-1)/55 1:30 
nudC 
(MSMEI_1904) 
pRC20_1904_F/ 
pRC20_1904_R 
Touchdown AccuSure™ 72(-1)/62 2:10 
MSMEI_1905 
(removing 
BamHI site) 
pRC20_1905_F/ 
1905_BamHInull_59mer 
Two-step AccuSure™ n/a 0:40 
MSMEI_1905 
pRC20_1905_F/ 
pRC20_1905_R 
Touchdown AccuSure™ 71(-1)/59 0:40 
MSMEI_4267 
pRC20_4267_F/ 
pRC20_4267_R 
Touchdown AccuSure™ 68(-1)/57 2:10 
MSMEI_6092 
pRC20_6092_F/ 
pRC20_6092_R 
Touchdown AccuSure™ 68(-1)/58 2:00 
inhA 
(MSMEI_3070) 
pRC20_3070_F/ 
pRC20_3070_R 
Touchdown AccuSure™ 68(-1)/57 2:10 
arr 
(MSMEI_1186) 
pRC20_1186_F/ 
pRC20_1186_R 
Two-step Phusion® n/a 0:15 
MSMEI_3093 
pRC20_3093_F/ 
pRC20_3093_R 
Two-step Phusion® n/a 0:25 
katG left 
fragment 
(MSMEI_6216) 
pRC20_6216_F/ 
6216_int_R 
Two-step Phusion® n/a 0:12 
katG right 
fragment 
(MSMEI_6216) 
6216_int_F/ 
pRC20_6216_R 
Two-step Phusion® n/a 0:23 
katG 
(MSMEI_6216) 
pRC20_6216_F/ 
pRC20_6216_R 
Overlap Biomix™ Red See Table 2.9 
Inverse PCR 3053/3054 Three-step Biomix™ Red 44 2:00 
Ligation-
mediated PCR 
salgd/OligoF or OligoG Three-step AccuSure™ 55 2:20 
a Times for touchdown PCR reactions are in the format: phase I annealing temperature (temperature 
change per step) / phase II annealing temperature. 
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Two-step PCR 
A two-step PCR protocol was used when the Tm of one or both primers in a primer pair was 
higher than 70 °C when using Phusion® polymerase, or 72 °C when using any other DNA 
polymerase. 
Table 2.6: Two-step PCR thermal cycle. 
Step Temperature (°C) a Time (min) a No. of cycles 
Initial Denature 98 / 95 2:00 / 7:00 1 
Denaturation 98 / 95 0:30 
30 
Extension 68 / 72 0:30 / 1:30 Kb-1 
Final Extension 68 / 72 10:00 1 
a Denaturation temperature and time, and extension temperature and time were dependant on the 
polymerase used (Phusion® / AccuSure™). 
 
Three-step PCR 
A three-step PCR was used when the average Tm of a primer pair was below 65°C and the Tm 
of the primers were within 2°C of each other. 
Table 2.7: Three-step PCR thermal cycle. 
Step Temperature (°C) a Time (min) a No. of cycles 
Initial Denature 95 2:00 / 7:00 1 
Denaturation 95 0:30 
30 Annealing See Table 2.5 0:30 
Extension 72 0:30 / 1:30 Kb-1 
Final Extension 72 10:00 1 
a Denaturation and extension time were dependant on the polymerase mix used (Biomix™ Red / 
AccuSure™). 
 
Touchdown PCR 
A Touchdown PCR was used to amplify targets when the average Tm of a primer pair was 
greater than 65 °C and less than 72 °C and/or when the temperature difference within a 
primer pair was more than 2 °C. All touchdown PCR reactions were performed with 
AccuSure™. 
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Table 2.8: Touchdown PCR thermal cycle.
Phase Step Temperature (°C) a Time (min) a No. of cycles 
 Initial Denature 95 7:00 1 
Phase I 
Denaturation 95 0:30 
8-15 cycles 
Touchdown 
Annealing 
(-1 °C/cycle) 
See Table 2.5 0:30 
Extension 72 1:30 Kb-1 
Phase II 
Denaturation 95 0:30 
25 cycles Annealing See Table 2.5 0:30 
Extension 72 1:30 Kb-1 
 Final Extension 72 10:00 1 
a The number of cycles performed during phase I was equal to the number required to get from the 
phase I annealing temperature to the phase II annealing temperature using 1 °C increments per 
cycle. 
 
Overlap PCR 
Overlap PCR was used to remove the BamHI restriction site from the katG gene 
MSMEI_6216. Phase I used 1x Biomix™ Red, equimolar katG left and right fragments as the 
template (70 nM each), and ddH2O to bring the reaction volume to 25 µL. The katG left and 
right fragments were amplified using the protocols described in Table 2.5, and cleaned and 
concentrated as described in section 2.6.1.6, before use in the overlap PCR reaction. The 
primers listed in Table 2.5 were added prior to starting phase II, in a volume equal to that of 
the reaction in phase I, containing  1x Biomix™ Red and sufficient ddH2O to bring the final 
reaction volume to 50 µL. 
Table 2.9: Overlap PCR thermal cycle. 
Phase Step Temperature (°C) Time (min) No. of cycles 
 Initial Denature 95 2:00 1 
Phase I 
Denaturation 95 0:30 
15 cycles Annealing 39 0:30 
Extension 72 1:00 
95 °C hold to add reagents for phase II 
Phase II 
Denaturation 95 0:30 
25 cycles Annealing 0:30 0:30 
Extension 72 1:30 
 Final Extension 72 10:00 1 
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2.6.3.3. Restriction endonuclease digestions  
Restriction endonuclease reactions were run according to the manufacturer’s instructions 
with the supplied buffers unless otherwise specified. Restriction endonuclease reactions 
were heat inactivated according to the manufactures instructions where specified, and 
cleaned and concentrated as described in section 2.6.1.6. Completed restriction reactions 
were electrophoresed (section 2.6.1.4) alongside undigested control DNA to confirm 
successful digestion. 
2.6.3.4. Blunting of DNA ends 
T4 DNA polymerase was used to blunt the ends of DNA fragments according to the 
manufacturer’s protocol. NEBuffer 2 was used in place of the supplied CutSmart™ buffer. 
Blunting reactions were inactivated with 10 mM ethylenediaminetetraacetic acid (EDTA) at 
75 °C for 20 minutes. 
 
2.6.3.5. DNA phosphatase treatment 
Antarctic phosphatase was used to remove the phosphates from the 5’ ends of DNA 
fragments according to the manufacturer’s protocol. 
 
2.6.3.6. DNA ligations 
T4 DNA ligase was used to ligate DNA fragments together according to the manufacturer’s 
protocol. Ligations were run overnight at room temperature and diluted five-fold prior to 
use in transforming chemically competent cells.  
 
2.6.4. Generation of substrate for inverse PCR 
Inverse PCR was used to identify transposon insertion sites in the genome of M. smegmatis 
mc2155 and was performed as described by Billman-Jacobe et al. (2006). Briefly, gDNA was 
isolated from mutant strains as described in section 2.6.1.1. Digests were performed with 
600 ng gDNA and the restriction enzymes RsaI or EagI in 20 µL reactions according to the 
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manufacturer’s protocol (section 2.6.3.3). The reactions were heat inactivated but not 
cleaned and concentrated. An 18 µL aliquot of the restriction digest was then transferred to 
a ligation reaction setup according to the manufacturer’s instructions (section 2.6.3.6) in a 
total volume of 50 µL. Ligations were incubated overnight at room temperature, and then 
stored at -20 °C. For inverse PCR reactions 8 µL ligation mixture was used in a total reaction 
volume of 25 µL. 
 
2.6.5. Generation of substrate for ligation mediated PCR 
Ligation-mediated PCR was used to identify insertion sites in the genome of M. smegmatis 
mc2155 and was performed essentially as described by Prod’hom et al. (1998). Briefly, the 
linker was made by annealing the oligonucleotides salgd and salpt (Table 2.4) in equimolar 
(25 µM) concentrations in 1x Phusion® high-fidelity PCR buffer in a 200 µL PCR tube. The 
mixture was heated to 80 °C in a thermal cycler and cooled to 4 °C over one hour. Digests 
were performed with 250 ng gDNA isolated from mutants as describe in section 2.6.1.1 using 
the restriction enzyme SalI in 20 µL reactions according to the manufacturer’s instructions 
(section 2.6.3.3). Digest reactions were heat inactivated but not cleaned and concentrated. 
The linker was ligated to the SalI digested gDNA (section 2.6.3.6) according to the 
manufacturer’s instructions for one hour at 16 °C. Ligation reactions were performed in 10 
µL volumes containing 5 µL of the digest reaction mixture and 25 pmol linker. Ligations were 
heat inactivated at 65 °C for 10 minutes then re-digested with SalI in a 15 µL reaction 
according to the manufacturer’s instructions. Digestion reactions were heat inactivated but 
not cleaned and concentrated, and diluted 10-fold in ddH2O. A 5 µL aliquot of the diluted 
restriction digest mixture was used as template in the ligation-mediated PCR (section 
2.6.3.2) in a total reaction volume of 50 µL. 
 
2.6.6. Transformation of E. coli DH5α 
2.6.6.1. Generation of chemically competent E. coli cells 
Generation of chemically competent E. coli DH5α cells was performed as described by 
Sambrook & Russell (2001) with the following alterations. Cells were re-suspended in twice 
35 
 
the volume of 0.1 M CaCl2, 14% (v/v) glycerol than stated, and frozen in 100 µL aliquots 
at -80 °C. 
 
2.6.6.2. Heat shock transformation of E. coli cells 
Chemically competent E. coli DH5α were transformed by heat shocked as described by 
Sambrook & Russell (2001). Briefly, aliquots of cells stored at -80 °C were thawed on ice for 
20 minutes following the addition of up to 10 µL of the DNA to be transformed. A sample of 
E. coli was also transformed with 10 µL ddH2O to act as a negative control. Cells were 
heat-shocked in a heat block at 42 °C for 90 seconds, and then chilled on ice for five minutes. 
Following heat-shock 900 µL LB was added to the cells before recovery for 1 hour at 37 °C 
before plating on LA supplemented with the appropriate antibiotics (section 2.5.1). 
 
2.6.7. Transformation of M. smegmatis mc2155 
2.6.7.1. Generation of electrocompetant M. smegmatis cells 
Generation of electroporation competent M. smegmatis mc2155 cells was performed as 
described by Goude and Parish (2009). Cells were frozen in 200 µL aliquots at -80 °C.  
 
2.6.7.2. Electroporation of M. smegmatis cells 
Electrocompetant cells of M. smegmatis mc2155 were transformed by electroporation as 
described by Goude and Parish (2009). Briefly, 200 µL 10% glycerol (v/v) cooled to -20 °C was 
added to 200 µL of frozen cells which were thawed on ice for 1.5 hours in 2 mm gap 
electroporation cuvettes. A maximum of 5 μL of the plasmid to be transformed was added 
before electroporation, which was performed at 2500 V, 25 µF, and 1000 Ω. Cells were then 
added to 600 µL LB in 1.5 mL micro-centrifuge tubes and recovered for two hours at 37 °C 
before plating on LA supplemented with the appropriate antibiotics (section 2.5.1). 
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2.6.8. Construction of strain MRC10 
The plasmid pRC10 was constructed by removing the nitrile inducible operon from plasmid 
pNIT-1 as depicted in Figure 2.2. A digest was setup with 1 µg of plasmid pNIT-1 and the 
restriction enzymes XbaI and NotI according to the manufacturer’s instructions (section 
2.6.3.3). Both single XbaI and NotI digestion reactions, as well as a double XbaI/NotI reaction 
were performed. The 4.8 Kb band in the XbaI/NotI double digestion reaction, which was the 
backbone of the pNIT-1 plasmid, was gel extracted (section 2.6.1.5). To blunt the ends of the 
DNA fragment, 250 ng of the pNIT-1 plasmid backbone was treated with T4 DNA polymerase 
(section 2.6.3.4). The blunted pNIT-1 plasmid backbone was then ligated with T4 DNA ligase 
(section 2.6.3.6) under dilute conditions (0.5 ng∙mL-1 DNA) to promote circularisation. 
Ligation products were transformed into E. coli DH5α (section 2.6.6.2), and selected on LA 
with 50 µg∙mL-1 kanamycin. Several individual transformants were grown up overnight and 
plasmid mini-prepped (section 2.6.1.2). These plasmids were digested with SpeI (section 
2.6.3.3), which cuts the pNIT-1 backbone once, to check the size of the plasmid. This plasmid 
was called pRC10, and was transformed into M. smegmatis mc2155 (section 2.6.7.2) to 
generate strain MRC10. 
 
Figure 2.1: Digestion of pNIT-1 and plasmid maps.  (A) Single and double restriction endonuclease 
digestions of plasmid pNIT-1. Single digests with NotI and XbaI resulted in a 6.2 Kb fragment. The 
double digest resulted in a 4.8 and 1.4 Kb fragment (pNIT-1 plasmid backbone and nitrile inducible 
operon respectively). Plasmid maps of (B) pNIT-1 and (C)  pRC10 with relevant features shown: OriE, 
E. coli pUC origin of replication; OriM, mycobacterial pAL5000 origin of replication; aph, kanamycin 
resistance gene; NIT operon, nitrile inducible operon. 
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2.6.9. Construction of plasmid pRC20 
Plasmid pRC20 was constructed to enable tetracycline inducible gene expression in 
M. smegmatis mc2155, with semi-quantitative measurement of gene expression provided by 
a green fluorescent protein (GFP) reporter gene. The plasmid pRC20 was constructed by 
removing the luciferase genes (luxAB) from the plasmid pKW08_Lx, and replacing it with the 
GFP gene as depicted in Figure 2.2. A digest was performed with 3 µg of plasmid pKW08_Lx 
and the restriction enzymes BamHI and HindIII according to the manufacturer’s instructions 
(section 2.6.3.3). Both single BamHI and HindIII digestions, as well as a double BamHI/HindIII 
digestion were performed. The 5.9 Kb band that corresponded to the pKW08_Lx plasmid 
backbone was gel extracted (section 2.6.1.5). The GFP gene was amplified by PCR from 
plasmid pLL192_hsp60 as described in section 2.6.3.2, and digested with BamHI as described 
in section 2.6.3.3. The GFP PCR product was cleaned and concentrated as described in 
section 2.6.1.6. GFP was ligated into the backbone of plasmid pKW08_Lx as described in 
section 2.6.3.6 using a 3:1 insert to vector molar ratio. Ligations were transformed into E. 
coli DH5α (section 2.6.6.2), and selected on LA with 50 µg∙mL-1 hygromycin B. Several 
individual transformants were grown up overnight and plasmid midi-prepped (section 
2.6.1.3). These plasmids were digested with BamHI (section 2.6.3.3), which cuts the 
pKW08_Lx backbone once, to check the size of the plasmid. This plasmid was called pRC20 
and was further verified by sequencing with the primer TetRO_int (Table 2.4) which targets 
the multiple cloning site, and reads into the downstream GFP gene. 
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Figure 2.2: Generation of pKW08 derivative pRC20. (A) Single and double restriction endonuclease 
digestions of plasmid pKW08_Lx were performed. Single digests with HindIII and BamHI resulted in 
an 8.0 Kb fragment. A double digest resulted in 5.9 and 2.1 Kb fragments (pKW08_Lx plasmid 
backbone and luxAB genes respectively). The GFP gene was also digested with BamHI/HindIII. 
Plasmid map of (B) pKW08_Lx and (C) pRC20 with relevant features shown: OriE, E. coli pUC origin of 
replication; OriM, mycobacterial pAL5000 origin of replication; hygR, hygromycin B resistance gene; 
luxAB, luciferase genes A and B; GFP, green fluorescent protein; TetRO, tetracycline regulon including 
the gene tetR, the operator tetO, and the promoter Ptet. 
 
2.6.9.1. Construction of pRC20 gene insert vectors 
Genes were cloned into pRC20 to generate the expression vectors for the complementation 
and overexpression assays. Gene inserts were amplified by PCR as described in section 
2.6.3.2, and were digested along with plasmid pRC20 with BamHI as described in section 
2.6.3.3. To decrease self-ligation of the plasmid backbone, pRC20 was treated with Antarctic 
phosphatase as described in section 2.6.3.5. Gene inserts were then ligated into the pRC20 
backbone using T4 DNA ligase as described in section 2.6.3.6, using a 3:1 insert to vector 
molar ratio. Ligations were transformed into E. coli DH5α (section 2.6.6.2), and selected on 
LA with 50 µg∙mL-1 hygromycin B. Several transformants were selected and grown up in 
overnight cultures as described in section 2.5.2, with the cultures used for plasmid 
mini-preparation the next day (section 2.6.1.2). These isolated plasmids were sent for 
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sequencing using the primer TetRO_int to confirm gene insert orientation, and sequence 
fidelity. Correct plasmid constructs were transformed into the relevant strains as described 
in section 2.6.7.2. 
 
2.6.10. Random transposon mutagenesis of M. smegmatis mc2155 
Random transposon mutants of M. smegmatis mc2155 were generated using the pCG79 
plasmid as described by Guilhot et al. (1994). Briefly, electrocompetent M. smegmatis 
mc2155 cells were transformed with plasmid pCG79 which harbours the Tn611 transposon 
(Figure 3.1) and selected on LA supplemented with 20 µg∙mL-1 kanamycin at 30 °C for 4 - 5 
days. Several successful transformants were colony purified by re-streaking on fresh LA and 
left for another 4 – 5 days at 30 °C. Cells were scraped off the plates and re-suspended in 
supplemented LB (section 2.5) containing 14% glycerol (v/v). Dilutions of 1x10-2 - 1x10-6 of 
the cell suspensions were frozen down at -80 °C. Aliquots of the dilutions were plated in 
duplicate on fresh LA plates, and incubated at 41 °C to determine the optimal dilution for 
obtaining individual transposon mutants (approximately 100-200 colonies per plate). Further 
mutants were then generated by plating the optimal dilution on supplemented LA plates 
with incubation at 41 °C for 3 – 5 days. 
 
2.7. Transposon mutant collection construction 
The transposon mutant collection was generated as a mother stock that was sub inoculated 
to generate the daughter stock. The daughter stock was used for screening purposes. The 
mother stock was reserved as a backup for regenerating plates from the daughter stock if a 
plate was damaged, lost, or contaminated, etc.  
 
2.7.1. Generation of mother stock 
Each plate of the transposon mutant collection contained both random transposon mutants 
and a control strain MRC10 (section 2.6.8) as depicted in Figure 2.3. The control strain 
MRC10 was built into the library to provide a standard against which the other mutants on 
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the plate could be compared, enabling comparison of different mutants across separate 
plates of the collection, and between different conditions. MRC10 was used as the control as 
it met the minimum standards for growing under assay conditions (kanamycin resistant). 
Random transposon mutants of M. smegmatis mc2155 were generated as described in 
section 2.6.9.1, and transferred to individual wells of 384-well plates containing 50 µL of 
supplemented LB (section 2.5) using sterile toothpicks. A 50 µL aliquot of a mid-log phase 
culture of the control strain MRC10 was added to each of the control wells, and 50 µL ddH2O 
was added to the outside wells. Plates were wrapped in plastic cling film to prevent 
evaporation, and incubated at 41 °C with shaking at 150 rpm for 48 hours prior to the 
addition of 35 µL of 80% (v/v) glycerol to each well. Plates were sealed with AlumaSeal® CS 
aluminium plate seals (Sigma-Aldrich) before brief vortexing, and storage at -80 °C. This 
process was repeated for 32 separate 384-well plates to generate the mother stock of the 
complete transposon mutant collection of 7680 mutants. The plates of the mother stock 
were numbered M01 - M32. 
 
 Figure 2.3: Layout of transposon mutant collection plates. Each plate of the collection contained 
240 individual transposon mutants with each well inoculated with a separate mutant strain. The 
control strain MRC10 was added to the second outermost ring of wells. 
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2.7.2. Generation of daughter stock 
The daughter stock was generated before the addition of glycerol and freezing down of the 
mother plates for the first time. Plates of the daughter stock were generated by sub 
inoculating from the mother stock plates to fresh 384-well plates setup as descried in section 
2.7.1. Sub inoculation was performed by pinning with 384-pin long pin RePads® (Singer). 
RePads® were processed after each use as described in appendix section 1. Plates were 
wrapped in plastic cling film and incubated at 41 °C with shaking at 150 rpm for 48 hours 
before the addition of glycerol and freezing as in section 2.7.1. This process was repeated to 
generate a daughter plate for each mother plate of the transposon mutant collection. Plates 
of the daughter stock were labelled D01 – D32 with the numbers corresponding to the plates 
in the mother stock. 
 
2.7.3. Generation of mini-hit libraries 
The transposon mutant collection was assayed for drug hypersensitivity, as described in 
section 2.8.1, with the most sensitive mutants from the primary assay transferred to smaller 
mini-hit libraries. The 120 most sensitive mutants for each drug identified in the primary 
assay for drug hypersensitivity were picked into mini-hit libraries in the layout described in 
Figure 2.4. Three mini-hit libraries were constructed, one for isoniazid, one for rifampicin, 
and one for bedaquiline. The mini-hit libraries consisted of two 96-well plates, each with 60 
transposon mutants corresponding to the 60 most sensitive mutants identified from the 
transposon mutant libraries A and B respectively. The mini-hit libraries plates contained 
100 µL supplemented LB (section 2.5) in the inner 60 wells, and 100 µL ddH2O in the 
outermost wells. The 120 most sensitive mutants were picked into individual wells of the 
mini-hit libraries using sterile toothpicks. Mutants were transferred into the mini-hit library 
in the order that they appeared in the complete transposon mutant collection. Following 
strain sub-inoculation from the transposon mutant collection, plates were grown at 41 °C 
with shaking at 150 rpm for 48 hours. To each well of the mini-hit libraries 70 µL 80% 
glycerol (v/v) was added, the plates were sealed with AlumaSeal® CS plate seals and briefly 
vortexed before storage at  -80 °C. 
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Figure 2.4: Layout of mini-hit library plates. Each plate of the mini-hit library contained 60 
transposon mutants in the internal wells. 
 
2.8. Growth-inhibition assays 
2.8.1. Assay for Drug hypersensitivity 
The transposon mutant collection was assayed for drug hypersensitivity using a primary 
high-throughput assay that utilised resazurin reduction as a surrogate measure of 
growth-inhibition. A secondary assay was run on the most sensitive mutants identified in the 
primary assay to validate their sensitivity. The secondary assay used endpoint optical density 
at 600 nm (OD600) to determine growth-inhibition. All assays using transposon mutants were 
assayed at 41 °C in order to maintain the transposon insertion while under the potential 
selective pressure caused by drug treatment. 
 
2.8.1.1. Primary assay for drug hypersensitivity 
For the primary assay for drug hypersensitivity the transposon mutant collection was split 
into two halves (Library A and Library B) with 16 plates per library. These libraries were 
assayed separately and their results processed independently. 
The plates of a mutant library were sub-inoculated from the frozen daughter stock by 
pinning into fresh 384-plates setup as in section 2.7.1. Plates were wrapped in cling film and 
incubated at 41 °C with shaking at 150 rpm for 72 hours. Plates were then sub-inoculated 
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into fresh 384-well plates setup identically, and incubated for a further 24 hours. Plates were 
then used to sub-inoculate 384-well plates setup to assay for drug sensitivity as described in 
Figure 2.5, using the screening concentration of drug which was determined as described in 
section 3.2.3.1. 
 
Figure 2.5: Plate setup for primary assays for drug hypersensitivity. The outermost wells were split 
into two halves, the media alone and treatment media controls. The MRC10 controls were also split 
into two, the untreated MRC10 controls and the treated MRC10 controls. The media alone and 
untreated MRC10 controls received no drug treatment in all assays, while the treatment media and 
treated MRC10 controls received the same treatment as the transposon mutants. 
Assay plates were wrapped in cling film then incubated for 48 hours at 41 °C with shaking at 
150 rpm. To each well 0.4 volumes of 0.03% resazurin sodium salt (w/v) (appendix section 
8.1) was then added. Plates were left for a further two hours at 41 °C without shaking, 
before reading the fluorescence of the wells of each plate using a PerkinElmer EnSpire®, 
2300 multilable reader. Fluorescence measurements were performed at an excitation 
wavelength of 530 nm and an emission wavelength of 590 nm. The primary assay for drug 
hypersensitivity was run three independent times for each drug and for media alone. 
Processing of the resulting data is described in section 3.2.3. 
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2.8.1.2. Secondary assay for drug-hypersensitivity 
The mini-hit libraries constructed as described in section 2.7.3 were assayed for drug 
hypersensitivity using the secondary assay. The same drug concentration was used in the 
secondary assay as was used in the primary assay (section 3.2.3.1). 
The frozen mini-hit library stocks were used to sub-inoculate new 96-well plates setup as 
described in section 2.7.3. Sub-inoculation of the mini-hit libraries was performed using a 
metal 96-pin metal pinning tool, which was processed after each pinning as described in 
appendix section 1. Plates were wrapped in cling film and incubated at 41 °C for 48 hours, 
before pinning into fresh 96-well plates setup as described in section 2.7.3, and incubated 
for a further 24 hours. Assay plates were setup containing either 100 µL media, or 100 µL 
treatment containing the drug at the screening concentration, in every well of a 96-well 
plate as described in Figure 2.6.  
 
Figure 2.6: Plate setup for secondary assays for drug hypersensitivity. The outermost wells 
contained media alone (treated or untreated), while the inner 60 wells contained the transposon 
mutants and media (treated or untreated). 
The media alone and media with drug assay plates were run in parallel, sub-inoculated form 
the same overnight mini-hit library plate. Additionally, two of each media alone and 
treatment assay plate were run at the same time to serve as biological duplicates. The assay 
plates were inoculated from the overnight mini-hit library plate using the 96-pin tool before 
incubation at 41 °C for 48 hours. At the assay endpoint the OD600 of each well of the assay 
plates was read using the PerkinElmer EnSpire®, 2300 multilable reader. Multiple readings 
were taken for each well using the three-by-three circular pattern function in the 
plate-reader software, reading 21 individual points per well, and outputting the average 
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OD600 for each well. The experiment was run three independent times for each secondary 
assay. Assay data was processed as described in section 3.2.4. 
 
2.8.2. Isoniazid analogue screen 
Isoniazid analogues were tested for their activity against WT M. smegmatis mc2155. To a 
96-well plate 100 µL of LB was added to all wells. As described in Figure 2.7, 100 µg∙mL-1 of 
each of the 30 analogues as well as an isoniazid control were added to separate wells. A 
further 50 µL media was added to the outermost wells, and 50 µL of a mid-log phase culture 
of M. smegmatis mc2155 diluted to an OD600 of 0.05 was added to each of the 60 internal 
wells.  
 
Figure 2.7: Plate layout for isoniazid analogue screen. The outermost wells contained media alone, 
while the inner 60 wells received M.  smegmatis cells alone, or cells and drug (isoniazid or isoniazid 
analogue). Each of the blue wells on the figure received a separate isoniazid analogue. 
The assay plate was wrapped in plastic cling film and incubated at 37 °C for 48 hours. The 
endpoint OD600 was measured using the PerkinElmer EnSpire®, 2300 multilable reader as 
described in section 2.8.1.2. The OD600 values for each well were normalised by subtracting 
the median OD600 of the media only wells. The growth percentage was calculated for 
M. smegmatis in each of the wells containing isoniazid or an isoniazid analogue compared to 
the median OD600 of the media and cells control wells. 
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2.8.3. Dose-response assay 
Dose-response assays were performed using serially diluted drug to determine drug 
minimum inhibitory concentration (MIC). The MIC was defined as the minimum 
concentration of drug to inhibit growth by more than 90%. Dose-response assays were run in 
96-well plates with the plate setup as shown in Figure 2.8. Each plate was dived into two 
halves (dilutions A and B), with separate drugs run in each half for the basic dose-response 
assays, or the same drug with and without tetracycline for the complementation and 
overexpression assays Each dilution (A or B) provided three technical replicates at each drug 
concentration, one replicate per row. The three technical replicates were setup using the 
same bacterial culture All dose-response assays were setup with mid-log phase cultures at a 
final OD600 of 0.05 for M. smegmatis mc2155 or 0.1 for M. tuberculosis H37Rv.  
 
Figure 2.8: Plate layout for dose-response assays. The outermost wells contained media alone, 
columns 2 – 10 contained two-fold serially diluted drug, and column 11 contained no drug and 
served as the 100% growth control. Cells were added to all 60 internal wells. 
To all internal plate wells except column 2, 50 µL media was added, and 100 µL media added 
to all external wells. To column 2, 100 µL media less the volume of drug to be added was 
aliquoted. The drug was added to column 2 to give a concentration in the column 2 wells at 
twice the final desired concentration. The drug was then serially diluted across the plate left 
to right (column 2 – column 10) transferring 50 µL from column to column with mixing by 
pipetting up and down 10 times. After mixing the final dilution in row 10, 50 µL was drawn 
into the pipette and discarded. To each of the internal 60 wells, 50 µL of cells were then 
added at a concentration twice the desired final concentration (OD600 of 0.05 for 
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M. smegmatis or an OD600 of 0.1 for M. tuberculosis). Plates were wrapped with cling film 
and incubated for 48 hours under the conditions specific for each strain as described in 
section 2.5.3. Endpoint OD600 was measured with the PerkinElmer EnSpire®, 2300 multilable 
reader as described in section 2.8.1.2. The OD600 values were normalised by subtracting the 
median OD600 of the media only wells. The OD600 of each drug dilution triplicate was 
averaged, and compared to the average OD600 of the 100% growth control triplicate to 
calculate the growth-inhibition at each drug concentration. MICs were calculated for each 
separate assay, with experiments repeated three independent times and the mean MIC 
calculated across the separate assays. 
 
2.9. Growth curve assay 
Growth curve assays were performed in 96-well plates, using the plate setup described in 
Figure 2.9. To each of the wells 50 µL supplemented LB (section 2.5) was added, with an 
additional 50 µL added to the outside wells. To the internal 60 wells 50 µL aliquots of an 
overnight culture for each strain (section 2.5.3.1), diluted to an OD600 of 0.05, were added. A 
single culture of each strain was used to setup the assay, with each culture aliquoted into 
multiple wells to provide biological replicates for each strain, enabling an averaging of the 
growth rates.  Plates were wrapped in plastic cling film and incubated at 41 °C with shaking 
at 150 rpm for 72 hours total. Every 24 hours, starting at 0 hours, the OD600 of the wells was 
measured using the PerkinElmer EnSpire®, 2300 multilable reader as described in section 
2.8.1.2. The median OD600 of the on plate biological replicates for each strain were averaged 
for each time point. The assay was run three independent times, with the mean OD600 of 
each strain averaged across the three assays for each time point. 
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Figure 2.9: Growth curve assay plate setup. The outermost wells contained media alone. The inner 
60 wells were divided between the three strains tested, D11, Tn::arr, and Tn::MSMEI_3093. 
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3. Isolation of drug hypersensitive mutants of M. smegmatis mc2155 
3.1. Introduction 
To date, little work has been done on studying drug sensitising mutations for the 
anti-mycobacterial drugs isoniazid, rifampicin, and bedaquiline, with most research instead 
focused on studying resistance inducing mutations and altered transcription upon drug 
exposure. As drug hypersensitivity is a recessive phenotype it cannot be selected for in the 
same manner as resistant mutants, i.e. in a heterogeneous culture, as sensitive mutants will 
fail to grow and be lost. This limitation is overcome by the prior construction of a collection 
of mutants that are then assessed for sensitivity independently. Different methods for the 
generation of mycobacterial mutant collections for phenotypic screening exist, with 
transposon mutagenesis favoured due to the inherent labelling of the site of the mutation by 
the transposon insertion.  
 
3.1.1. Transposon mutagenesis with Tn611 
Tn611 is based on the Tn610 transposon, which has two inverted IS6100 insertion elements 
flanking a sulphonamide resistance gene sul3, replaced with a gene for kanamycin resistance 
(aph) to generate Tn611. Insertion of Tn611 into a vector that contained both a temperature 
sensitive pAL5000 mycobacterial origin of replication and an E. coli origin (pUC) of replication 
generated a plasmid named pCG79 (Figure 3.1). This transposon has been shown to insert 
into the genome of M. smegmatis randomly with no insertional hotspots detected (Billman-
Jacobe et al., 2006; Guilhot et al., 1994); additionally, insertion is a rare event with only one 
insertion per cell being reported (Billman-Jacobe et al., 2006; Guilhot et al., 1994). Insertion 
into the mycobacterial genome occurs by a “copy and paste” mechanism resulting in 
duplication of one of the insertion elements (Martin et al., 1990), although other possible 
insertional methods have been reported such as a “cut and paste” mechanism (Guilhot et 
al., 1994). Insertion of the Tn611 transposon into the genome has been shown to be stable 
in the absence of any selective pressure (Guilhot et al., 1994). However, the stability of the 
insertion under selective pressure is not known. 
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Figure 3.1: Plasmid pCG79 and transposition. Insertion of Tn611 into the target DNA via a replicative 
mechanism results in duplication of one of the two IS6100 elements and insertion of the entire 
pCG79 vector. 
 
3.1.2. Assaying for drug hypersensitivity 
Growth-inhibition is commonly measured to assess the inhibitory effect of different 
conditions in bacteria. A number of techniques are used to measure growth, and therefore 
growth-inhibition, with direct counting of colony forming units (CFUs) being the gold 
standard as it is the most direct observation of cell number. However, OD600 is commonly 
used as a surrogate for CFU measurements as CFU measurements are impractical for higher 
throughput analyses. Recently, resazurin, a blue weakly fluorescent dye,  has been utilised as 
another alternate method to CFUs for measuring the growth of mycobacteria (Palomino and 
Portaels, 1999). Resazurin is reduced to the pink, highly fluorescent product resorufin in the 
presence of NADH, and is used as a measure of oxidative phosphorylation. The dye is 
commonly used as a viability indicator as only living cells will produce the required NADH, 
however, recent work has demonstrated a strong correlation between the reduction of 
resazurin and CFUs for measuring the growth of logarithmic cultures of M. smegmatis 
(Bassett et al., 2013). Measurement of resazurin reduction as an indicator of growth in 
micro-titre plates is much more suitable for high throughput analyses of mycobacteria than 
the more direct measure of growth OD. This is because resazurin, and the reduced resorufin, 
diffuse easily through a liquid medium resulting in a uniform fluorescence and therefore 
instil a requirement of only one measurement per well. In contrast, OD based measurements 
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of mycobacteria in micro-titre plates require multiple readings per well to generate reliable 
measurements of cell growth, owing to the characteristic cell clumping. However, unlike CFU 
and OD based measurements, the fluorescence generated from the reduction of resazurin is 
a relative measure of growth, with longer incubation times resulting in different absolute 
fluorescence values. For the purposes of screening a transposon mutant collection, the 
inclusion of a standard strain that acts as an untreated (100% growth) control in each library 
plate allows standardisation of the growth-inhibition as measured by resazurin reduction, 
enabling the direct comparison between separate library plates. The reduction of resazurin 
is also affected by the metabolic states of the cultures which, similar to other indirect 
measure of cell number, can lead to false positives (Pethe et al., 2010). This limitation can be 
overcome by using a secondary assay to validate the drug hypersensitivity of mutants using 
an endpoint OD measurement. Although using OD results in a lower throughput assay, using 
it as a validation assay for a limited number of the most sensitive mutants from the primary 
assay overcomes this limitation.  
 
3.1.3. Objectives of Chapter Three 
The goal of Chapter Three was to generate drug hypersensitive mutants of M. smegmatis 
mc2155. These mutants were then studied to identify the underlying genetic basis and the 
information used to investigate drug mode of action in Chapters Four and Five of this thesis 
To achieve this goal the following specific aims were addressed: 
 Construction of a random transposon mutant collection in M. smegmatis mc2155 
using Tn611 
 Development of a high-throughput assay for identifying drug hypersensitive mutants 
 Development of a secondary assay to validate mutants identified as drug 
hypersensitive in the primary assay 
Drug hypersensitive mutants were generated in order to identify novel components of the 
mode of action of the front line anti-TB drugs isoniazid, rifampicin, and bedaquiline. A 
collection of M. smegmatis mc2155 transposon mutants were generated in order to assay for 
increased drug hypersensitivity and identify mutant strains of interest.  Sensitivity of these 
mutants was ultimately characterised in terms of MICs. 
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3.2. Methods 
3.2.1. Estimation of unique mutants versus library size 
The expected number of unique mutants in a random transposon mutant collection was 
estimated for a range of collection sizes using the Poisson distribution (Equation 3.1 and 
Equation 3.2), and the following assumptions: 
 The percentage of essential genes in M. smegmatis mc2155 is the same as that 
previously described for M. tuberculosis (Sassetti et al., 2001) 
 The Tn611 transposon inserts into the genome of M. smegmatis in a random manner, 
i.e. lacks insertional hot spots (Guilhot et al., 1994) 
 The probability of the transposon inserting into an open reading frame (ORF) is 
identical for all ORFs regardless of their size 
𝑷(𝒙) =
𝒆−
𝑳
𝑮 . (𝑳/𝑮)
𝒙
 
Equation 3.1: Poisson estimation of the standard distribution. Where L is equal to the total number 
of mutants in the library, and G is equal to the number of genes in the M. smegmatis genome that 
the transposon can insert into.  
𝒎 = 𝑮(𝟏 − 𝒆−
𝑳
𝑮) 
Equation 3.2: Calculation for the estimated number of unique mutants in a library of size L. For a 
given library size (L) and based upon the above assumptions the number of unique mutants is 
estimated to be equal to m. 
 
G was estimated based on the percentage of non-essential genes in M. tuberculosis H37Rv, 
i.e. 86.3% of its genome; G is therefore equal to 86.3% of the 6752 genes in the 
M. smegmatis mc2155 genome or 5827 genes. It was determined that a library size of 
approximately 7680 transposon mutants, which equates to approximately 1.1-fold whole 
genome coverage, would be suitable for screening for drug hypersensitivity. At this library 
size it is expected to contain 4267 unique mutants, interrupting 73.2% of the genes 
predicted to be able to sustain transposon insertions (non-essential genes) (Figure 3.2). In 
order to increase the proportion of genes knocked out, a significant increase in the number 
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of mutants would be required. For example, 20,000 or 60,000 mutants would be required to 
obtain 95% or 100% of genes knocked out, respectively. The aim of this thesis was to identify 
pathways related to drug mode of action, as opposed to a single gene whose product was 
affected by a drug and therefore, it was not critical to have every possible gene knocked out 
within this library. Additionally, the smaller size of the library constructed in this thesis 
facilitates screening in high-throughput. Libraries with 1.1-fold genome coverage have been 
used previously for similar studies (Alexander et al., 2003; Daugherty et al., 2011). 
 
Figure 3.2: Number of unique mutants versus library size. Line graph describing the expected 
number of unique mutants (m) for a given library size (L) estimated using the Poisson distribution. 
Library completeness is the number of expected mutants (m) as a percentage of the number of the 
predicted non-essential genes for M. smegmatis.  Line intersect indicates chosen library size of 7680 
transposon mutants. 
 
3.2.2. Construction of the transposon mutant collection 
A collection of 7680 transposon mutants was built in 32 384-well plates, with 240 individual 
transposon mutants per plate as described in section 2.7. As discussed in the chapter 
introduction, the fluorescence from resazurin reduction generates a relative measure of 
growth-inhibition for that plate. In order to compare the fluorescence values and therefore 
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growth-inhibition of mutants across multiple plates a standard was included in each plate of 
the library. The selected standard was an untreated control strain (MRC10) that would 
represent maximal growth (maximal resazurin reduction) for that plate, against which the 
resazurin reduction of the mutant strains on that plate were standardised. To compare 
growth-inhibition of mutants across separate plates of a library it was essential the 
treatment conditions were the same. To test this, half of the MRC10 control strain wells 
remained untreated, while the other half were treated with the same drug concentration as 
the transposon mutants, with statistical testing being used to check that the treated-MRC10 
control behaved the same across all plates of a library. 
 
3.2.3. Primary assay for drug hypersensitivity 
The assays for identifying drug hypersensitive mutants were performed using drug 
concentrations that gave minor but measureable growth-inhibition, with screening 
concentrations for each drug optimised as described below in section 3.2.3.1. At these 
concentrations mutants that displayed hypersensitivity to a drug could be differentiated 
from the average growth-inhibition levels of the mutant libraries. Drugs were screened 
against the transposon mutant libraries as described in section 2.8.1. For logistical reasons 
the 32 plate transposon mutant collection was split into two smaller 16 plate libraries for the 
purpose of performing the primary assay, Library A and Library B. The data analysis for the 
primary assays against each library were performed independently to prevent any bias 
resulting from different assay conditions. To quantify drug sensitivity, a factor of inhibition 
(FI) was calculated for each mutant strain for each drug. This value is the reciprocal of the 
growth of the strain when treated versus untreated, with higher values representing 
increased inhibition in the assay (Equation 3.4). The output from the primary assay was a list 
of mutants ordered from highest to lowest sensitivity to the drug used.  
To calculate the FI, the relative fluorescence values from the reduction of resazurin were 
normalised by removing the background, giving the relative fluorescence units (RFU) for 
each well of the plate. The in-plate untreated-MRC10 control, which represented maximal 
resazurin reduction (therefore maximal growth), was averaged to give RFUUTMRC10 that was 
55 
 
used to standardise the RFU values of the treated-MRC10 control and mutant strains across 
the rest of the plate using Equation 3.3. 
sRFUmyco = 100 ∙ (
RFUmyco
RFUUTMRC10
) 
Equation 3.3: Calculation of standardised RFU values for transposon mutants. Where RFUmyco is the 
normalised RFU and sRFUmyco is the standardised RFU for a given strain. 
The FI for each mutant strain (and treated-MRC10 control) was calculated according to 
Equation 3.4. An FI value of 1 represented no inhibition while a value greater than 1 
represented an increased inhibition, with the greater the FI value the greater the strain was 
inhibited. 
FI =  
1
(
µtreated
µuntreated
)
 
Equation 3.4: Calculation of FI for mutants.  Where µtreated and µuntreated are the mean sRFUmyco values 
with and without drug treatment respectively. Means were calculated over three independent 
experiments. 
 
The on plate treated-MRC10 control was used to test that all plates for a given condition 
were behaving the same throughout all experimental replicates. The median sRFU values of 
the treated-MRC10 from each plate of a library were pooled and tested for normal 
distribution (D'agostino and Pearson omnibus normality test), with data normalised as 
required using transformations listed in the results sections for each drug. A one-way 
ANOVA was performed to test if there was a significant difference in the average inhibition 
of the treated-MRC10 control strain across all plates of a mutant library before directly 
comparing the growth-inhibition of the mutants to determine the 60 most sensitive. The 60 
most sensitive mutants from each library (Library A and Library B), for each drug, were 
combined into mini-hit libraries as described in section 2.7.3. 
3.2.3.1. Optimising screening concentrations 
Two separate plates from the transposon mutant libraries, selected at random, were grown 
with and without drug to optimise drug screening concentrations. A range of concentrations 
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of drug were used, and these were selected by determining the MIC versus MRC10 as a 
starting reference point, with MICs determined by dose-response assay described in section 
2.8.3. The median FI for each different drug concentration test plate was determined by 
averaging the FI values for all mutants within a given condition. A drug concentration that 
gave a median FI value in the range of 1.18 - 1.42 was selected as the screening 
concentration for that drug. This FI range represents a median inhibition of 15 - 30%.  
 
3.2.4. Secondary assay for drug hypersensitivity 
The secondary assay was run to reduce the number of false positives resulting from the use 
of resazurin reduction as a measure of growth, instead using the more biologically relevant 
measure of growth, OD at 600 nm (OD600) as discussed in the introduction to this chapter. 
The mini-hit libraries comprised of the 60 most sensitive mutants for a give drug from each 
library (120 total), and were expected to capture most if not all the true positive hits from 
the initial screen, while minimising the number of mutants for validation. These mini-hit 
libraries were screened as described in 2.8.1.2. A plate containing only the strain MRC10 was 
also run against each drug for comparison. 
 
3.3. Results 
3.3.1. Drug screening concentration optimisation 
The two frontline anti-TB drugs isoniazid and rifampicin, and the novel anti-mycobacterial 
bedaquiline, were assayed against the transposon mutant libraries to find drug 
hypersensitive mutants. The MIC concentrations for these compounds against the control 
strain MRC10, and the screening concentrations used are listed in Table 3.1. Screening 
concentrations were chosen as described in section 3.2.3.1. Work on bedaquiline was 
performed in collaboration with the laboratory of Professor Gregory Cook at the University 
of Otago. 
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Table 3.1: MIC values for anti-TB drugs versus MRC10 and optimised screening concentrations.   
Drug MICa ± se 
Screening 
concentration 
Isoniazid 6.12 ± 0.56 µM 6.00 µM 
Rifampicin 0.72 ± 0.12 µM 0.26 µM 
Bedaquiline 29.3 ± 7.32 nM 10.8 nM 
aMIC values represent mean values across three independent experiments with standard error (se) 
presented. 
 
3.3.2. Growth of the treated-MRC10 control strain in LB 
The growth of the treated-MRC10 controls were examined for variability between plates 
within each library when grown in media (LB) alone. The sRFU values of the treated-MRC10 
control strain were normally distributed in both libraries, and were examined using a 
one-way ANOVA. No significant difference between the sRFU values of the treated-MRC10 
control strain across the separate plates from the three independent experimental replicates 
was found for either library; therefore, screening for hypersensitive transposon mutants 
proceeded. 
 
3.3.3. Control strains for quantitating drug hypersensitivity 
Ten mutant strains were randomly selected from the mutant libraries to act as control 
strains for the dose-response assays. The MICs of these control strains for isoniazid, 
rifampicin, and bedaquiline were determined (Figure 3.3). The MIC values of the control 
strains used were consistent for each of the drugs tested (Kruskal-Wallis test; significance 
cut off of p < 0.05).  The mean of all 10 control strains was used for the initial dose-response 
assays to quantify drug hypersensitivity.   
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Figure 3.3: Comparison of MIC of random mutant control strains. Average MIC values of 10 random 
control transposon mutant strains versus (A) isoniazid, (B) rifampicin, and (C) bedaquiline. Mutants 
are labelled according to the mutant library plate they were picked from. Column heights represent 
mean MICs across three independent experiments with standard error bars shown. 
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3.3.4. Isoniazid 
3.3.4.1. Primary assay for drug hypersensitivity 
The primary assay for isoniazid hypersensitivity was performed at a concentration of 6 µM 
(Table 3.1). As the sRFU values for the treated-MRC10 controls within each library were 
normally distributed one-way ANOVAs were performed on untransformed data. The 
one-way ANOVAs did not show a significant difference in mean sRFU for the treated-MRC10 
control across all plates within either library (A or B) (p > 0.05), therefore analysis of the 
assay data continued as described in section 3.2.3. 
The median inhibition of mutant library A versus isoniazid was approximately 19% (Figure 
3.4). The 60 most sensitive mutants from library A, representing mutants that were at least 
1.9 times more sensitive to isoniazid than the library median, were picked into the isoniazid 
mini-hit library.  
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Figure 3.4: Mutant library A versus 6 µM isoniazid. (A) Frequency distribution of FI values, and (B) FI 
linear profile, from library A versus 6 µM isoniazid. The median FI across mutant library A was 1.21, 
and the median FI for the treated-MRC10 control was 1.26. The dotted line indicates the cut-off for 
the 60 most sensitive mutants, and lies at FI = 2.30. The FI value for each mutant represents the mean 
FI across three independent experiments. 
 
The median inhibition of mutant library B versus isoniazid was approximately 13% (Figure 
3.5). The 60 most sensitive mutants from library B, representing mutants that were at least 
2.0 times more sensitive to isoniazid than the library median, were picked into the isoniazid 
mini-hit library. 
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Figure 3.5: Mutant library B versus 6 µM isoniazid. (A) Frequency distribution of FI values, and (B) FI 
linear profile, from library B versus 6 µM isoniazid. The median FI across mutant library B was 1.15, 
and the median FI for the treated-MRC10 control was 1.19. The dotted line indicates the cut-off for 
the 60 most sensitive mutants, and lies at FI = 2.29. The FI value for each mutant represents the mean 
FI across three independent experiments. 
 
3.3.4.2. Secondary assay for drug hypersensitivity 
A secondary assay was performed in order to validate the hypersensitivity to isoniazid of the 
120 most sensitive mutants (60 from each library) identified in the primary assay. Each 
hypersensitive mutant was tested against the screening concentration of isoniazid (Table 
3.1) and growth-inhibition was determined by endpoint OD600 measurement as described in 
section 3.2.4. The concentration of isoniazid used in the secondary assay was the same as 
that used in the primary assay (6 µM). Table 3.2 shows the 12 most sensitive mutants from 
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the secondary assay against the isoniazid mini-hit library. The growth-inhibition of mutants 
in the secondary assay against the isoniazid mini-hit library showed a median 
growth-inhibition of 23.0%, similar to the growth-inhibition of the MRC10 control strain at 
23.6%. Three mutants, myco7437, myco2576, and myco5016 stood out, showing greater 
than 80% inhibition.  
Table 3.2: Growth-inhibition of top secondary assay hits versus isoniazid. 
Strain Growth-inhibitiona ± se (%) 
myco7437 97.9 ± 0.84 
myco2576 87.3 ± 9.29 
myco5016 85.5 ± 5.91 
myco3113 61.9 ± 19.8 
myco0409 54.3 ± 14.3 
myco6166 54.2 ± 12.4 
myco2100 49.8 ± 13.2 
myco1897 49.6 ± 15.6 
myco6192 48.7 ± 18.5 
myco6482 46.5 ± 12.0 
myco2659 45.5 ± 2.78 
myco7102 45.2 ± 12.6 
MRC10 23.6 ± 5.48 
aGrowth-inhibition values represent mean values across three independent assays with standard 
errors (se) presented. 
 
3.3.4.3. Quantification of mutant hypersensitivity 
The isoniazid MIC was determined by dose-response assay (section 2.8.3) for the 12 most 
sensitive mutants from the secondary assay in order to quantify mutant sensitivity. Isoniazid 
MICs for the 12 strains were compared to an MIC value averaged across the 10 random 
transposon mutant control strains (section 3.3.3). All of the 12 isoniazid hypersensitive 
mutants from the secondary assay showed some level of increased sensitivity compared to 
the control MIC (Table 3.3). The three mutants that stood out in the secondary assay also 
showed the greatest change in isoniazid MIC. These mutants, myco2576, myco5016, and 
myco7437, showed a greatly increased sensitivity to isoniazid with a decrease in MIC of 
greater than two-fold compared to the control MIC, with myco2576 and myco5016 showing 
a greater than four-fold decrease in MIC. 
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Table 3.3: Sensitivity of transposon mutants to isoniazid. 
Strain MIC ± se (µM) 
myco2576 1.56 ± 0.00 
myco5016 1.56 ± 0.00 
myco7437 3.12 ± 0.00 
myco2100 4.17 ± 1.04 
myco3113 5.21 ± 1.04 
myco0409 5.21 ± 1.04 
myco6166 5.21 ± 1.04 
myco1897 6.25 ± 0.00 
myco6192 6.25 ± 0.00 
myco6482 6.25 ± 0.00 
myco2659 6.25 ± 0.00 
myco7102 6.25 ± 0.00 
Tn Control 7.08 ± 0.54 
Isoniazid MICs for the 12 mutants most sensitive to isoniazid identified in the secondary assay, 
averaged over three independent experiments. The transposon (Tn) control value represents the 
mean of the 10 randomly selected mutant control strains. Standard errors (se) are presented. 
 
3.3.5. Rifampicin 
3.3.5.1.  Primary assay for drug hypersensitivity 
The primary assay for rifampicin hypersensitivity was performed at a concentration of 
0.26 µM (Table 3.1). As the sRFU values for the treated-MRC10 controls within each library 
were normally distributed one-way ANOVAs were performed on untransformed data. The 
one-way ANOVAs did not show a significant difference in mean sRFU for the treated-MRC10 
control across all plates of either library A or B (p > 0.05), therefore analysis of the assay data 
continued as described in section 3.2.3. 
The median inhibition of mutant library A versus rifampicin was approximately 24% (Figure 
3.6). The 60 most sensitive mutants from library A, representing mutants that were at least 
1.78 times more sensitive to rifampicin than the library median, were picked into the 
rifampicin mini-hit library. 
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Figure 3.6: Mutant library A versus 0.26 µM rifampicin. (A) Frequency distribution of FI values, and 
(B) FI linear profile, from library A versus 0.26 µM rifampicin. The median FI across mutant library A 
was 1.32, and the median FI for the treated-MRC10 control was 1.60. The dotted line indicates the 
cut-off for the 60 most sensitive mutants, and lies at FI = 2.35. The FI value for each mutant 
represents the mean FI across three independent experiments. 
The median inhibition of mutant library B versus rifampicin was approximately 5% (Figure 
3.7). The 60 most sensitive mutants from library B, representing mutants that were at least 
1.72 times more sensitive to rifampicin than the library median, were picked into the 
rifampicin mini-hit library. 
 
65 
 
 
Figure 3.7: Mutant library B versus 0.26 µM rifampicin. (A) Frequency distribution of FI values, and 
(B) FI linear profile, from library B versus 0.26 µM rifampicin. The median FI across mutant library B 
was 1.05, and the median FI for the treated-MRC10 control was 1.36. The dotted line indicates the 
cut-off for the 120 most sensitive mutants, and lies at FI = 1.81. The FI value for each mutant 
represents the mean FI across three independent experiments. 
 
3.3.5.2. Secondary assay for drug hypersensitivity 
A secondary assay was performed In order to validate the hypersensitivity to rifampicin of 
the 120 most sensitive mutants (60 from each library) identified in the primary assay. Each 
hypersensitive mutant was tested against the screening concentration of rifampicin (Table 
3.1) and growth-inhibition was determined by endpoint OD600 measurement as described in 
section 3.2.4. The concentration of rifampicin used in the secondary assay was the same as 
that used in the primary assay (0.26 µM). Table 3.4 shows the 12 most sensitive mutants 
from the secondary assay against the rifampicin mini-hit library. The median 
growth-inhibition of the entire mini-hit library was 8.46%, compared to 13.4% 
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growth-inhibition for the control strain MRC10. The mutant with the highest sensitivity was 
myco2694, which showed greater than 95% inhibition. In addition, two mutants myco1030 
and myco4003, stood out with greater than 60% inhibition. 
Table 3.4: Growth-inhibition of top secondary assay hits versus rifampicin. 
Strain Growth-inhibitiona ± se (%) 
myco2694 97.7 ±  1.92 
myco4005 70.0 ± 22.0 
myco1030 61.0 ± 19.1 
myco5231 45.0 ± 17.2 
myco0163 39.1 ± 20.0 
myco7011 38.1 ± 31.9 
myco891 38.0 ± 25.8 
myco5826 35.2 ± 21.6 
myco6762 35.1 ± 33.8 
myco6859 33.6 ± 4.56 
myco2642 31.3 ± 11.3 
myco5883 31.1 ± 0.73 
MRC10 13.4 ± 0.30 
aGrowth-inhibition values represent mean values across three independent assays with standard 
errors (se) presented. 
 
3.3.5.3. Quantification of mutant hypersensitivity 
The rifampicin MIC was determined by dose-response assay (section 2.8.3) for the 12 most 
sensitive mutants from the secondary assay in order to quantify mutant sensitivity. 
Rifampicin MICs for the 12 strains were compared to an MIC value averaged across the 10 
random transposon mutant control strains (section 3.3.3). In general, the mutant strains 
showed an increased sensitivity to rifampicin compared to the control strain with 11 of the 
12 strains showing a decrease in MIC compared to the control MIC (Table 3.5). The two most 
sensitive mutants from the secondary assay had the greatest decrease in rifampicin MIC, 
whereby myco2694 showed an almost eight-fold decrease in MIC, while mutant myco4005 
showed a four-fold decrease in MIC. The remaining mutants showed a two-fold or less 
decrease in MIC to rifampicin compared to the control strain. 
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Table 3.5: Sensitivity of transposon mutants to rifampicin. 
Strain MIC ± se (µM) 
myco2694 0.09 ± 0.03 
myco4005 0.16 ± 0.00 
myco5826 0.26 ± 0.05 
myco6762 0.26 ± 0.05 
myco1030 0.31 ± 0.00 
myco0163 0.31 ± 0.00 
myco7011 0.31 ± 0.00 
myco5231 0.52 ± 0.10 
myco891 0.52 ± 0.10 
myco2642 0.52 ± 0.10 
myco5883 0.52 ± 0.10 
myco6859 0.63 ± 0.00 
Tn Control 0.64 ± 0.04 
Rifampicin MICs for the 12 mutants most sensitive to rifampicin identified in the secondary assay, 
averaged over three independent experiments. The transposon (Tn) control value represents the 
mean of the 10 randomly selected mutant control strains. Standard errors (se) are presented. 
 
3.3.5.4. Growth curve of rifampicin hypersensitive mutant myco4005 
Interestingly, it was noticed that the rifampicin hypersensitive strain myco4005 (with a 
four-fold reduction in MIC) took longer to grow than all other rifampicin hypersensitive 
mutant strains. A growth curve experiment (section 2.9) was performed to measure the 
reduced growth rate. A control strain (random transposon mutant strain D11), and the 
rifampicin hypersensitive mutant myco2694 reached stationary phase by 24 hours, whereas 
the strain myco4005 took approximately 24 hours longer (48 hours total) to reach stationary 
phase (Figure 3.8). 
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Figure 3.8: Growth curve of rifampicin hypersensitive strains. Growth of the rifampicin 
hypersensitive strains myco2694 and myco4005, and the random transposon mutant control strain 
D11, was measured every 24 hours by OD600 up to 72 hours. Values shown are log2 transformed 
mean OD600 values across three independent experiments with standard error bars. 
 
3.3.6. Bedaquiline 
3.3.6.1. Primary assay for drug hypersensitivity 
The primary assay for bedaquiline hypersensitivity was performed at a concentration of 
10.8 nM (Table 3.1). As the sRFU values for the treated-MRC10 controls within each library 
were normally distributed one-way ANOVA were performed on untransformed data. The 
one-way ANOVAs did not show a significant difference in mean sRFU for the treated-MRC10 
control across all plates or either library A or B (p > 0.05), therefore analysis of the assay data 
continued as described in section 3.2.3. 
The median inhibition of mutant library A versus bedaquiline was approximately 49% (Figure 
3.9). The 60 most sensitive mutants from library A, representing mutants that were at least 
1.76 times more sensitive to bedaquiline than the library median, were picked into the 
bedaquiline mini-hit library. 
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Figure 3.9: Mutant library A versus 10.8 nM bedaquiline. (A) Frequency distribution of FI values, and 
(B) FI linear profile, from library A versus 10 nM bedaquiline. The median FI across mutant library A 
was 1.97, and the median FI for the treated-MRC10 control was 2.37. The dotted line indicates the 
cut-off for the 60 most sensitive mutants, and lies at FI = 3.47. The FI value for each mutant 
represents the mean FI across three independent experiments. 
 
The median inhibition of mutant library B versus bedaquiline was approximately 37% (Figure 
3.10). The 60 most sensitive mutants from library B, representing mutants that were at least 
1.6 times more sensitive to bedaquiline than the library median, were picked into the 
bedaquiline mini-hit library. 
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Figure 3.10: Mutant library B versus 10.8 nM bedaquiline. (A) Frequency distribution of FI values, 
and (B) FI linear profile, from library B versus 10.8 nM bedaquiline. The median FI across mutant 
library B was 1.58, and the median FI for the treated-MRC10 control was 1.90. The dotted line 
indicates the cut-off for the 60 most sensitive mutants, and lies at FI = 2.53. The FI value for each 
mutant represents the mean FI across three independent experiments. 
 
 
3.3.6.2. Secondary assay for drug hypersensitivity 
A secondary assay was performed In order to validate the hypersensitivity to bedaquiline of 
the 120 most sensitive mutants (60 from each library) identified in the primary screen. Each 
hypersensitive mutant was tested against the screening concentration of bedaquiline (Table 
3.1) and growth-inhibition was determined by endpoint OD600 measurement as described in 
section 3.2.4. The concentration of bedaquiline used in the secondary assay was the same as 
that used in the primary assay (10.8 nM). Table 3.6 shows the 12 most sensitive mutants 
from the secondary assay against the bedaquiline mini-hit library. Data for the mutant 
myco2908 is included as sequencing by collaborators at the University of Otago revealed 
that it had a transposon insertion in atpB. This gene encodes the A subunit of the ATPase F0 
domain, linking it to the target of bedaquiline, the C subunit of the ATPase F0 domain. 
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Mutant myco2908 was the 18th most sensitive mutant identified in the secondary assay for 
bedaquiline. The mutants in the secondary assay against the bedaquiline mini-hit library 
showed a median inhibition of 39.3% compared to only 15.5% inhibition for the control 
MRC10. Three mutants, myco3011, myco5040, and myco6564, stood out, showing greater 
than 80% inhibition, while the remaining 10 mutants all showed over 50% inhibition.  
Table 3.6: Growth-inhibition percentage of top secondary assay hits versus bedaquiline. 
Strain Growth-inhibitiona ± se (%) 
myco3011 83.8 ± 2.94 
myco5040 83.5 ± 5.68 
myco6564 82.7 ± 0.96 
myco2833 77.2 ± 1.67 
myco4393 73.4 ± 3.98 
myco1994 72.5 ± 6.19 
myco3491 70.5 ± 9.21 
myco2664 70.5 ± 5.07 
myco1917 69.5 ± 0.52 
myco2176 68.4 ± 5.41 
myco0934 61.5 ± 6.75 
myco6539 61.1 ± 8.37 
myco2908 54.3 ± 8.65 
MRC10 15.5 ± 2.40 
aGrowth-inhibition values represent mean values across three independent assays with standard 
error (se) presented. 
 
3.3.6.3. Quantification of mutant hypersensitivity 
The bedaquiline MIC was determined by dose-response assay (section 2.8.3) for the 12 most 
sensitive mutants from the secondary assay in order to quantify mutant sensitivity. 
Bedaquiline MICs for the 12 strains were compared to an MIC value averaged across the 10 
random transposon mutant control strains (section 3.3.3). Of the 12 mutants most sensitive 
to bedaquiline from the secondary assay, only nine showed some level of increased 
sensitivity when quantified according to their MIC (Table 3.7). Two strains showed a two-fold 
or greater decrease in MIC compared to the control strain, myco1994 and myco2908. 
Interestingly, three strains, myco934, myco4393, and myco6539 had higher MIC values than 
the control mutant average (Table 3.7). 
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Table 3.7: Sensitivity of transposon mutants to bedaquiline. 
Strain MIC ± se (nM) 
myco1994 18.6 ± 3.75 
myco2908 22.5 ± 0.00 
myco2833 26.3 ± 9.92 
myco2664 33.8 ± 11.3 
myco3011 33.8 ± 11.3 
myco3491 37.5 ± 7.50 
myco5040 37.5 ± 7.50 
myco6564 37.5 ± 7.50 
myco1917 37.5 ± 7.50 
myco2176 37.5 ± 7.50 
Tn Control 45.8 ± 3.25 
Myco0934 60.0 ± 15.0 
myco4393 60.0 ± 15.0 
myco6539 75.0 ± 15.0 
Bedaquiline MICs for the 12 mutants most sensitive to bedaquiline identified in the secondary assay, 
and myco2908, averaged over three independent experiments. The transposon (Tn) control value 
represents the mean of the 10 randomly-selected mutant control strains. Standard errors  (se) are 
presented. 
 
3.4. Discussion 
The aim of this chapter was to identify mutants of M. smegmatis mc2155 that were 
hypersensitive to isoniazid, rifampicin, and bedaquiline. To this end, a library of random 
Tn611 transposon mutants was constructed and screened for drug hypersensitivity. Mutants 
that were hypersensitive were identified for all three drugs and the sensitivities quantified 
by MIC for the 12 mutants most sensitive in each secondary assay. 
 
3.4.1. Screening for drug hypersensitivity 
The assay undertaken in this thesis to identify drug hypersensitive mutants in a Tn611 
transposon mutant collection was successful, with mutants identified that were sensitive to 
all of the drugs tested (isoniazid, rifampicin, and bedaquiline). The assay was run at a 
concentration of drug that caused minor growth-inhibition across the mutant libraries, 
allowing those mutants that were hypersensitive to the drug to be differentiated from the 
rest of the transposon mutants. The original target was to use a drug concentration that 
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caused 15 –30% median growth-inhibition across a library, however after performing the 
assays it became apparent that greater variation in the compound’s screening concentration 
can still successfully identify hypersensitive mutants. Specifically, the lowest average 
inhibition was 5% in the rifampicin versus library B assay; and the highest was 49% in the 
bedaquiline versus library A assay. These results indicate the assay for drug hypersensitivity 
developed in this thesis was more sensitive than initially suspected. This conclusion is also 
supported by the increased number of rifampicin hypersensitive mutants identified in this 
assay compared to a previous one performed by Alexander et al. (2003). In the previous 
study only one mutant was isolated that showed increased rifampicin sensitivity, and is likely 
a combined effect of the different type of assay and drug concentration used. Other factors 
such as library coverage may have also had an impact; both the collection of mutants used in 
this assay, and that by Alexander et al. (2003) contained 7680 mutants, therefore there 
would likely be a large, but not complete overlap between the two different libraries. The 
assay by Alexander et al. (2003) used an endpoint metric that was the presence or absence 
of growth on solid media containing antibiotic compared to the assay setup used in this 
study, where a strain’s growth does not need to be completely inhibited to be detected. This 
demonstrates the general higher sensitivity achieved with a qualitative endpoint growth-
inhibition assay compared to a quantitative growth versus no growth metric. 
The assay for drug hypersensitivity was designed for high-throughput with the reduction of 
resazurin used as the endpoint measure of growth-inhibition. As discussed in the 
introduction resazurin reduction provides a relative measure of growth-inhibition, with 
other factors including incubation time with the dye affecting the absolute fluorescence 
achieved by a culture. The library plates were designed to contain an in-plate control strain, 
MRC10, to enable standardisation whereby the fluorescence of untreated MRC10 was used 
as the maximum fluorescence standard to which all other strains on the plate were 
compared. The reliability of this control was confirmed when the libraries were grown in LB 
alone and the median standardised fluorescence of the treated-MRC10 showed no 
significant difference across all plates within a library. The treated-MRC10 controls were also 
compared for the assays against isoniazid, rifampicin, and bedaquiline, and showed no 
significant differences within either library for all drugs. This result indicates that the 
treatment conditions were the same for all plates within a library, and that it was valid to 
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directly compare the sensitivity of the mutants between separate plates within a library. As 
the libraries were screened separately the data analysis was also performed separately to 
avoid any library bias due to different treatment conditions between libraries A and B. It was 
noted that the treatment conditions were significantly different between the assays against 
Library A and Library B for rifampicin and bedaquiline, therefore a library bias would have 
existed had the data been analysed together. 
As discussed in the chapter introduction, the use of resazurin, while useful in improving 
assay throughput, also added a risk of introducing false positives. To overcome this, a 
secondary assay that used endpoint OD600 was used to validate the sensitivity of the 60 most 
sensitive mutants from each library for each drug. It was expected that this number of 
mutants would contain most if not all the true positives, while being small enough to screen 
in the lower throughput of OD600 based measurement of growth. To this end, the median 
growth-inhibition of the mini-hit libraries for each of the three drugs was compared to the 
MRC10 control. It was observed that the median inhibition of the isoniazid and rifampicin 
mini-hit libraries by the respective drugs was approximately equal to the inhibition of 
MRC10. This suggests that the majority of mutants within these mini-hit libraries were not 
sensitive to the drugs and were false positives. Interestingly, median inhibition of the 
bedaquiline mini-hit library was approximately twice that of the MRC10 strain, suggesting 
that most of the mutants in the bedaquiline mini-hit library were true positives and 
hypersensitive to bedaquiline. This high true positive rate may be due to the mode of action 
of bedaquiline, which inhibits the ATPase enzyme, with mutations in many of the pathways 
that utilise ATP potentially sensitising the bacteria to bedaquiline (Andries et al., 2005; Koul 
et al., 2007). These results confirm the original assumption that the top 60 mutants from 
each library would contain most if not all of the true hits. 
It was observed that the growth-inhibition values generated from the secondary assay had 
relatively large errors associated with them, likely due to the way in which the assay was 
setup. In order to sub-inoculate the 96-well plates for the secondary assay, a 96 well pinning 
tool was used in order to replicate the manner in which the primary assay was setup. This 
pinning resulted in the occasional transfer of visible clumps of cells, and this variation in 
starting cell number likely affected the final growth measurement. Two biological replicates 
were performed for each assay replicate, however increasing this to three of four biological 
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replicates would likely have reduced the errors; additionally, sub-inoculation of the assay 
plates by pipetting would have likely decreased variation in the assay. Despite these larger 
errors the secondary assay was successfully used to validate the sensitivity of the mutants 
identified in the primary assay.  
 
3.4.2. Quantifying drug sensitivity 
MICs were determined for the top 10% of sensitive mutants (12 strains) from the secondary 
assays for each of the drugs tested, and were used as a convenient metric for quantifying 
drug sensitivity. For bedaquiline an additional mutant, myco2908, was included as it 
contained a transposon insertion within atpB, a gene associated with the known mode of 
action of bedaquiline, as identified by collaborators at the University of Otago. The control 
for this assay was an averaged MIC across 10 random mutant strains from the transposon 
libraries. The random mutant strains were included to account for differences in basal 
sensitivity between a transposon mutant and the non-transposon mutant control MRC10 as 
a result of the transposon insertion. These 10 mutant control strains were not identified as 
hypersensitive to isoniazid, rifampicin, or bedaquiline in either the primary or secondary 
assays. However, to eliminate the likelihood of accidently choosing a single random 
transposon mutant strain that had an altered sensitivity to one of the drugs, an average 
across the 10 strains was used. It was found that there was no significant difference in the 
MIC values between the control strains for isoniazid, rifampicin, or bedaquiline.  
Most of the top 10% of drug hypersensitive mutants from the secondary assay examined 
showed a two-fold or less decrease in MIC compared to the control average. Several 
mutants with a greater than two-fold difference in MIC were identified for each respective 
drug: three for isoniazid, two for rifampicin, and two for bedaquiline.  These were fewer 
mutants than expected, possibly representing a limitation of using MIC to quantify the 
sensitivity of these mutants. Additionally, the transposon control average MIC to bedaquiline 
was found to be lower than that of several validated bedaquiline sensitive mutants. This 
would indicate that the 10 random mutant control strains may also be hypersensitive to 
bedaquiline, which would agree with the high true positive rate observed for the secondary 
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assay for bedaquiline. Therefore, these random transposon strains may not have been the 
most reliable control for the assay determining MIC values for bedaquiline. 
 
3.4.3. Summary 
A transposon mutant collection was constructed in a 384-well format and was screened in 
high-throughput for mutants that were hypersensitive to isoniazid, rifampicin, and 
bedaquiline. For each drug, 12 validated hypersensitive mutants had their sensitivities 
quantified by determining their MICs for the relevant drug, with three mutants from the 
isoniazid assay, two from the rifampicin assay, and one mutant from the bedaquiline assay, 
standing out. The genotypic basis for drug hypersensitivity for these 36 validated mutants 
will be further examined in Chapter Four. 
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4. Genotypic validation of drug hypersensitive mutants of 
M. smegmatis 
4.1. Introduction 
As discussed in Chapter Three, the advantage of transposon mutagenesis is that the site of 
the genetic mutation responsible for the drug hypersensitivity is labelled by the transposon 
sequence. Rapid identification of the transposon insertion site facilitates downstream 
genetic analysis including complementation of the transposon mutant with an intact 
plasmid-borne copy of the gene, or overexpression of the identified gene in a WT strain. 
Complementation determines whether the identified gene is responsible for the drug 
hypersensitivity phenotype. In mutants where loss of function of the mutated gene causes 
drug hypersensitivity, complementation of this gene will likely restore the drug sensitivity to 
levels similar to that seen in WT. Over-expression of these genes of interest in WT allows 
further characterisation of their role in drug sensitivity, such as whether overexpression 
results in sensitivity similar to WT or a dramatic increase in drug resistance. 
Complementation and over-expression experiments, along with information gleaned from 
the literature, can be combined to generate a more encompassing description of drug mode 
of action. 
  
4.1.1. Transposition site identification 
A major advantage of the use of transposons for random mutagenesis is that the site of 
insertion is labelled with a known DNA sequence (i.e. the transposon). The first step in 
identifying the site of mutation is to digest the mutant gDNA with a restriction enzyme to 
yield DNA fragments that contain the junction between the end of the transposon and the 
flanking gDNA sequence. Multiple techniques exist for amplifying this transposon DNA/gDNA 
junction; for example, inverse PCR involves ligating the hybrid transposon DNA/gDNA 
fragments under dilute conditions to produce circularised DNA. The flanking gDNA region 
can then be amplified from two primers based within the transposon DNA sequence 
(Billman-Jacobe et al., 2006). An alternative method is ligation-mediated PCR, where a linker 
is ligated to the transposon DNA/gDNA junction containing fragments and this construct is 
amplified using a primer from the linker and a primer from the transposon sequence 
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(Prod’hom et al., 1998). Sequencing of the PCR products from either inverse PCR or 
ligation-mediated PCR allows pinpointing of the junction between transposon and gDNA and 
therefore the specific transposon insertion site.  
 
4.1.2. Conditional gene expression in mycobacteria 
A number of different constitutive and conditional promoter systems have been developed 
to allow the extra-chromosomal or integrated expression of genes in mycobacteria (Blokpoel 
et al., 2005; Brown and Parish, 2006; Carroll et al., 2005, 2007; Ehrt et al., 2005; Pandey et 
al., 2009; Stover et al., 1991; Triccas et al., 1998). Conditional promoters come in a number 
of varieties including on/off type promoters and titrateable promoters, both of which can be 
actively induced and/or repressed by small molecules depending on the specific promoter. 
Tetracycline inducible promoters are routinely used in mycobacteria for conditional gene 
expression, and are activated when tetracycline binds to a repressor protein, allowing the 
RNA polymerase access to the promoter and resulting in induction of gene expression 
(Figure 4.1). The common limitation of the conditional expression vectors, including the 
tetracycline inducible vectors, is that the promoter can be leaky, with potentially high levels 
of basal expression in the absence of the inducer tetracycline. Newer generation vectors, 
such as plasmid pKW08 (Williams et al., 2010), have been constructed to limit basal 
expression in mycobacteria, although the vector is still leaky in E. coli, which is routinely used 
for sub-cloning. A derivative of plasmid pKW08 will be used for the conditional gene 
expression in M. smegmatis mc2155 in this thesis.  
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Figure 4.1: Tetracycline inducible promoter of plasmid pKW08. (A) The repressor protein TetR, 
encoded by tetR, binds the tetO operator region and prevents transcription from the promoter Ptet. 
(B) The inducer (tetracycline) binds the repressor protein (TetR) and prevents binding of TetR to tetO, 
allowing transcription from Ptet. 
 
4.1.3. Objectives of Chapter Four 
The goal of Chapter Four was to identify the genetic basis for the drug hypersensitivity 
phenotype of the 12 most sensitive transposon mutants validated in each secondary assay 
(isoniazid, rifampicin, and bedaquiline assays for drug hypersensitivity) in Chapter Three.  
To achieve this goal the following specific aims were addressed: 
 Identification of the transposon insertion site in the 12 mutants most hypersensitive 
to isoniazid, rifampicin, and bedaquiline from Chapter Three 
 Complementation of a select few transposon mutants to confirm the role of the gene 
containing the transposon insertion in these strains drug sensitivity 
 Overexpression of genes containing or adjacent to Tn611 insertions in drug 
hypersensitive mutants to further characterise their role in drug sensitivity 
The site of Tn611 insertion in the isoniazid, rifampicin, and bedaquiline hypersensitive 
mutants of M. smegmatis mc2155 was determined using either inverse PCR or 
ligation-mediated PCR. Genes identified as containing, or adjacent to Tn611 insertions were 
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expressed from the tetracycline inducible promoter of pRC20, a derivative of plasmid 
pKW08, in Tn611 mutants for complementation assays, or in WT M. smegmatis mc2155 for 
overexpression assays. 
 
4.2. Methods 
4.2.1. Transposon insertion site identification 
Two different methods were used to identify the insertion site of the Tn611 in the mutant 
strains of M. smegmatis mc2155: inverse PCR or ligation-mediated PCR. Inverse PCR was 
performed initially, however was not successful for generating sequences for all of the 
mutants tested. In such cases, ligation-mediated PCR was subsequently performed to enable 
identification of the transposon insertion site. 
 
4.2.1.1. Inverse PCR 
Substrates for inverse PCR were generated as described in section 2.6.4, and inverse PCR 
performed as described in section 2.6.3.2. The products from inverse PCR were 
electrophoresed on a 1% agarose gel (section 2.6.1.4). Inverse PCR produced two products: 
one of constant size (approximately 1 Kb) that corresponded to an internal transposon PCR 
product; and a variable sized band that correlated to the product containing the 
gDNA/junction. Gel extraction was performed to isolate the variably sized band of interest as 
described in section 2.6.1.5. The gDNA flanking the Tn611 insertion was subsequently 
sequenced using primer 3054 ( Table 2.4. 
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Table 2.4). If a PCR product could not be generated by inverse PCR from the RsaI generated 
fragments, or the PCR product did not provide a useful sequence, the inverse PCR process 
was repeated using another restriction enzyme, EagI. The protocol for EagI based inverse 
PCR was identical to RsaI based inverse PCR except that the DNA fragments were generated 
by EagI digestion instead (section 2.6.4.) 
 
 
Figure 4.2: Inverse PCR. RsaI digested gDNA from a Tn611 insertional mutant is circularised by 
ligating under dilute conditions. The outward facing transposon primers 3053 and 3054 are then able 
to amplify the gDNA/transposon DNA junction. Red bars represent Tn611 DNA, while yellow bars 
represent M. smegmatis mc2155 gDNA. 
 
4.2.1.2. Ligation-mediated PCR 
In cases where inverse PCR with either RsaI or EagI digestion failed to produce a PCR product 
or produced a PCR product that failed to give a useful sequence, ligation-mediated PCR was 
used instead. ligation-mediated PCR was performed as described previously by Prod’hom et 
al., (1998) and as depicted in Figure 4.3. The substrate for ligation-mediated PCR was 
generated as described in section 2.6.5, and ligation-mediated PCR performed as described 
in section 2.6.3.2. PCR products were electrophoresed on 1% agarose gels (section 2.6.1.4) 
and successful PCR reactions were cleaned and concentrated (section 2.6.1.6) and 
sequenced with salgd and OligoF (Table 2.4).  
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Figure 4.3: Ligation-mediated PCR. The linker (blue), composed of the non-phosphorylated oligos 
salgd and salpt, is ligated to SalI digested transposon mutant DNA fragments. While the longer salgd 
oligo strand can ligate to the DNA fragment due to the fragments 5’ phosphate group, the shorter 
salpt strand lacks its own phosphate so cannot ligate and subsequent heating during PCR results in 
the salpt oligo being displaced. The second digestion with SalI ensures no unwanted products are 
amplified during PCR due to improper initial SalI digestion. The fragment containing the gDNA 
flanking the transposon mutant is selectively amplified by PCR using the linker primer salgd, and 
OligoF. 
 
4.2.1.3. Sequence processing 
The PCR products generated by inverse PCR or ligation-mediated PCR as described 
previously, were sequenced as described in section 2.6.2. Sequences of the PCR products 
generated from inverse PCR or ligation-mediated PCR were analysed identically using the 
bioinformatics software Geneious 5.6.6 (www.geneious.com) as follows. The returned DNA 
sequence was aligned with the DNA sequence from the end of the Tn611 transposon using 
the Geneious “pairwise align” function with default settings to identify the junction between 
the transposon and gDNA. The sequence of the gDNA from the transposon DNA/gDNA 
junction until the first relevant restriction site (RsaI or EagI or SalI), or until the end of the 
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sequence (whichever was shorter), was used as the input for a nucleotide Basic Local 
Alignment Search Tool (BLAST) analysis at the ncbi BLAST website 
(http://blast.ncbi.nlm.nih.gov). The nucleotide BLAST was performed against the non-
redundant nucleotide database using default settings to identify the genomic region 
matching the gDNA sequence generated from inverse PCR/ligation-mediated PCR. Once 
identified, the corresponding genomic region was used as a reference sequence against 
which the PCR generated gDNA sequence was aligned in Geneious using the “align to 
reference” tool with default settings. From this reference alignment the exact location of the 
Tn611 insertion in the M. smegmatis mc2155 genome was determined. The identity, 
function, and known M. tuberculosis homologues of genes containing transposon insertions, 
or genes adjacent to intergenic transposon insertions, was determined using databases 
including tuberculist (Lew et al., 2011), smegmalist (Kapopoulou et al., 2011), and the TBDB 
(Galagan et al., 2010). If no M. tuberculosis homologue was given for a M. smegmatis gene 
on any of these databases then none was reported in the tables of results for each drug later 
in this chapter. 
 
4.2.2. Optimisation of tetracycline concentration for induction of gene 
expression from plasmid pRC20 
The plasmid pRC20 was used for both the complementation and overexpression assays, and 
the optimal tetracycline inducer concentration was determined for each of these assays 
separately. Dose-response assays measuring endpoint GFP fluorescence and 
growth-inhibition with varying concentrations of tetracycline were performed to optimise 
the tetracycline concentrations (section 2.8.3). For the complementation assays, the 
complementation strains and empty vector controls were grown in 0, 2.5, 5, 10, 20, or 40 
ng∙mL-1 tetracycline, under the same conditions as the complementation assays (specifically 
41 °C and 20 µg∙mL-1 kanamycin and hygromycin B). For the overexpression assays, the 
empty vector control strain MRC20 was grown in 0, 5, 10, 20, 40, or 80 ng∙mL-1 tetracycline, 
under the same conditions as the overexpression assays (37 °C and 50 µg∙mL-1 hygromycin 
B). The optimal tetracycline concentration for each assay was determined as the 
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concentration that provided maximal GFP fluorescence, and therefore gene expression from 
the tetracycline inducible promoter of pRC20, while causing minimal growth-inhibition. 
 
4.2.3. Complementation of transposon mutants 
Complementation was performed using the vector pRC20 expressing the WT copy of the 
gene containing or adjacent to the Tn611 insertion in the relevant mutant strain. The WT 
copies of the genes were amplified by PCR from M. smegmatis mc2155 (section 2.6.3.2) 
before being cloned into the BamHI site in plasmid pRC20 as described in section 2.6.9.1. 
Sequencing was performed to check the orientation and fidelity of the insert as described in 
section 2.6.2. Constructs that were in the correct orientation and did not contain errors were 
transformed into the relevant transposon mutant strain (section 2.6.7.2). One gene used for 
complementation, MSMEI_1905, contained a BamHI site within its ORF which was removed 
by PCR using a long (60-mer) primer to remove the restriction site by creating a silent 
mutation (Table 2.5). The removal of the restriction site was confirmed by sequencing as 
described in section 2.6.2. 
Empty vector control strains were generated for each transposon mutant strain by 
transforming the transposon mutant strains with pRC20 (section 2.6.9). Complementation 
assays were performed as dose-response assays as described in section 2.8.3. The MIC of the 
relevant drug was determined for the complementation strains and empty vector controls, 
both with and without vector induction by tetracycline. 
 
4.2.4. Overexpression of M. smegmatis genes 
The vectors expressing the genes of interest generated for the complementation assays 
were also transformed into WT M. smegmatis mc2155 to generate the corresponding 
overexpression strains. Overexpression assays were performed as dose-response assays as 
described in section 2.8.3. The MIC of the relevant drug was determined for the 
overexpression strains, both with and without vector induction by tetracycline. Control 
strains for the overexpression assay included an empty vector negative control strain 
(MRC20), and an additional negative control strain that expressed a random gene from 
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M. smegmatis mc2155. This negative control strain overexpressed MSMEI_4267, the gene in 
which the random transposon control strain D11 contained a Tn611 insertion. MSMEI_4267 
encodes a putative iron-sulfur oxidoreductase. For the overexpression assays against 
isoniazid an additional positive control expressing the gene encoding the known target of 
isoniazid, inhA (MSMEI_3070), was included. 
 
4.3. Results 
4.3.1. Isoniazid 
4.3.1.1. Transposon insertion site identification 
The transposon insertion sites were able to be identified for the 12 mutants most sensitive 
to isoniazid identified in Chapter Three, using either inverse PCR or ligation-mediated PCR as 
described in section 4.2.1. (Table 4.1). 
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Table 4.1: Transposon insertion sites in isoniazid hypersensitive mutants.  
Mutant 
Strain 
Tn611 insertion location (ORF) Putative Identification 
Common 
Name 
Nearest H37Rv 
homologue 
Gene 
Length (bp) 
POI 
myco0409 MSMEI_3684 acetylornithine aminotransferase argD Rv1655 1173 152 
myco1897 MSMEI_5538 Multiple antibiotic resistance regulator marR Rv0880 432 385 
myco2100 
55 bp downstream of MSMEI_1210 
96 bp upstream of MSMEI_1211 
MSMEI_1210 – PAPS reductase 
MSMEI_1211 - conserved hypothetical protein 
- 
- 
- 
- 
909 
1437 
- 
- 
myco2576 MSMEI_1904 NADH pyrophosphatase nudC Rv3199c 936 710 
myco2659 MSMEI_0062 ftsk/spoiiie family protein eccCa1 Rv3870 2229 2072 
myco3113 
47 bp upstream MSMEI_4423 
338 bp upstream of MSMEI_4424 
MSMEI_4423 - conserved hypothetical protein 
MSMEI_4424 – Major Membrane Protein 1 
- 
- 
- 
- 
1278 
924 
- 
- 
myco5016 MSMEI_1905 Glutaredoxin-like protein - Rv3198A 249 59 
myco6166 MSMEI_5554 Conserved hypothetical protein - Rv0862c 2256 666 
myco6192 MSMEI_5244 K+ transporting ATPase, A subunit kdpA Rv1029 1671 391 
myco6482 MSMEI_5460 putative transcriptional regulator - - 951 332 
myco7102 
103 bp upstream of MSMEI_4764 
36bp downstream of MSMEI_4765 
MSMEI_4764 - integral membrane transporter 
MSMEI_4765 – Alkylhydroperoxidase 
- 
ahpD 
- 
Rv2429 
1323 
534 
- 
- 
myco7437 MSMEI_6092 Fur Family Transcriptional Regulator - - 465 204 
Isoniazid hypersensitive mutants are organised by their location in the mutant collection in ascending order. Transposon point of insertion (POI) is counted 
from the start of the gene.  
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The myco7437 mutant strain contained a transposon insertion in a putative ferric uptake 
regulator (Fur) type transcriptional regulator (MSMEI_6092). KatG, the enzyme responsible 
for the activation of isoniazid, is regulated by the Fur type regulator FurA. Due to the 
relationship between a Fur type regulator and the mode of action of isoniazid, the similarity 
between MSMEI_6092 and other Fur type regulators (FurA and FurB type) from 
M. smegmatis and M. tuberculosis was investigated. A protein alignment (Geneious 
“pairwise alignment”, default settings) was performed with the two known M. smegmatis 
mc2155 homologs of FurA, FurA1SMEG (MSMEI_6215) and FurA2SMEG (MSMEI_3379), as well 
as FurB (MSMEI_4376), along with FurA and FurB from M. tuberculosis H37Rv (Rv1909c and 
Rv2359 respectively). The protein alignment showed that MSMEI_6092 is much more similar 
to the FurA proteins than FurB (Table 4.2). However, the two M. smegmatis FurA proteins 
are much more similar to each other and Rv1909c than to MSMEI_6092.  
Table 4.2: Protein similarity matrix of Fur proteins from M. smegmatis mc2155 and M. tuberculosis 
H37Rv.  
Protein FurATB FurA1SMEG FurA2SMEG 
MSMEI_ 
6092 
FurBSMEG FurBTB 
FurATB - 68 69.1 56.4 24.3 24.6 
FurA1SMEG 68 - 65.1 56.6 22.1 24.6 
FurA2SMEG 69.1 65.1 - 53.4 22.1 21.6 
MSMEI_6092 56.4 56.6 53.4 - 25.7 26.9 
FurBSMEG 24.3 22.1 22.1 25.7 - 76.7 
FurBTB 24.6 24.6 21.6 26.9 76.7 - 
Percentage similarity of amino acid sequences for M. smegmatis mc2155 and M. tuberculosis H37Rv 
FurA and FurB proteins and the Fur-like protein encoded by MSMEI_6092. 
 
4.3.1.2. Complementation of isoniazid hypersensitive mutants 
The three mutants most hypersensitive to isoniazid identified in Chapter Three, myco2576, 
myco5016, and myco7437, were selected for complementation using the genes that were 
identified in 4.3.1.1 as containing the Tn611 insertion in these strains. These strains were 
selected for complementation as they were greater than two-fold more sensitive to isoniazid 
than the control whereas the remaining nine hypersensitive strains were between 1.1- and 
1.7-fold more sensitive (section 3.3.4.3). It was expected that the greater sensitivity of the 
selected strains would make it easier to determine whether or not complementation was 
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successful. The mutant strains myco2576, myco5016, and myco7437 are henceforth referred 
to by the ORF containing the Tn611 insertion: Tn::nudC, Tn::MSMEI_1905, and 
Tn::MSMEI_6092 respectively. A complementation construct containing MSMEI_6092 was 
unable to be produced. Sequencing results showed that expression plasmids with 
MSMEI_6092 in the forward direction could be recovered, with a number of constructs 
containing no insert, or deletions of part of the downstream GFP gene (Figure 4.4).  
 
 
Figure 4.4: Alignments of pRC20 MSMEI_6092 constructs. Sequencing results from the pRC20 
constructs containing MSMEI_6092, aligned with a reference sequence. Construct sequences from six 
recovered clones are shown, with clone number shown on the left hand side. Solid black bars 
represent sequence that matches the reference, while the thin black lines represent gaps in the 
sequence. Constructs 3, 8, 9, and 11 appear to have no insert, while constructs 4 and 5 contain 
deletions of part of the GFP gene. All other constructs recovered had MSMEI_6092 in the reverse 
orientation with no deletions.  
 
The complementation strains for Tn::nudC and Tn::MSMEI_1905 were created by 
transforming each mutant strain with the pRC20 vector containing either the nudC or 
MSMEI_1905 construct respectively. Each mutant strain was also transformed with pRC20 
that did not contain a construct (i.e. empty vector controls). The inducer concentration was 
optimised for the complementation studies, with GFP fluorescence used as a relative 
measure of vector induction, as described in section 4.2.2. As there was no difference 
between the response of any of the mutant strains or the empty vector strains, these results 
were analysed together. A tetracycline concentration of 20 ng∙mL-1 was found to provide the 
highest fluorescence, however this concentration showed a substantial increase in 
growth-inhibition compared to the lower tetracycline concentrations (Figure 4.5). A 
tetracycline concentration of 10 ng∙mL-1 provided an approximate four-fold increase in 
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fluorescence, with minimal growth-inhibition, when averaging the response of the four 
strains, and was therefore selected as the inducer concentration to be used for the 
complementation assays. 
 
Figure 4.5: Optimisation of inducer concentration for complementation assays. (A) Average 
endpoint growth relative to the untreated control, and (B) average endpoint RFU of Tn::nudC and 
Tn::MSMEI_1905 empty vector control and complemented strains grown in different tetracycline (Tc) 
concentrations. Column heights represent mean values from three independent experiments with 
standard error bars shown. 
 
The MIC of isoniazid for the relevant complementation strains and the empty vector controls 
was determined by a dose-response assay (Figure 4.6). There was no change in the MIC of 
isoniazid for either of the empty vector controls upon induction with tetracycline. The 
complemented Tn::nudC strain showed an increased resistance to isoniazid upon induction, 
with a greater than 10-fold increase in the MIC, while there was no change in the MIC of 
isoniazid for the complemented Tn::MSMEI_1905 strain upon vector induction. 
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Figure 4.6: Complementation of isoniazid hypersensitive transposon mutants. The MIC of isoniazid 
for the Tn::nudC and Tn::MSMEI_1905 empty vector controls (EV) and complemented strains (C) was 
determined with and without vector induction with 10 ng∙mL-1 tetracycline (Tc). Column heights 
represent mean MIC over three independent experiments, with standard error bars shown. For those 
columns that have no error bars the standard error was zero. The highest tested concentration of 
isoniazid was 100 µM and MICs greater than the highest tested concentration are indicated by a 
caret (^). 
 
4.3.1.3. Overexpression of genes related to isoniazid hypersensitivity 
The inducer concentration for the overexpression assay was optimised by growing the 
empty vector control strain (MRC20) in different concentrations of the inducer tetracycline. 
It was found that a tetracycline concentration of 20 ng∙mL-1 gave the highest increase in 
fluorescence (six-fold) with minimum growth-inhibition. Therefore, 20 ng∙mL-1 was selected 
as the tetracycline concentration for the overexpression assays (Figure 4.7). 
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Figure 4.7: Optimal inducer concentration for MRC20. (A) Average endpoint growth relative to the 
untreated control, and (B) average endpoint RFU of the empty vector control strain MRC20 grown in 
different tetracycline (Tc) concentrations. Column heights represent mean values from three 
independent experiments with standard error bars shown. 
 
The roles of the genes nudC and MSMEI_1905 in isoniazid sensitivity were further examined 
by overexpressing each gene in WT M. smegmatis mc2155. Background sensitivity of WT 
M. smegmatis mc2155 to isoniazid upon vector induction was determined by way of a 
dose-response assay against the empty vector control strain MRC20. A two-fold increase in 
the MIC of isoniazid was observed upon vector induction with 20 ng∙mL-1 tetracycline (Figure 
4.8). Therefore for the genes of interest, only changes in the MIC of isoniazid that were 
greater than two-fold after induction were considered to be biologically significant.  
 
Figure 4.8: Dose response curve of MRC20 versus isoniazid ± inducer.  Data points represent the 
mean growth of the MRC20 strain with or without 20 ng∙mL-1 of the inducer tetracycline (Tc) over 
three independent experiments with standard error bars shown. 
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The MICs of isoniazid for the nudC and MSMEI_1905 overexpression strains were 
determined by dose-response assay, along with the following control strains: an empty 
vector control, an inhA overexpression control, and an MSMEI_4267 random gene 
overexpression control (Figure 4.9). Overexpression of nudC and inhA resulted in a greater 
than 100-fold increase in the MIC of isoniazid, from approximately 10 µM in the un-induced 
overexpression strain, to greater than the highest tested concentration of 1 mM in the 
induced overexpression strain. The MSMEI_1905 overexpression strain did not show any 
change in the MIC of isoniazid following induction, nor did the random gene expression 
control strain (MSMEI_4267). 
 
Figure 4.9: Overexpression strains versus isoniazid. MICs of isoniazid for gene overexpression strains 
including empty vector (EV) control MRC20, with and without induction with 20 ng.mL-1 tetracycline 
(Tc).  Column heights represent mean MICs over three independent experiments with standard error 
bars shown. For those columns that have no error bars the standard error was zero. The highest 
tested concentration of isoniazid was 1 mM, with MIC values greater than the highest tested 
concentration indicated with a caret (^). 
 
4.3.2. Rifampicin 
4.3.2.1. Transposon insertion site identification 
The transposon insertion sites were able to be identified for 11 of the 12 mutants most 
hypersensitive to rifampicin identified in Chapter Three, using either inverse PCR or 
ligation-mediated PCR as described in section 4.2.1. (Table 4.3). 
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Table 4.3: Transposon insertion sites in rifampicin hypersensitive mutants.  
Mutant 
Strain 
Tn611 insertion location (ORF) Putative Identification 
Common 
Name 
Nearest 
H37Rv 
homologue 
Gene 
Length (bp) 
POI 
myco0163 MSMEI_6730 proline-rich 28 kDa antigen mtc28 Rv0040c 945 399 
myco0891 Undefined Transposase ISMsm2 - 987 - 1086 97 
myco1030 MSMEI_6040 penicillin binding protein ponA2 Rv3682 2454 260 
myco2642 
19 bp downstream of MSMEI_6263 
>1000 bp upstream of  MSMEI_6264 
MSMEI_6263 - ESX-1 transcriptional regulator 
MSMEI_6264 - Conserved hypothetical protein 
espR 
Rv3849 
- 
405 
492 
- 
- 
myco2694 MSMEI_1186 rifampicin ADP-ribosyl transferase arr - 429 224 
myco4005 MSMEI_3093 
ribosomal large subunit pseudouridine synthase 
D 
 Rv1540 930 528 
myco5826 
98 bp downstream of MSMEI_1800 
52 bp upstream of MSMEI_1801 
MSMEI_1800 - TetR like transcriptional regulator 
MSMEI_1801 - Adenosylhomocysteinase 
- 
ahcY 
Rv3249C 
Rv3248C 
714 
1458 
- 
- 
myco5883 Undefined Transposase ISMsm4 - 1323 348 
myco6762 MSMEI_0227 metallopeptidase zmp1 Rv0198c 2001 774 
myco6859 MSMEI_6301 O-methyltransferase omt Rv1153c 819 722 
myco7011 MSMEI_5621 Cell envelope-related transcriptional attenuator - Rv0822c 2379 502 
Rifampicin hypersensitive mutants are organised by their location in the mutant collection in ascending order. Transposon point of insertion (POI) is counted 
from the start of the gene. For the undefined mutant myco0891 the range of gene lengths of the four possible insertion sites is given. 
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Two mutants, myco0891 and myco5883, contained Tn611 insertions in two different 
insertion elements, each of which is present in multiple copies within the genome of 
M. smegmatis mc2155. Myco0891 contains a transposon insertion in an ISMsm2 transposase 
gene that occurs four times in the M. smegmatis mc2155 genome at MSMEI_0054, 
MSMEI_3431, MSMEI_4411, and MSMEI_5518. Myco5883 contains a transposon insertion 
within an ISMsm4 transposase that occurs four times in the M. smegmatis mc2155 genome 
at MSMEI_0419, MSMEI_1205, MSMEI_2757, and MSMEI_5245. The entire sequences 
generated for both of these mutants were within the ORFs of the transposase genes, 
therefore the specific copies of ISMsm2 or ISMsm4 that contained the insertions could not 
be determined by inverse PCR or ligation-mediated PCR.  
 
4.3.2.2. Complementation of rifampicin hypersensitive mutants 
The mutant strains selected for complementation, myco2694 and myco4005, were eight-fold 
and four-fold more sensitive to rifampicin respectively (Chapter Three) compared with a less 
than two-fold increase in sensitivity for the other mutant strains. It was expected that the 
greater sensitivity of these strains would make it easier to determine whether or not 
complementation was successful. The mutant strains myco2694 and myco4005 are 
henceforth referred to by the ORF containing the Tn611 insertion: Tn::arr and 
Tn::MSMEI_3093 respectively. Although vectors for the complementation of each strain 
were constructed, an empty vector control strain was not constructed for Tn::MSMEI_3093. 
No colonies grew when Tn::MSMEI_3093 was transformed with the empty vector pRC20, 
despite four experimental repeats. As there was no suitable control, complementation of 
Tn::MSMEI_3093 was not performed. Due to the already well characterised activity of Arr in 
M. smegmatis, the complementation of the Tn::arr mutant was to serve as a positive control 
for the complementation of rifampicin hypersensitive mutants. As such, complementation of 
Tn::arr was not pursued once it was decided to not pursue complementation of 
Tn::MSMEI_3093. 
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4.3.2.3. Overexpression of genes related to rifampicin hypersensitivity 
Background sensitivity of WT M. smegmatis to rifampicin upon vector induction was 
determined by way of a dose-response assay against the empty vector control strain MRC20. 
No change in the MIC of rifampicin for MRC20 was observed upon induction with 20ng∙mL-1 
tetracycline (Figure 4.10). 
 
Figure 4.10: Dose response curve of MRC20 versus rifampicin ± inducer. Data points represent the 
mean growth of the MRC20 strain with or without 20 ng∙mL-1 of the inducer tetracycline (Tc) over 
three independent experiments with standard error bars shown. 
The role of MSMEI_3093 in rifampicin sensitivity was examined by overexpressing 
MSMEI_3093 in WT M. smegmatis mc2155. The MIC of rifampicin for the empty vector 
control strain MRC20, the MSMEI_3093 overexpression strain, and the MSMEI_4267 random 
gene overexpression control strain were determined by a dose-response assay with and 
without induction with 20ng∙mL-1 tetracycline (Figure 4.11). The MIC of rifampicin did not 
change for any of the three strains upon vector induction, with all strains showing an 
approximately equal MIC. 
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Figure 4.11: Overexpression strains versus rifampicin. MICs of rifampicin for gene overexpression 
strains including empty vector (EV) control MRC20, with and without induction with 20 ng∙mL-1 
tetracycline (Tc). Column heights represent mean MICs over three independent experiments with 
standard error bars shown. For those columns that have no error bars the standard error was zero. 
 
4.3.3. Bedaquiline 
4.3.3.1. Transposon insertion site identification 
The transposon insertion sites were able to be identified for eight of the 12 mutants most 
hypersensitive to bedaquiline identified in Chapter Three, using either inverse PCR or 
ligation-mediated PCR. Table 4.4 summarises the sequencing results. As mentioned in 
Chapter Three, the decision to pursue bedaquiline was made late into the thesis and due to 
time constraints the study of bedaquiline hypersensitive mutants did not progress to 
complementation or overexpression assays. 
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Table 4.4: Transposon insertion site for bedaquiline hypersensitive mutants.  
Mutant 
Strain 
Tn611 insertion location (ORF) Putative Identification 
Common 
Name 
Nearest H37Rv 
homologue 
Gene Length 
(bp) 
POI 
myco0934 MSMEI_3416 MmpL family protein MmpL5 Rv0676c 2910 1961 
myco1994 MSMEI_3189 Glutamyl aminopeptidase - - 1002 931 
myco2176 MSMEI_3358 Esterase - Rv1288 1353 827 
myco2833 
77 bp upstream of MSMEI_2671 
181 bp upstream of MSMEI_2672 
Biotin sulfoxide reductase 
Conserved hypothetical protein 
bisC 
- 
Rv1442 
Rv2721c 
2292 
2436 
- 
- 
myco2908 MSMEI_4815 ATP synthase F0 domain, A subunit atpB Rv1304 777 563 
myco3011 MSMEI_4123 Conserved hypothetical protein yfiH Rv2149c 714 462 
myco4393 MSMEI_5136 Transmembrane protein - Rv1072 837 770 
myco5040 MSMEI_5828 PPE family protein - - 1107 423 
Bedaquiline hypersensitive mutants are organised by their location in the mutant collection in ascending order. Transposon point of insertion (POI) is 
counted from the start of the gene.  
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4.4. Discussion 
4.4.1. Identification of transposon insertion sites 
Two different techniques, inverse PCR and ligation-mediated PCR, were used in the 
identification of the Tn611 insertion sites in the drug hypersensitive mutants. Both inverse 
PCR and ligation-mediated PCR rely upon endonuclease digestion of the transposon mutant 
DNA to generate fragments that contain both the end of the transposon, and the adjacent 
gDNA into which it has inserted. Inverse PCR was initially used for identifying the Tn611 
insertion site using RsaI digestion as described by Billman-Jacobe et al. (2006). In this study 
inverse PCR was unable to generate the product containing the Tn611 end and the flanking 
gDNA for some of the mutant strains, amplifying only the internal transposon product. 
Additionally, in some cases a PCR product was generated but the end of the transposon was 
too close to an RsaI site resulting in very short fragments from which no reliable sequence 
matches could be made. In order to overcome this, the inverse PCR method was repeated 
using EagI digestion for those mutant strains where RsaI based inverse PCR failed. Inverse 
PCR using these EagI digested samples enabled identification of the Tn611 insertion site for 
several more, but not all of the transposon mutants, likely due to the same reasons as the 
failure of RsaI based inverse PCR. Ligation-mediated PCR was used as an alternative method 
for identifying the mutation site for those mutant strains where inverse PCR using either 
restriction enzyme was unsuccessful. Ligation-mediated PCR utilises SalI digestion to 
generate DNA fragments containing the transposon DNA/gDNA junction, and a DNA linker to 
allow selective amplification of this junction. Utilisation of ligation-mediated PCR resulted in 
identification of the mutation site for the majority of mutants where inverse PCR was 
unsuccessful. However, the mutation sites could not be identified for one rifampicin 
hypersensitive mutant and for five of the bedaquiline hypersensitive mutants, using either 
inverse PCR or ligation-mediated PCR due to an inability to generate PCR products for 
sequencing. The reason for the inability to generate products for these mutant strains is 
unknown, although due to the late inclusion of bedaquiline in the study significantly less 
time was spent troubleshooting the identification of Tn611 insertion in the bedaquiline 
hypersensitive mutants than those for isoniazid and rifampicin. Future investigations utilising 
other methods such as ligating the DNA fragments containing the gDNA/transposon DNA 
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junction into a vector and sub-cloning into E.coli (Billman-Jacobe et al., 2006) may yield more 
information on the transposon insertion site for these remaining mutants.  
 
4.4.2. Genetic complementation 
The three mutants most sensitive to isoniazid and two mutants most sensitive to rifampicin 
as determined in Chapter Three were selected for complementation. These particular 
mutants were selected for complementation as they showed a large change in the MIC of 
isoniazid or rifampicin than the remainder of the 12 most sensitive mutants. These mutants 
were prioritised for complementation as it was expected that the large decrease in the MIC 
of the relevant drug for these mutants would make it easier to determine whether or not 
complementation was successful. 
Complementation was performed for the isoniazid hypersensitive mutant strains Tn::nudC 
and Tn::MSMEI_1905. Complementation of a third isoniazid hypersensitive mutant, 
Tn::MSMEI_6092, was unable to be completed due to deletions that occurred in all of the 
MSMEI_6092 expression constructs that did not contain the gene in the reverse orientation. 
The deletions that occurred in the MSMEI_6092 construct may have been due to the 
expression of this gene being toxic to E. coli. Although expression of MSMEI_6092 was not 
induced when the vector was sub-cloned, the tetracycline inducible promoter of pRC20 is 
leaky in E. coli DH5α in which the vector sub-cloning was performed.  
Additionally, although a complementation strain was able to be constructed for the 
rifampicin hypersensitive mutant Tn::MSMEI_3093, no empty vector control strain could be 
built (section 4.3.2.2). The mutant Tn::MSMEI_3093 contains the Tn611 insertion within the 
ribosomal large subunit pseudouridine synthase gene and therefore may have defective 
translation. This mutant displayed a slow growth phenotype and it is possible that the 
addition of the hygromycin B antibiotic, an aminoglycoside and inhibitor of transcription, 
required to maintain the plasmid within the host, prevented the strain Tn::MSMEI_3093 
containing pRC20 from growing. Interestingly, the ability to generate the Tn::MSMEI_3093 
complementation strain suggests that it was possible to complement whatever was 
preventing the generation of the empty vector control e.g. hygromycin sensitivity. However, 
this was not examined further in the present study. As no empty vector control could be 
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built for Tn::MSMEI_3093 complementation of this strain was not completed. Consequently, 
it was decided to not attempt complementation of Tn::arr by itself, as the activity of Arr in 
M. smegmatis is already well characterised (Alexander et al., 2003; Dabbs et al., 1995; Quan 
et al., 1999), and the complementation of Tn::arr was only to serve as a control for the 
complementation of rifampicin hypersensitive mutants.  
 
4.4.3. Gene overexpression 
To further characterise the genetic basis of drug hypersensitivity for mutants hypersensitive 
to isoniazid (Tn::nudC and Tn::MSMEI_1905), and rifampicin (Tn::MSMEI_3093) the genes 
containing the Tn611 insertions were overexpressed in WT M. smegmatis mc2155. It was 
found that MRC20 in the presence of the inducer tetracycline had an approximate two-fold 
increase in the MIC of isoniazid, while no change in the MIC of rifampicin was observed. The 
reason for the increased isoniazid MIC observed upon vector induction is unknown. Further 
investigation into the interaction between isoniazid and tetracycline may reveal whether 
there is an overlap between the modes of action of the two drugs or whether the expression 
of GFP influences susceptibility to isoniazid.  
 
4.4.4. Polar effects of Tn611 insertion 
At least six of the hypersensitive transposon mutants contained the Tn611 insertion within 
an intergenic region, suggesting that Tn611 exerts a polar effect on the genes surrounding 
the insertion site. A polar effect also appears responsible for the isoniazid hypersensitive 
phenotype of the Tn::MSMEI_1905 mutant as complementation of this mutant with 
MSMEI_1905 failed to recover WT isoniazid sensitivity. Interestingly, the gene that is 
adjacent to MSMEI_1905 is nudC, which is known to be involved in isoniazid detoxification.  
Therefore, although the most likely candidate genes responsible for the drug 
hypersensitivity phenotype are those that contain a transposon insertion, it is possible that 
polar effects on the adjacent genes also play a role. As complementation was not performed 
for all of the most sensitive mutants, it is not possible to say with certainty which gene is 
responsible for the sensitivity phenotype for the remaining hypersensitive mutants 
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identified in this study. Further investigations into the effect of complementing the 
remaining hypersensitive mutants may reveal the extent that polar effects of Tn611 play a 
role in drug hypersensitivity.  
 
4.4.5. Genotypes related to isoniazid hypersensitivity 
4.4.5.1. Links to known isoniazid mode of action and resistance 
mechanisms 
Four of the 12 mutants most hypersensitive to isoniazid, as determined in Chapter Three, 
had a transposon insertion in or adjacent to genetic loci connected to aspects of the known 
mode of action and/or resistance mechanisms for isoniazid. These genes were: nudC, which 
encodes the NADH pyrophosphatase NudC (two mutants: Tn::nudC and Tn::MSMEI_1905); 
eccCa1, the ESX-1 conserved component Ca; and the ahpCD operon, which encodes the 
heterodimeric alkylhydro peroxide reductase AhpCD. The identification of these four 
mutants with known links to the mode of action of isoniazid validates the use of the assays 
in Chapter Three for investigating isoniazid mode of action.   
NudC (MSMEI_1904) is known to be involved in isoniazid detoxification in M. smegmatis 
mc2155 and M. bovis BCG (Wang et al., 2011). Specifically, NudC has been shown to 
hydrolyse the INH-NAD adduct, which is the active form of isoniazid.  The mutant Tn::nudC 
generated in this thesis contains a transposon insertion within the ORF of nudC, and likely 
represents a loss of function mutation. Interestingly, the mutant Tn::MSMEI_1905 contained 
a Tn611 insertion in the gene MSMEI_1905 which is immediately adjacent to the nudC gene 
in M. smegmatis mc2155. Complementation experiments showed that expression of nudC 
was able to complement the isoniazid hypersensitive phenotype measured in the Tn::nudC 
mutant, while expression of MSMEI_1905 had no effect on the isoniazid hypersensitivity of 
the Tn::MSMEI_1905 mutant. Therefore, it is possible that the isoniazid hypersensitivity of 
the Tn::MSMEI_1905 mutant was due to a polar effect on the expression of the adjacent 
nudC gene. Further investigation into this, such as measuring nudC gene expression levels 
using qPCR, would reveal whether nudC expression levels are lower in the Tn::MSMEI_1905 
mutant than in WT M. smegmatis. To further characterise the role of nudC and MSMEI_1905 
in isoniazid sensitivity each gene was overexpressed in WT M. smegmatis as described in 
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section 4.3.1.3. Overexpression of nudC resulted in increased resistance to isoniazid, 
consistent with the complementation experiments. These results corroborate those 
published by Wang et al. (2011), and strongly support the role of NudC in the detoxification 
of the INH-NAD adduct. Overexpression of MSMEI_1905 did not alter sensitivity to isoniazid, 
again consistent with the results from the complementation experiments. The 
overexpression results further confirm that MSMEI_1905 was not responsible for the 
isoniazid hypersensitive phenotype in this mutant strain.  
Myco2659 contained an insertion in the ESX-1 conserved component Ca1 (eccCa1, 
MSMEI_0062) which is also known to be involved in the mode of action of isoniazid. ESX-1 is 
a type-VII secretion system that plays an important role in excreting proteins involved in 
virulence in mycobacterial species (Pym et al., 2002, 2003). It is loss of the ESX-1 locus, which 
is located in the region of difference 1 (RD1), that is partly responsible for the attenuation of 
the M. bovis BCG vaccine strain (Brosch et al., 2007; Pym et al., 2002, 2003). It has previously 
been shown that EccCa1 is required for proper function of the ESX-1 system, and that loss of 
function mutants of eccCa1 in a related mycobacterial species, M. marinum, exhibit reduced 
secretion of ESAT-6, a protein secreted by the ESX-1 machinery (Joshi et al., 2012). In 
addition, EccCa1 interacts with components of the cell wall biosynthesis machinery, 
including components of the FASII system which is the pathway inhibited by isoniazid (Joshi 
et al., 2012). Joshi et al. (2012) demonstrated that Tn::eccCa1 mutants produced 30% - 40% 
less total mycolic acid compared to WT, suggesting that EccCa1 stabilizes mycolic acid 
biosynthesis. Interestingly, Tn::eccCa1 mutants were also more sensitive to ethionamide, an 
analogue of isoniazid that also inhibits InhA. Therefore, it is likely that the Tn::eccCa1 mutant 
(myco2659) identified in this thesis is hypersensitive to isoniazid due to a partially inhibited 
mycolic-acid biosynthesis pathway resulting from an absence of functional EccCa1. 
The third genetic locus related to the mode of action of isoniazid that was identified in this 
thesis was the ahpCD operon, with the mutant myco7102 containing a Tn611 insertion 36 bp 
downstream of the ahpCD operon (MSMEI_4765/4766). The proteins AhpC and AhpD 
together function as a heterodimeric alkylhydro peroxidase that protects mycobacteria from 
oxidative damage induced by alkylhydro peroxides (Chen et al., 1998). M. tuberculosis 
isoniazid resistant katG mutants often have reduced catalase activity resulting in increased 
oxidative stress. AhpCD is up regulated in M. tuberculosis katG mutants, where it 
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compensates for the reduced KatG activity and resulting increased oxidative stress 
(Dhandayuthapani et al., 1996; Sherman et al., 1996). Overexpression of AhpCD has been 
shown to increase resistance to isoniazid, while conversely, loss of function ahpCD mutants 
appear to show increased sensitivity to isoniazid, due to an altered oxidative stress response 
and concomitant altered katG expression (Zhang et al., 1996). Although myco7102 does not 
contain a Tn611 insertion within the ahpC or ahpD ORFs, its close proximity likely has a polar 
effect upon the expression of the ahpCD operon resulting in the observed isoniazid 
hypersensitivity. This could be confirmed by quantitative PCR to measure the expression of 
ahpCD in the myco7102 mutant. 
 
4.4.5.2. Identification of potentially novel aspects of isoniazid’s mode 
of action 
Other isoniazid hypersensitive mutants identified in this thesis were found to contain Tn611 
insertions in genes that represent potentially novel aspects to the aforementioned known 
modes of action. Other mutants contain Tn611 insertions in genes that have no known links 
to the known mode of action of isoniazid, and represent either novel aspects of the known 
mode of action, or aspects of novel modes of action. 
Tn::MSMEI_6092 contained a Tn611 insertion in a gene encoding a Fur-like protein 
(MSMEI_6092). There are two classes of Fur proteins, Fur A and Fur B, and MSMEI_6092 was 
determined to be more closely related to the FurA type proteins. Fur like regulators regulate 
various aspects of the interlinked process of iron metabolism and the oxidative stress 
response (Dussurget and Smith, 1998). FurA is the regulator for expression of KatG, a 
catalase/peroxidase responsible for detoxification of hydrogen peroxides, and the activation 
of isoniazid. M. smegmatis mc2155 has two copies of katG, each with its own furA regulator 
immediately upstream of the katG ORF. The furA like gene encoded by MSMEI_6092 is not 
near a katG, or katG like gene, and has no direct homolog in M. tuberculosis. As an 
expression construct for MSMEI_6092 could not be constructed in this thesis it was not 
possible to complement the Tn::MSMEI_6092 strain and confirm if the mutation of this gene 
was in fact responsible for the isoniazid hypersensitivity of this strain. It is possible that the 
Tn611 insertion in Tn::MSMEI_6092 had a polar effect on a nearby gene, however the known 
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link between the oxidative stress response, isoniazid, and the pro-drug activating role of 
KatG, strongly suggests it is loss of function of the MSMEI_6092 gene product that results in 
the isoniazid hypersensitivity phenotype of this strain. The furA like gene encoded by 
MSMEI_6092 may have a regulatory role for one or both of the katG genes in M. smegmatis. 
Measurement of katG expression levels in the Tn::MSMEI_6092 mutant would reveal the 
relationship between this furA like gene and KatG. Alternatively, MSMEI_6092 may regulate 
other components of the oxidative stress response, indirectly effecting katG expression. 
Myco1897 and myco6482 contained transposon insertions within transcriptional regulators 
that have homologs in other bacterial species that are involved in multi-drug resistant 
phenotypes. Myco1897 contained an insertion in a multiple antibiotic resistance (Mar) type 
regulator (MarR, MSMEI_5538). In E. coli MarR mediates multiple antibiotic resistance 
through regulation of the genes marA and marB (Cohen et al., 1993), for which mycobacteria 
lack obvious homologs. Interestingly, expression of E. coli marA in M. smegmatis has been 
shown to increase resistance to a range of antibiotics including isoniazid (McDermott et al., 
1998). A MarRAB system was recently characterised in M. smegmatis that MSMEI_5538 was 
not a part of, and which showed no role in isoniazid sensitivity (Zhang et al., 2014). This 
suggests that M. smegmatis may have more than one MarRAB system, perhaps with 
different substrate specificities. 
 Myco6482 contained a transposon insertion in MSMEI_5460, which encodes a putative 
transcriptional regulator of unknown function, and has no clear homolog in M. tuberculosis. 
Bowman and Ghosh (2014) found that expression of MSMEI_5460 was up-regulated in a 
multi-drug resistant KO mutant of MSMEI_5969, which encodes an anti-sigma factor 
proposed to be involved in regulating the 28 sigma factors in M. smegmatis. It was proposed 
that up-regulation of genes including MSMEI_5460 was responsible for the observed 
multi-drug resistant phenotype of this KO strain. The role of these transcriptional regulators 
in a multi-drug resistance phenotype could be further investigated by examining the 
cross-sensitivity of these strains to other antibiotics, and determining which genes they 
regulate. 
Myco2100 and myco3113 contained Tn611 insertions within gene clusters that appear to be 
involved in sulfur metabolism. Altered sulfur metabolism is linked to a deficient oxidative 
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stress response (Dussurget and Smith, 1998). These strains may compensate for the 
increased level of basal oxidative stress by increasing katG expression, resulting in an 
increasing sensitivity to isoniazid as in AhpCD mutants of mycobacteria (Dhandayuthapani et 
al., 1996; Sherman et al., 1996). Further investigation into the expression levels of katG in 
myco2100 and myco3113 may reveal whether this is the case.  
Myco0409 contained an insertion within argD, which lies in the middle of the arginine 
biosynthesis cluster. Because of this genetic organisation, even if the cause of isoniazid 
sensitivity in this strain is not due to a mutation in argD specifically but due to a polar effect, 
it is very likely that arginine biosynthesis would be disrupted. Almost all of the genes in the 
arginine biosynthesis cluster have been shown to be essential for in vitro growth of 
M. tuberculosis H37Rv by transposon based mutagenesis (Sassetti et al., 2003), with the 
exception of argR, which is a negative regulator of arginine biosynthesis (Maas, 1994). To 
the best of my knowledge, there has not been any literature published examining a link 
between arginine metabolism and isoniazid activity. In addition, arginine biosynthesis is not 
known to be linked to the oxidative stress pathway. Therefore, these results may represent a 
novel aspect of the mode of action of isoniazid and a novel role for the arginine biosynthesis 
machinery.  
Myco6166 contained a transposon insertion in a conserved hypothetical protein with 
predicted helicase and DNA binding activity (MSMEI_5554). MSMEI_5554 likely encodes a 
transcriptional regulatory protein and may regulate genes involved in the isoniazid mode of 
action, such as oxidative stress response genes. However, the H37Rv homolog Rv0862c has 
no known reported function so the role of MSMEI_5554 remains unclear. 
Myco6192 contains a transposon insertion within the potassium transporter encoding gene 
kdpA. The KdpA protein functions in a complex with KdpB and KdpC (KdpABC) as a potassium 
transporter, and is stabilised by the co-transcribed gene product KdpF (Gannoun-Zaki et al., 
2013). Overexpression of KdpF caused altered cell morphology in M. bovis BCG in a study by 
Gannoun-Zaki et al., (2013). Although, no change in isoniazid resistance was seen when KdpF 
was overexpressed; however, investigation into altered resistance in KdpF loss of function 
mutants was not performed. 
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4.4.6. Genotypes related to rifampicin hypersensitivity 
4.4.6.1. Links to known rifampicin mode of action and resistance 
mechanisms 
After sequencing the Tn611 insertion sites of 11 of the 12 mutants most hypersensitive to 
rifampicin, as determined in Chapter Three, it was found that three mutants had a 
connection to known rifampicin resistance mechanisms. These three mutants had Tn611 
insertions in arr, which encodes the rifampicin ADP-ribosyl transferase Arr, and ponA2, 
which encodes the penicillin binding protein PonA2. The third mutant had an insertion in the 
gene adjacent to the lipoprotein signal peptidase lspA. The identification of these three 
mutants with known links to the mode of action of rifampicin validates the use of the assay 
used in Chapter Three for investigating rifampicin mode of action.  
Arr  is involved in a known mechanism of rifampicin inactivation in M. smegmatis, whereby 
Arr attaches a ribose moiety to rifampicin resulting in loss of activity (Dabbs et al., 1995; 
Quan et al., 1999; Tanaka et al., 1996). A Tn::arr mutant of M. smegmatis has previously 
been identified in an assay for hypersensitive rifampicin transposon mutants (Alexander et 
al., 2003). As the activity of arr in WT M. smegmatis is already well characterised, 
complementation of the Tn::arr mutant, and overexpression of arr in WT M. smegmatis 
were not performed in this thesis.  
The second mutant with known links to the mode of action of rifampicin was myco1030, 
which contained a transposon insertion in ponA2, a penicillin binding protein. PonA2 is 
suspected to play a role in altering peptidoglycan cross-linking in the mycobacterial cell wall 
during the switch to stationary phase in M. tuberculosis (Vandal et al., 2009). Vandal et al. 
(2009), showed that a M. tuberculosis H37Rv Tn::ponA2 mutant had slightly increased 
sensitivity to rifampicin and other lipophilic drugs, but no increased sensitivity to 
non-lipophilic drugs such as isoniazid. A ponA2 KO mutant of M. smegmatis also previously 
demonstrated increased sensitivity to rifampicin, along with reduced stationary-phase 
survival and an altered cell wall (Patru and Pavelka, 2010). The findings from these previous 
studies suggest that the sensitivity of the Tn::ponA2 mutant identified in this thesis is not 
rifampicin specific; however, this was not further investigated in this thesis. 
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Myco4005 contained a transposon insertion in a gene encoding the ribosomal large subunit 
pseudouridine synthase D (MSMEI_3093). M. smegmatis mc2155 MSMEI_3092 and 
MSMEI_3093 share the same genetic organisation as the H37Rv homologs, which are 
co-transcribed. Therefore, MSMEI_3093 is likely also co-transcribed with MSMEI_3092, 
which encodes the lipoprotein signal peptidase lspA. A previous study demonstrated that 
overexpression of lspA in H37Rv leads to increased resistance to rifampicin (Pathak, 2013). 
Interestingly, Pathak (2013) also showed that overexpression of lspA also led to increased 
resistance to isoniazid in M. tuberculosis. In this thesis it was found that overexpression of 
MSMEI_3093 resulted in no change in the MIC of rifampicin, which may indicate that a polar 
effect on lspA is the genotypic cause for the rifampicin hypersensitivity observed in this 
strain. Complementation with MSMEI_3093 would determine the role of this gene in the 
rifampicin hypersensitivity of the Tn::MSMEI_3093 strain. Complementation of this strain 
was not performed in this study as no suitable empty vector control could be constructed. 
Future complementation of this strain with MSMEI_3093 and lspA would allow the gene 
responsible for hypersensitivity to be determined. 
 
4.4.6.2. Identification of potentially novel aspects of rifampicin’s mode 
of action 
The remaining rifampicin hypersensitive mutants that the Tn611 insertion site was identified 
for have either tentative links, or no clear links to the known mode of action and/or 
detoxification mechanisms for rifampicin, and represent potentially novel modes of action or 
detoxification mechanisms. 
Myco0163 contained a transposon insertion within mtc28, which encodes a 28 kDa secreted 
antigen. Mtc28 contains large proline rich regions that have been implicated in modulating 
the interaction between penicillin binding proteins (PBP) and peptidoglycan (PG) metabolism 
(Manca et al., 1997; Patru and Pavelka, 2010). Therefore, as with the ponA2 mutant, the 
hypersensitivity of this strain may not be specific to rifampicin; however, this was not further 
investigated in this thesis. 
The mutant myco2642 contained a Tn611 insertion 19 bp downstream of the ESX-1 regulator 
EspR (MSMEI_6263), and over 1000 bp upstream of MSMEI_6264. EspR drives expression of 
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ESX-1 genes, increasing pump activity  (Raghavan et al., 2008). As discussed in 
section 4.4.5.1, the ESX-1 system is involved in secretion of proteins that are important for 
mycobacterial virulence. The transposon mutant myco2642 is predicted to have a loss of 
activity of the espR gene product and therefore decreased ESX-1 activity. To the best of my 
knowledge, no links between a defect in EspR and/or the ESX-1 system and rifampicin 
sensitivity exist within the literature. As ESX-1 is involved in pumping out many substrates 
the specific mechanism for rifampicin hypersensitivity in myco2642 is unknown, however it 
represents a potentially novel role for EspR, and by association ESX-1, in the rifampicin mode 
of action, or its detoxification. 
Myco5826 contains a transposon insertion 98 bp downstream of a gene encoding a 
predicted TetR like transcriptional regulator (MSMEI_1800). To the best of my knowledge no 
links between the rifampicin mode of action and this gene, or the M. tuberculosis homolog 
(Rv3249c), exist in the literature. Identification of the genes regulated by this TetR 
transcriptional regulator would facilitate understanding the basis for the rifampicin 
hypersensitivity of this strain 
Myco6762 contains a transposon insertion in the gene encoding the metallopeptidase Zmp1 
(MSMEI_0227). The M. tuberculosis Zmp1 homolog has been shown to be involved in 
pathogenicity whereby Zmp1 prevents formation of the inflammasome, a protein complex 
involved in modulating the host response to M. tuberculosis infection (Ferraris and Rizzi, 
2011; Ferraris et al., 2011; Master et al., 2008). No links between this process and the mode 
of action of rifampicin could be identified in the literature so the mechanism of rifampicin 
hypersensitivity in myco6762 remains unknown.  
Myco6859 contains a Tn611 insertion in MSMEI_6301, which encodes the 
O-methyltransferase (omt). O-methyltransferase is involved in methylation of the cell wall of 
M. smegmatis (Jeevarajah et al., 2002). No link between omt or the M. tuberculosis homolog 
Rv1153c, and altered rifampicin sensitivity could be found in the literature.  
Myco7011 contained a Tn611 insertion in a gene encoding a cell envelope-related 
transcriptional attenuator (MSMEI_5621). The M. tuberculosis homolog, Rv0822c, has been 
shown to be significantly up-regulated in an RD1 deletion mutant of H37Rv (Mostowy et al., 
2004). RD1 is one of the major regions of the genome of M. bovis BCG that is missing 
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compared to the genome of M. bovis and M. tuberculosis. The absence of RD1 has been 
shown to be largely responsible for the attenuation of BCG, due to the loss of the ESX-1 
type-VII secretion system. The relationship of this gene to the RD1 locus suggests this gene 
may be involved in the regulation of ESX-1, similar to the rifampicin hypersensitive Tn::espR 
mutant also identified in this thesis. Therefore, these results strongly implicate a role for 
ESX-1 in the rifampicin mode of action or detoxification.  
 
4.4.7. Genotypes related to bedaquiline hypersensitivity 
4.4.7.1. Links to known bedaquiline mode of action and resistance 
mechanisms 
Characterisation of the Tn611 insertion sites of the 12 mutants most hypersensitive to 
bedaquiline as determined in Chapter Three, revealed that two mutants had connections to 
known aspects of the mode of action and/or resistance mechanisms for bedaquiline These 
two mutants had Tn611 insertions in atpB, which encodes the ATP synthase F0 domain A 
subunit, and mmpL5, which encodes a transmembrane transporter. The identification of 
these two mutants with Tn611 insertions within or adjacent to genes with known links to the 
mode of action of bedaquiline validates the use of the assays used in Chapter Three for 
investigating bedaquiline mode of action.  
Myco2908 contained a Tn611 insertion in the atpB gene, which encodes subunit A of the 
ATP synthase F0 domain. The F-ATP synthase consists of two domains, F0 and F1, which 
function together to generate ATP. The F0 unit is composed of the A, B, and C subunits and 
the known target of bedaquiline is the C subunit of the ATP synthase F0 domain encoded by 
atpE (Andries et al., 2005; Koul et al., 2007). In M. tuberculosis, atpB and atpE are 
co-transcribed as an operon; therefore, the Tn::atpB mutant identified in this thesis may also 
have altered atpE expression (Roback et al., 2007; Sala et al., 2009). Interestingly the H37Rv 
homolog of atpB has been shown to be essential in M. tuberculosis by transposon 
mutagenesis (Griffin et al., 2011; Sassetti et al., 2003). The requirement for atpB in 
M. tuberculosis for viability, suggests that there is some functional redundancy in 
M. smegmatis as a viable Tn::atpB mutant was generated in this thesis. The bedaquiline 
hypersensitivity of this mutant may be due to a general defect in the ATP synthase, or more 
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specifically due to altered expression of the target of bedaquiline atpE; however, this was 
not further investigated in this thesis. 
The second mutant with links to the known mode of action of bedaquiline was myco0934, 
which contained a Tn611 insertion in mmpL5 (MSMEI_3416). The homologous 
M. tuberculosis protein is an efflux pump that is proposed to pump bedaquiline out of the 
cell. Increased expression of mmpL5 in H37Rv was found to increase bedaquiline resistance 
(Andries et al., 2014; Hartkoorn et al., 2014). The mutant Tn::mmpL5 identified in this study 
therefore likely has increased bedaquiline sensitivity due to a loss of MmpL5 efflux activity, 
resulting in increased intracellular concentrations of bedaquiline. 
 
4.4.7.2. Identification of potentially novel aspects of bedaquiline’s 
mode of action 
The remaining bedaquiline hypersensitive mutants that were sequenced were found to 
contain Tn611 insertions in genes with no link to the known mode of action of bedaquiline. 
These therefore represent potentially novel aspects of the mode of action or detoxification 
mechanisms of bedaquiline.  
Myco1994 contains a transposon insertion in MSMEI_3189, which encodes a M42 type 
glutamyl aminopeptidase for which there is no apparent M. tuberculosis homolog. No 
information in the literature relating this gene to any aspects of the bedaquiline mode of 
action could be found, therefore, the mechanism of bedaquiline hypersensitivity for this 
mutant remains unclear. 
Myco2833 contains a transposon insertion 77 bp upstream of the gene encoding the biotin 
sulfoxide reductase (bisC, MSMEI_2671), and 181 bp upstream of MSMEI_2672, which 
encodes a conserved hypothetical protein. As discussed previously, Tn611 exerts a polar 
effect on nearby genes and therefore it is possible that the Tn611 insertion in myco2833 is 
disrupting the function of bisC or MSMEI_2672. Protein BLAST results suggest the product of 
MSMEI_2672 is involved in cell wall biosynthesis. The gene product of MSMEI_2672 contains 
a conserved region consisting of four repeats of a 54 aa sequence named LGFP. The LGFP 
repeats are proposed to be involved in anchoring the protein to the cell wall, with these 
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repeats found in proteins required for stabilising the cell wall in Methanosarcina acetivorans 
(Adindla et al., 2004). Alternatively, the Tn611 insertion in myco2833 may be causing 
hypersensitivity to bedaquiline by a polar effect on MSMEI_2671 gene expression, although 
the exact mechanism of sensitivity is unclear. Generation of knock out mutants of each gene 
would determine which gene is responsible for the bedaquiline hypersensitivity of this 
strain. 
Myco3011 contained a transposon insertion within the gene MSMEI_4123, which encodes a 
conserved hypothetical gene named yfiH. The genetic neighbourhood of yfiH includes a 
number of genes involved in cell division including ftzQ and ftsZ, a genetic organisation 
conserved in M. tuberculosis H37Rv (Doerks et al., 2012; Weiling Hong et al., 2013). The 
conserved genetic region within which yfiH resides suggests that YfiH is involved in the 
process of cell division and/or cell wall maintenance, similar to its genetic neighbours. 
Therefore, the bedaquiline hypersensitivity of this strain may be due to deficient cell wall 
division/maintenance.  
Myco4393 contained a transposon insertion in MSMEI_5136, which encodes a putative 
transmembrane protein. Both MSMEI_5136, and its M. tuberculosis homolog Rv1072, reside 
in a relatively conserved genomic region encoding genes related to fatty acid metabolism. 
Interestingly, Rv1072 has been identified as a gene required for late stage survival of 
mycobacteria in a guniea pig infection model, as well as being up-regulated during oxidative 
stress and nutrient limitation (Betts et al., 2002; Kaushal et al., 2002; Manganelli et al., 2002; 
Schnappinger et al., 2003).  
Myco5040 contains a transposon insertion within the gene MSMEI_5828, which encodes a 
PPE family protein that contains the characteristic ~180 bp proline-proline-glutamic acid 
motif at the N-terminus. Little is known about the function of PPE proteins, which together 
with PE proteins (with a characteristic 100 bp proline-glutmaic acid N-terminal motif) 
comprise 10% of the M. tuberculosis genome; The M. smegmatis genome only contains four 
PPE genes (Nair et al., 2009). Adjacent to MSMEI_5828 is MSMEI_5829, which encodes a 
lipid transfer protein ltp2, and is part of a conserved operon spanning MSMEI_5829 to 
MSMEI_5834 in M. smegmatis, and the homologs Rv3540c to Rv3545c in M. tuberculosis 
H37Rv. This conserved region has been shown to be involved in cholesterol metabolism in 
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both M. smegmatis and M. tuberculosis (García-Fernández et al., 2013; Uhía et al., 2012). 
This operon is likely defective in the myco5040 mutant due to polar effects of the Tn611 
insertion, which would lead to dysfunctional cholesterol metabolism. Therefore, a defective 
cholesterol metabolism may be responsible for the bedaquiline hypersensitivity of this 
strain, and may represent a novel aspect of the mode of action of bedaquiline. To the best of 
my knowledge, no clear links between cholesterol metabolism and bedaquiline exist in the 
literature.  
 
4.4.8. Summary 
In summary, the Tn611 insertion site for 31 drug hypersensitive mutants of M. smegmatis 
were identified in this chapter; 12 isoniazid hypersensitive strains, 11 rifampicin 
hypersensitive strains, and 8 bedaquiline hypersensitive strains. Of the isoniazid 
hypersensitive mutants, four had links to either the known mode of action or detoxification 
pathways of isoniazid: ahpC, eccCa1, and nudC which was identified twice with two separate 
mutants. Of the rifampicin hypersensitive mutants, two had connections to either the known 
mode of action or detoxification pathways of rifampicin: arr and ponA2. Of the bedaquiline 
hypersensitive mutants, two mutants had links to either the known mode of action or 
detoxification pathways of bedaquiline: atpB and mmpL5. Collectively, these results validate 
the use of the assay used in this thesis for identifying genes related to drug mode of action. 
The remaining 23 mutants found to be hypersensitive to isoniazid, rifampicin, or bedaquiline 
that the insertion sites were identified for had no clear links to the known mode of action or 
detoxification pathways for each drug, and therefore represent novel aspects of either drug 
mode of action or detoxification mechanisms. As complementation of the transposon 
insertion was not attempted for the majority of drug hypersensitive mutants validated in 
Chapter Three, it is not possible to definitively identify the gene responsible for the observed 
drug hypersensitivity. However, for a number of strains the genes containing or adjacent to 
the Tn611 insertion site provide promising links to the mode of action of isoniazid, 
rifampicin, and bedaquiline respectively. Specifically, three isoniazid hypersensitive mutants 
contained Tn611 insertions either within or adjacent to genes linked to the oxidative stress 
response, which is known to interact with isoniazid via KatG. Interestingly, two genes related 
to the type-VII secretion systems ESX-1 were identified as containing Tn611 insertions in 
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rifampicin hypersensitive mutants. To the best of my knowledge no link between rifampicin 
and the ESX-1 locus exists in the literature. There were no such apparent trends in the 
bedaquiline hypersensitive mutants; however, this is likely a limitation of the number of 
mutants sequenced for each compound. Had more drug hypersensitive mutants had their 
Tn611 insertion sites identified, more trends in terms of pathways containing Tn611 
insertions may have become apparent.   
114 
 
5. Characterising drug sensitivity phenotypes of Tn611 mutants 
5.1. Introduction 
Identifying the cross-sensitivity of the drug hypersensitive mutants identified in Chapter 
Three, and the differential-sensitivity to analogues of the drug that they were first identified 
as being hypersensitive to, can be used to generate more information on the specific role of 
the genes harbouring Tn611 insertions. Cross-sensitivity testing of the hypersensitive 
mutants generates information on whether the drug sensitivity of the mutants identified in 
Chapter Three is drug specific or a result of a general multi-drug resistance mechanism (drug 
non-specific). Differential-sensitivity to analogues of the drug that the mutant strain is 
hypersensitive to, where the mutants strains are either more or less sensitive to the 
analogues than the parent drug, can be used to group mutants that appear to contain 
insertions in genes involved in similar aspects of the drug’s mode of action or drug resistance 
mechanisms. This approach is similar to target based whole-cell drug screening, whereby 
target information is integrated into screening for anti-mycobacterial activity (Ioerger et al., 
2013; Nisa et al., 2010). The information from these assays for cross- and differential-
sensitivity can be used to generate a more complete description of the drug mode of action. 
 
5.1.1. Analogues of anti-tuberculosis drugs 
The design and synthesis of drug analogues makes it possible to improve upon the 
properties of the originally isolated compound or to examine the mode of action of the drug. 
In the case of anti-TB drugs, analogues have been developed in an effort to improve 
anti-mycobacterial activity, especially against drug resistant strains, or to improve 
pharmacokinetic properties. For example, rifapentine  is an analogue of rifampicin that has 
an increased half-life in the plasma of patients, allowing less frequent dosing (Acocella et al., 
1971; Benator et al., 2002; Keung et al., 1999). This improves the likelihood that patients will 
adhere to the drug regimen, reducing the probability of rifapentine resistance occurring in 
the patient. Isoniazid was an intermediate generated when synthesising analogues of 
nicotinic acid with improved mycobacterial activity (Pansy et al., 1952). Isoniazid was found 
to have much greater activity than the other analogues of nicotinic acid that retained activity 
against TB, including pyrazinamide and ethionamide. 
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Analogues are also used when studying drug structure-activity relationships (SAR), whereby 
the differential activity of the various analogues can provide information on key parts of the 
drug that are required for activity. This type of study can be combined with analysis of 
hypersensitive mutant strains to identify analogues that are less active against the mutants 
than expected. Differential-sensitivity of the mutant strain to different drug analogues 
indicates that the mode of action of the analogue differs in some way to that of the original 
drug, or that the analogue is resistant to a specific detoxification mechanism that defends 
against the original drug. As drugs are pleiotropic their complete anti-mycobacterial activity 
is likely to stem from a combination of both the action against the primary target and action 
against lesser secondary targets. Close structural analogues are generally expected to retain 
the complete mode of action of the parent drug; however, the activity against the specific 
target that generates most of its anti-mycobacterial activity may be altered and a secondary 
target of the parent drug may then take over to generate most of its anti-mycobacterial 
activity. As such, analogues that preferentially work via these secondary targets can be used 
as tools to identify these secondary targets, generating information on the overall mode of 
action of the parent drug. As the primary goal of the research described in this thesis was to 
gain a better understanding of the mode of action of these drugs in M. tuberculosis, it is 
important that analogues that transposon mutants demonstrate hypersensitivity to are 
active in M. tuberculosis. Any analogues that lack activity in M. tuberculosis are likely to have 
a mode of action specific to M. smegmatis. 
 
5.1.2. Isoniazid, rifampicin, and bedaquiline hypersensitive mutants 
The hypersensitive M. smegmatis mutant strains studied were the isoniazid hypersensitive 
mutants Tn::nudC and Tn::MSMEI_6092; the rifampicin hypersensitive mutants Tn::arr and 
Tn::MSMEI_3093; and the bedaquiline hypersensitive mutants Tn::atpB and 
Tn::MSMEI_3189. NudC has recently been demonstrated to be able to hydrolyse the 
INH-NAD adduct responsible for the inhibition of InhA (Wang et al., 2011). MSMEI_6092 
encodes a Fur like protein of unknown function that likely regulates some aspect of the 
oxidative stress response. Arr is a known rifampicin-inactivating enzyme that works by 
ribosylating rifampicin (Dabbs et al., 1995; Quan et al., 1999). MSMEI_3093 encodes the 
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ribosomal large subunit pseudouridine synthase D, although rifampicin hypersensitivity in 
the Tn::MSMEI_3093 strain may be due to altered transcription of the adjacent gene lspA 
(Pathak, 2013). Subunit A of the ATP synthase, encoded by atpB, is a subunit of the F0 
domain of the ATP synthase that is inhibited by bedaquiline. MSMEI_3189 encodes a 
glutamyl aminopeptidase, although the genetic basis of bedaquiline hypersensitivity for 
Tn::MSMEI_3189 remains unclear. These mutants were selected for further characterisation 
as they demonstrated the largest increases in sensitivity to the drugs tested; therefore it was 
reasoned that any cross-sensitivities or differential-sensitivities would be easier to identify 
than with the other mutants that showed a small increase in sensitivity. 
 
5.1.2. Objectives of Chapter Five 
The goal of Chapter Five was to further characterise a selection of the drug hypersensitive 
mutants identified in Chapter Three. Specific focus was given to the drug hypersensitive 
mutants’ cross-sensitivity to other drugs and their differential-sensitivity to analogues of the 
drug that they were initially identified as being hypersensitive to. 
To achieve this goal the following specific aims were addressed: 
 Determine cross-sensitivity of the isoniazid hypersensitive transposon mutants 
Tn::nudC and Tn::MSMEI_6092, the rifampicin hypersensitive mutants Tn::arr and 
Tn::MSMEI_3093, and the bedaquiline hypersensitive mutants Tn::atpB and 
Tn::MSMEI_3189 
 Determine the differential-sensitivity of the rifampicin hypersensitive mutants Tn::arr 
and Tn::MSMEI_3093, and the MSMEI_3093 overexpression strain, to the rifampicin 
analogue rifapentine 
 Determine the differential-sensitivity of Tn::nudC, and nudC, inhA, and katG 
overexpression strains, to isoniazid analogues active against M. smegmatis mc2155 
 Confirm activity in M. tuberculosis of analogues that M. smegmatis transposon 
mutant strains showed differential-sensitivity to 
To examine specificity of drug hypersensitivity, for each mutant that was identified in the 
primary testing (Chapters Three and Four) as being hypersensitive to one of the three drugs 
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considered (isoniazid, rifampicin, and bedaquiline), the cross-sensitivities were determined 
for the other two drugs. The overexpression strains created in Chapter Four were used in the 
differential-sensitivity assay, with the exception of the katG overexpression strain which was 
generated in this chapter. Preliminary sensitivity testing of isoniazid analogues in 
M. tuberculosis was performed against the virulent strain H37Rv. 
 
5.2. Methods 
5.2.1. Cross sensitivity testing of transposon mutants to other drugs 
The cross-sensitivity was determined for the isoniazid hypersensitive mutants Tn::nudC and 
Tn::MSMEI_6092, the rifampicin hypersensitive mutants Tn::arr and Tn::MSMEI_3093, and 
the bedaquiline hypersensitive mutants Tn::atpB and Tn::MSMEI_3189 to rifampicin and 
bedaquiline, isoniazid and bedaquiline, and isoniazid and rifampicin, respectively. 
Cross-sensitivity of the hypersensitive strains was quantified by MIC using dose-response 
assays (section 2.8.3), and compared to the mean random transposon mutant control MIC. 
MICs were presented as the MIC ratio between the hypersensitive mutant and the mean 
control MIC. 
 
5.2.2. Differential-sensitivity testing of transposon mutants to drug 
analogues 
The differential-sensitivities of the rifampicin hypersensitive mutant strains Tn::arr and 
Tn::MSMEI_3093 to rifapentine, and the differential-sensitivities of the isoniazid 
hypersensitive mutant Tn::nudC to a range of isoniazid analogues were determined. 
Differential-sensitivity was quantified by MIC using dose-response assays (section 2.8.3). MIC 
values were given as the MIC ratio between the hypersensitive mutant and the MIC for the 
control strain D11. Differential-sensitivity was defined as a greater than 1.5-fold difference in 
the MIC ratio of the analogue and the original drug (rifampicin or isoniazid). 
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5.2.2.1. Selection of isoniazid analogues for differential-sensitivity 
testing 
A total of 30 randomly selected isoniazid analogues were obtained from the National 
Institute of Health’s (NIH) Developmental Therapeutics Program (DTP) repository, along with 
a sample of isoniazid. All analogues were dissolved in 100% dimethyl sulfoxide (DMSO) at a 
concentration of 10 mg∙mL-1 and stored at -20 °C. A full list of the isoniazid analogues, 
including their structural information is listed in appendix section 8.4. The isoniazid 
analogues were tested against WT M. smegmatis mc2155 to determine their 
anti-mycobacterial activity (section 2.8.2), and only those analogues with sufficient activity 
were progressed into differential-susceptibility testing. Briefly, the analogues that showed 
greater than 75% growth-inhibition at a concentration of 100 µg∙mL-1 averaged (mean) 
across two separate experiments were taken to have sufficient activity for 
differential-sensitivity testing. The MICs of the isoniazid analogues that were active against 
M. smegmatis mc2155 were determined by dose-response assay (section 2.8.3).  
 
5.2.3. Overexpression strains versus isoniazid analogues 
The MICs of the isoniazid analogues to which Tn::nudC showed differential-sensitivity were 
determined for the nudC and inhA overexpression strains constructed in Chapter Four, along 
with the empty vector control and random gene overexpression control strain. 
Overexpression assays were performed as described in section 2.8.3. Briefly, the MIC of the 
relevant analogue was determined by dose-response assay for the overexpression strains, 
both with and without vector promoter induction by 20 ng∙mL-1 tetracycline. 
 
5.2.3.1. katG overexpression strain versus isoniazid analogues 
M. smegmatis mc2155 contains two homologues of katG, MSMEI_3380 and MSMEI_6216, 
with MSMEI_6216 sharing the greatest amino acid identity with the M. tuberculosis H37Rv 
katG gene, Rv1908c (appendix section 8.2). Therefore, for the purposes of this study 
MSMEI_6216 was used as the M. smegmatis mc2155 katG gene (katGsm) for the 
overexpression assay and was amplified by PCR from WT M. smegmatis mc2155 and cloned 
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into the BamHI restriction site in plasmid pRC20 (section 2.6.9.1). The native katGsm gene 
contains a BamHI site within its ORF, therefore overlap PCR was used to remove the 
restriction site by creating a silent mutation that was confirmed by sequencing (Table 2.9). 
Constructs of pRC20 containing katGsm were sequenced to check orientation and fidelity 
before transforming into WT M. smegmatis mc2155 to generate the katG overexpression 
strain (section 2.6.2 and 2.6.7.2). 
The katGsm overexpression assay was performed as described in section 2.8.3. Briefly, the 
MIC of the relevant analogue was determined by dose-response assay for the 
overexpression strain, both with and without vector promoter induction by 20 ng∙mL-1 
tetracycline. 
 
5.2.4. M. tuberculosis H37Rv versus isoniazid analogues 
Preliminary determination of the sensitivity of M. tuberculosis H37Rv to the isoniazid 
analogues that the Tn::nudC strain showed differential-sensitivity to was performed in the 
PC3 laboratory at University College Dublin (Dublin, Ireland). Sensitivity was quantified by 
MIC determination in a dose-response assay, with one experiment performed (section 
2.8.3). Briefly, MICs were determined by eye as the lowest concentration 24 hours after the 
addition of 50 µL 0.03% resazurin to each well of the assay plates.  
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5.3. Results 
5.3.1. Cross-sensitivities of hypersensitive mutants 
The cross-sensitivities of the hypersensitive mutants are presented in Table 5.1. The 
rifampicin hypersensitive mutant Tn::MSMEI_3093 showed a minor increase in resistance to 
isoniazid, and the bedaquiline hypersensitive mutants Tn::atpB and Tn::MSMEI_3189 
showed minor increases in resistance to rifampicin, with Tn::MSMEI_3189 also showing a 
minor increase in resistance to isoniazid. No mutants showed an increased sensitivity to any 
of the other drugs tested. 
Table 5.1: Cross-sensitivity of hypersensitive strains. 
 MIC ratio 
Strain Isoniazid Rifampicin Bedaquiline 
Isoniazid 
   
Tn::nudC - 1.2 0.67 
Tn::MSMEI_6092 - 1 1 
Rifampicin 
   
Tn::arr 1 - 1 
Tn::MSMEI_3093 0.5 - 1.2 
Bedaquiline 
   
Tn::atpB 1 0.5 - 
Tn::MSMEI_3189 0.5 0.5 - 
MIC ratios for hypersensitive mutants compared to the mean MIC of the random transposon mutant 
control strains for isoniazid, rifampicin, and bedaquiline. An MIC ratio of less than one (red shading) 
indicates increased resistance, while a ratio of more than one (green shading) indicates increased 
sensitivity, and a ratio of one (yellow shading) indicates no change in sensitivity for the 
hypersensitive mutant compared to the control strain D11. 
 
5.3.2. Differential-sensitivity of hypersensitive mutants 
5.3.2.1. Rifapentine versus rifampicin hypersensitive transposon 
mutants 
The differential-sensitivities of the two rifampicin hypersensitive strains Tn::arr and 
Tn::MSMEI_3093 to the rifampicin analogue rifapentine were determined (Table 5.2). Both 
of the rifampicin hypersensitive strains showed similar increases in sensitivity to rifapentine 
compared to the control strains as had been seen with the parent compound rifampicin. 
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Table 5.2: Sensitivity of rifampicin hypersensitive mutants to rifapentine. 
Drug 
MIC ratio 
Tn::arr Tn::MSMEI_3093 
Rifampicin 7.2 4.1 
Rifapentine 8 5 
MIC ratios for the rifampicin hypersensitive strains Tn::arr and Tn::MSMEI_3093 compared to the 
random transposon mutant control strain D11 for rifampicin and rifapentine. A larger MIC ratio 
indicates increased sensitivity of the hypersensitive mutant compared to the control strain D11. 
 
5.3.2.2. Isoniazid analogues tested in isoniazid hypersensitive 
transposon mutants 
A selection of isoniazid analogues obtained from the DTP repository were tested for activity 
against WT M. smegmatis mc2155 at 100 µg∙mL-1. A total of 14 of the 30 isoniazid analogues 
tested demonstrated greater than 75% growth-inhibition against WT M. smegmatis mc2155 
and were selected for differential-sensitivity testing of the isoniazid hypersensitive mutant 
Tn::nudC (Figure 5.2). The NSC numbers of the analogues that showed growth-inhibitory 
activity greater than the 75% cut-off were 6855, 23449, 27607, 33759, 33760, 33763, 36086, 
37379, 37800, 40350, 59320, 141142, 176757, and 322078. Information on these 14 
analogues can be found in appendix section 8.4, along with structural details. Interestingly, 
all 14 of these analogues with activity in M. smegmatis had the core structure of isoniazid, 
varying only in their side chains (Figure 5.1). The total 30 analogues originally tested had a 
range of structures, with only 19 of the analogues retaining the core structure of isoniazid. 
Therefore, some of the analogues found to be inactive against WT M. smegmatis mc2155 
also had the structure indicated below. 
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Figure 5.1: Structure of isoniazid analogues active against M. smegmatis mc2155. Structure of 
analogues of isoniazid that showed greater than 75% growth-inhibition of WT M. smegmatis mc2155 
at 100 µg∙mL-1 where R represents the various side chains that differed among the 14 analogues. 
Comparison of the activity against WT M. smegmatis mc2155 of all 19 analogues with the 
structure in Figure 5.1 revealed no patterns in terms of side chains of active and inactive 
isoniazid analogues (appendix section 8.4). 
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Figure 5.2: Growth-inhibition of WT M. smegmatis mc2155 by isoniazid analogues. Columns 
represent mean growth of WT M. smegmatis mc2155 in 100 µg∙mL-1 of each analogue across three 
independent experiments with standard error bars shown. Isoniazid analogues are named according 
to their NSC number. The dotted line at 25% growth indicates the activity cut-off of 75% 
growth-inhibition, with analogues that inhibited growth beyond this cut-off proceeding to the 
differential-sensitivity assay. 
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The MICs of the 14 isoniazid analogues were determined for the isoniazid hypersensitive 
strain Tn::nudC and the random transposon control strain D11, with the MIC ratios for these 
two strains given in Table 5.3. The Tn::nudC strain showed an increased sensitivity compared 
to D11 for all 14 isoniazid analogues tested. The Tn::nudC strain was 4.8-fold more sensitive 
to isoniazid compared to the control strain D11, and showed similar sensitivity to eight of 
the analogues. The Tn::nudC strain showed differential-sensitivity to the remaining six 
isoniazid analogues, showing only two – three-fold increases in sensitivity to these analogues 
compared to the control strain D11. The NSC numbers of the six analogues that Tn::nudC 
showed differential-sensitivity to were 27607, 33759, 37800, 40350, 141142, and 176757. 
There were no obvious patterns regarding the side chains of these analogues and their 
activity against Tn::nudC. 
Table 5.3: Sensitivity of Tn::nudC to isoniazid analogues. 
Isoniazid analogue 
(NSC number) 
MIC 
Ratio 
Side chain structure 
37800 2.0 
 
40350 2.0 
 
27607 2.4 
 
141142 2.4  
33759 2.7 
 
176757 3.0 
 
6855 4.0 
 
23449 4.0 
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36086 4.0 
 
59320 4.0 
 
322078 4.0 
 
33760 4.8 
 
33763 4.8 
 
37379 4.8 
 
Isoniazid (9659) 4.8 INH 
MIC ratios for the rifampicin hypersensitive strains Tn::arr and Tn::MSMEI_3093 compared to the 
control strain D11 for the 14 isoniazid analogues active against WT M. smegmatis mc2155. A larger 
MIC ratio indicates increased sensitivity of the hypersensitive mutant compared to the control strain 
D11. Side chains from the core isoniazid (INH) structure are shown. 
 
5.1.1. Isoniazid analogues versus overexpression strains 
The sensitivities of the nudC and inhA overexpression strains to the six isoniazid analogues 
that Tn::nudC showed differential-sensitivity to were determined and compared to the 
random gene overexpression control strain and the empty vector control (Figure 5.3). 
Induction of expression from either the empty vector control or the random gene control 
MSMEI_4267 with 20 ng∙mL-1 tetracycline did not increase the MIC of any of the analogues 
greater than the basal two-fold increase in resistance observed for the empty vector control 
versus isoniazid (Figure 4.8). Induction of inhA expression resulted in a greater than 10-fold 
126 
 
increase in resistance to analogues 37800, 141142, and 176757 and to isoniazid. Similarly, 
induction of nudC expression resulted in greater than 10-fold increases in resistance to 
analogues 37800, 141142, and 176757 and to isoniazid. No increase above the baseline was 
observed for the analogues, 27607 and 33759 when expression of either nudC or inhA was 
induced. No change in resistance was observed for analogue 40350 in any of the 
overexpression strains. 
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Figure 5.3: Overexpression strains tested with isoniazid analogues. MICs are presented for the 
nudC, inhA, random gene MSMEI_4267 control, and empty vector (EV) control overexpression strains 
versus isoniazid analogues with and without promoter induction by 20 ng∙mL-1 tetracycline (Tc). The 
DTP repository number for each of the analogues is written in italics. Column heights represent mean 
MICs across three independent experiments with standard error bars shown. MICs greater than the 
highest concentrations tested were indicated with the caret symbol (^). 
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The sensitivity of the katGsm (MSMEI_6216) overexpression strain to isoniazid following 
induction with tetracycline was assessed (Figure 5.4). The katGsm over-expression strain was 
four-fold more sensitive to isoniazid following vector induction.  
 
 
Figure 5.4: katGsm overexpression strain versus isoniazid. MIC of isoniazid for the empty vector (EV) 
control strain MRC20 and katGsm overexpression strain, with and without promoter induction by 
20 ng∙mL-1 tetracycline (Tc). Columns represent the mean MIC across three independent experiments 
with standard error bars shown. 
The MICs of the six isoniazid analogues that Tn::nudC showed differential-sensitivity to were 
determined for the katGsm overexpression strain (Figure 5.5). The katGsm overexpression 
strain showed increased sensitivity to all six isoniazid analogues following vector induction 
with tetracycline. The katGsm overexpression strain was five-fold more sensitive to the 
isoniazid analogue 40350, three-fold more sensitive to the analogues 27607, 33759, 141142, 
and 176757, and 2.5-fold more sensitive to the analogue 37800 following vector promoter 
induction.  
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Figure 5.5: katGsm overexpression strain versus isoniazid analogues. MICs of isoniazid analogues and 
isoniazid (INH), for the katGsm overexpression strain, with and without vector promoter induction 
with 20 ng∙mL-1 tetracycline (Tc). Columns represent mean MIC values across three independent 
experiments with standard error bars shown. 
 
5.1.2. Activity of isoniazid analogues in wild-type mycobacterial strains 
The six isoniazid analogues that showed differential activity against Tn::nudC (Table 5.3) 
were re-tested against WT M. smegmatis mc2155 to determine their MICs. Preliminary 
testing was also carried out to determine the MIC of the isoniazid analogues for 
M. tuberculosis H37Rv (Table 5.4). For M. smegmatis mc2155, analogues 37800 and 40350 
had low activity compared to isoniazid, with MICs that were approximately three-fold and 
seven-fold higher than the MIC of isoniazid. The remaining analogues showed activity 
comparable to isoniazid, with MICs within two-fold of the MIC of isoniazid. For 
M. tuberculosis H37Rv only the two analogues 141142 and 37800 had activities comparable 
to isoniazid, with MICs approximately two-fold higher than the MIC of isoniazid. The 
remaining analogues had MICs for M. tuberculosis that were at least 15-fold higher than that 
of isoniazid. 
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Table 5.4: MICs of isoniazid analogues for WT M. smegmatis and M. tuberculosis. 
 MIC ± se (µM) MIC (µM) 
INH Analogue 
(NSC Number) 
M. smegmatis 
mc2155 
M. tuberculosis 
H37Rv 
27607 45.3 ± 0.00 363 
33759 58.7 ± 19.5 312 
37800 113 ± 0.00 28.4 
40350 257 ± 85.8 172 
141142 62.9 ± 21.0 21.0 
176757 25.9 ± 0.00 207 
9659 (isoniazid) 34.2 ± 11.4 11.4 
MICs are presented for isoniazid and isoniazid analogues for WT M. smegmatis mc2155 and 
M. tuberculosis H37Rv. MICs for M. smegmatis represent mean MICs across three independent 
experiments with standard error (se) presented. MICs for M. tuberculosis H37Rv represent results 
from a single preliminary experiment. 
 
5.4. Discussion 
The first aim of this chapter was to characterise the cross-sensitivity of selected 
hypersensitive mutants identified in Chapter Three to other anti-mycobacterial drugs. The 
second aim was to investigate whether the hypersensitive mutants displayed 
differential-sensitivity to analogues of the drug that they were hypersensitive to. The 
sensitivities of relevant overexpression strains and of M. tuberculosis H37Rv were also 
determined for the isoniazid analogues that Tn::nudC demonstrated differential-sensitivity 
to, to further characterise their anti-mycobacterial activity. 
 
5.4.1. Cross-sensitivity of hypersensitive transposon mutants 
The two isoniazid, two rifampicin, and two bedaquiline hypersensitive mutants examined in 
this chapter were all tested for cross-sensitivity to the other two compounds of the three 
compounds used during the initial assay for drug hypersensitivity. None of the mutants 
examined showed cross-sensitivity to the other two drugs. This is in keeping with the fact 
that none of the mutant strains were identified in either the primary or secondary assays for 
drug hypersensitivity for more than one compound. These results indicate that the drug 
hypersensitivity of these six mutants is specific to the mode of action of these compounds, 
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rather than a generic mechanism of drug resistance across two or more of the three drugs 
used (isoniazid, rifampicin, and bedaquiline). This statement is supported by the known roles 
of NudC and Arr in isoniazid and rifampicin sensitivity, respectively, whereby both enzymes 
are involved in detoxification of a specific drug (Alexander et al., 2003; Dabbs et al., 1995; 
Wang et al., 2011). Furthermore, these findings validate the screening process undertaken in 
this study as a highly specific method to identify mutants hypersensitive to a specific drug. 
 
5.4.2. Differential-sensitivities of hypersensitive transposon mutants to 
drug analogues 
Differential-sensitivity of the transposon mutants to analogues of the three parent drugs 
indicates that the analogues have modified modes of action compared to the parent drug, or 
that the analogues carry modifications that enable them to resist specific detoxification 
mechanisms. In this thesis the differential-sensitivity of transposon mutants to drug 
analogues was defined as a greater than 1.5-fold difference in sensitivity to the analogue 
compared to the parent drug, where sensitivity was quantified in terms of the MIC ratio 
between the drug hypersensitive mutant and the random transposon control strain D11. 
Investigation into differential-sensitivities of the rifampicin hypersensitive mutants Tn::arr 
and Tn::MSMEI_3093 revealed that these strains showed the same increase in sensitivity to 
rifapentine compared to the control strain D11 as they did to rifampicin. The finding that the 
relative sensitivities of the mutant strains were comparable for both drugs indicates that the 
genes containing the Tn611 insertion or adjacent to the insertion in these strains play similar 
roles in the mode of action or detoxification for rifampicin and rifapentine. Specifically, these 
results indicate that Arr is able to ribosylate and thereby detoxify rifapentine as well as the 
parent compound rifampicin. This was expected because of the structural similarity between 
rifapentine and rifampicin, and the fact that rifapentine is used clinically instead of 
rifampicin due to its increased half-life in the patient over rifampicin, rather than because it 
has altered activity or a different mode of action against mycobacteria (Benator et al., 2002; 
Keung et al., 1999).  
The isoniazid hypersensitive strain Tn::nudC was also tested against a range of isoniazid 
analogues for differential-sensitivity. A total of 30 isoniazid analogues were randomly 
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selected and obtained from the DTP repository, as well as a sample of isoniazid as a control, 
and tested against WT M. smegmatis mc2155 to confirm their activity. Analogues that 
inhibited growth of WT M. smegmatis mc2155 by at least 75%, at a concentration of 
100 µg∙mL-1, were chosen for further investigation. This initial experiment was performed to 
remove compounds with activities that were too low to be practical for determination of an 
MIC. Of the original 30 analogues, 14 analogues inhibited growth of WT M. smegmatis 
mc2155 by at least 75%, and interestingly all of these analogues shared the same basic 
structure, retaining the core isoniazid scaffold but with modification of a side chain, as 
depicted in Figure 5.1. Interestingly, of the 30 isoniazid analogues tested, 19 had the 
structure depicted in Figure 5.1. From examining the side chains of these 19 analogues, no 
common motifs distinguished the 14 analogues that had activity from the five analogues that 
did not. It is possible that the side chains of these analogues may facilitate or inhibit the 
interaction of the analogue with KatG, may alter drug permeability, or may act via a 
combination of these and other unknown factors.  
The differential-sensitivity of the Tn::nudC strain to these 14 isoniazid analogues was tested 
by determining the MIC of these analogues for the Tn::nudC strain compared to the control 
strain D11. For isoniazid and eight of the analogues, Tn::nudC was approximately five-fold 
more sensitive than the D11 control strain. This suggests that these isoniazid analogues are 
acting in a similar manner to isoniazid, as had been predicted (section 5.1.1). Specifically, 
these results suggest that these analogues are interacting with NudC in the same way as 
isoniazid. Interestingly, Tn::nudC was only two – three-fold more sensitive than the control 
strain for six analogues (27607, 33759, 37800, 40350, 141142, and 176757). This suggests 
that the interaction between NudC and these six analogues is different to that of NudC and 
isoniazid. The finding that Tn::nudC was less sensitive than expected to these six analogues 
suggests that the protective role of NudC is less important for these six isoniazid analogues, 
and that its absence therefore has less of an effect on sensitivity. Interestingly, the isoniazid 
analogues that Tn::nudC showed differential-sensitivity to showed comparable activity to 
isoniazid (MICs within two-fold of the MIC of isoniazid), except for analogues 37800 and 
40350, which were less active (three- and seven-fold increase in MIC compared to isoniazid). 
The role of NudC in resistance to the six analogues that Tn::nudC showed 
differential-sensitivity to was further investigated by overexpressing nudC in WT 
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M. smegmatis mc2155. These six analogues were also tested against the inhA overexpression 
strain to examine if they had a modified primary target as well as a loss of interaction with 
NudC. 
Overexpression of nudC and inhA causes an increase in resistance to isoniazid by increasing 
the effective concentration of isoniazid needed to inhibit growth (Banerjee et al., 1994; 
Wang et al., 2011). In the present study it was found that overexpression of nudC or inhA 
had no effect on resistance to the isoniazid analogues 27607, 33759, and 40350. Combined 
with the lower than expected sensitivity of the Tn::nudC strain to these analogues, this 
finding suggests that NudC does not play a protective role for M. smegmatis mc2155 against 
these particular analogues. One possibility is that the side chains of these analogues may 
cause steric hindrance, preventing NudC from hydrolysing any NAD adducts formed by these 
analogues. Alternatively, analogues 27607, 33759, and 40350 may inhibit the growth of 
mycobacteria by a mechanism independent of an NAD adduct. Indeed, the finding that 
overexpression of inhA does not increase resistance to these analogues suggests that InhA is 
not involved in the mode of action of these analogues. As mentioned previously, WT 
M. smegmatis mc2155 was much less sensitive to analogue 40350 than isoniazid; however, 
analogues 27607 and 33759 showed activity in M. smegmatis similar to isoniazid which is to 
be expected if they are inhibiting the growth via a similar mode of action.  Interestingly, the 
structures of analogues 27607 and 33759 have very similar side chains, differing only in the 
halogen atom (chlorine and bromine, respectively). It is possible that the side chains of these 
three analogues have anti-mycobacterial activity independent of the core isoniazid 
structure. An explanation for the InhA-independent activity of these three analogues is that 
they may inhibit the growth of M. smegmatis mc2155 via secondary targets that are also part 
of the isoniazid mode of action. It would be of value to test the other isoniazid 
hypersensitive mutants identified in this thesis against isoniazid analogues 27607, 33759, 
40350 to determine whether any of these strains also show differential-sensitivity. However, 
this was considered outside the scope of the immediate study.  
The analogues 27607, 33759, and 40350 appeared to inhibit the growth of M. smegmatis 
mc2155 in an NAD adduct independent manner. It has been demonstrated that the NudC of 
M. tuberculosis species cannot hydrolyse the INH-NAD adduct, and likely does not play a 
protective role in this species (Wang et al., 2011). However, the same study demonstrated 
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that NudC from M. bovis BCG can hydrolyse the INH-NAD adduct and therefore may play a 
protective role in this species. Consequently, these analogues may have potential 
therapeutic applications in the treatment of M. bovis, which is responsible for a proportion 
of human TB disease, as well as disease of economically important livestock (Michel et al., 
2010). Additionally, these analogues may have potential therapeutic value in the treatment 
of clinical isoniazid resistant inhA mutant or M. tuberculosis. Further testing of the activity of 
these analogues against M. bovis or isoniazid resistant M. tuberculosis was considered 
outside the scope of the current study.  
Overexpression of nudC or inhA resulted in increased resistance to analogues 37800, 
141142, and 176757, indicating that these particular analogues are likely to be working via 
an NAD adduct and thus inhibiting the growth of M. smegmatis mc2155 in an 
InhA-dependant manner. The finding that the Tn::nudC strain showed less sensitivity to 
these analogues than expected can be explained by alternative detoxification mechanisms 
for these specific analogues.  
 
5.4.2.1. Role of KatG in activation of isoniazid analogues 
Isoniazid is a pro-drug that is activated by the catalase/peroxidase gene KatG. To test 
whether the isoniazid analogues were also activated by KatG, the sensitivity of a katG 
overexpression strain to these analogues was determined. Only the six isoniazid analogues 
that Tn::nudC showed differential-sensitivity to were tested against the katG overexpression 
strain.  M. smegmatis mc2155 contains two copies of katG encoded by MSMEI_3380 and 
MSMEI_6216; whereas, M. tuberculosis H37Rv only contains one copy of katG, encoded by 
Rv1908c. Alignment of the protein sequences of MSMEI_3380 and MSMEI_6216 with 
Rv1908c revealed that MSMEI_6216 showed greater amino acid identity with Rv1908c. 
MSMEI_6216 was therefore selected as the katG overexpression strain for use in this study 
as its higher protein similarity to the M. tuberculosis gene suggested it would be most likely 
have the isoniazid activating activity. Had this assumption been incorrect and the 
MSMEI_6216 overexpression strain not shown increased sensitivity to isoniazid then a 
MSMEI_3380 overexpression strain would have been used instead, or a Rv1908c 
overexpression strain.  The gene sequence for MSMEI_6216 contains a BamHI site, which 
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was removed by introducing a silent mutation. The product of the modified MSMEI_6216 
(katGsm) was able to activate isoniazid, as demonstrated by a four-fold increase in isoniazid 
sensitivity compared to the control strain. This result confirmed that the KatG enzyme 
encoded by MSMEI_6216 is capable of activating isoniazid and supported the initial selection 
of MSMEI_6216 for the katG overexpression assay. 
With the exception of the analogue 40350, the katG overexpression strain showed 
comparable levels of increased sensitivity to all the isoniazid analogues tested, indicating 
KatG is able to activate all six analogues. However, the overexpression strain showed a much 
greater increase in sensitivity to 40350 than the other five analogues suggesting that the low 
activity of this analogue is primarily due to reduced activation by KatG, possibly due to steric 
hindrance of the long side chain. Interestingly, these results indicate that although the three 
analogues 27607, 33759, and 40350 appear to inhibit M. smegmatis mc2155 independent of 
an NAD adduct, KatG is still able to activate these analogues. Although not pursued in this 
thesis, it would be valuable to know whether loss of function KatG mutants show decreased 
sensitivity to these analogues to confirm whether KatG is required for their activation. The 
apparent InhA- and NudC-independent mode of action of the three analogues 27607, 33759, 
and 40350 supports the idea that KatG-activated isoniazid reacts with more cellular 
components than just InhA (Argyrou et al., 2006; Mdluli et al., 1996, 1998; Rickman et al., 
2013; Timmins and Deretic, 2006). These analogues may therefore be useful tools for 
elucidating what these other activated products are, and the identity of their targets. 
 
5.4.3. Activity of isoniazid analogues against M. tuberculosis 
Preliminary testing was performed to establish the sensitivity of M. tuberculosis H37Rv to the 
six isoniazid analogues that Tn::nudC showed differential-sensitivity to. The two analogues 
37800 and 141142 showed activity similar to isoniazid, with MICs approximately two-fold 
greater than isoniazid. The remaining four analogues were inactive in M. tuberculosis H37Rv, 
with MICs greater than 15-fold higher than that of isoniazid. The analogue 141142 had the 
most similar structure to isoniazid; however, there was no obvious connection between the 
structure of the side chain and the activity of the analogues. The reason for the low activity 
of the remaining five analogues in M. tuberculosis H37Rv is unclear. However, further testing 
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of these analogues against M. tuberculosis is warranted to confirm the results from the 
single preliminary assay performed in this study.  
 
5.4.4. Summary 
None of the hypersensitive mutants tested showed cross-sensitivity to either of the other 
two drugs tested in this study. This indicates that the sensitivity of these mutants is specific 
to the original drug used in the screening process. Additionally, the two mutants identified in 
Chapter Three as being most hypersensitive to rifampicin showed no differential-sensitivity 
to the rifampicin analogue rifapentine. The isoniazid hypersensitive mutant Tn::nudC showed 
differential activity to six of the isoniazid analogues tested. Three of the six analogues likely 
work via an NAD adduct in an InhA-dependent manner similar to isoniazid. However, 
another detoxification mechanism in addition to NudC is suspected to exist for these 
analogues. The remaining three analogues (27607, 33759, and 40350) likely act in an 
InhA-independent manner that does not involve the formation of an NAD adduct. One 
possibility is that these analogues are inhibiting the growth of M. smegmatis mc2155 by 
mechanisms specific to their side chains. Alternatively, these analogues may be acting via a 
secondary isoniazid mode of action.  Interestingly the results presented here suggest that all 
of the six isoniazid analogues that demonstrated differential-activity against Tn::nudC can be 
activated by KatG, although it remains to be demonstrated if KatG is required for their 
activity. These results strongly support the concept that the mode of action of isoniazid is 
more complex than being mediated via inhibition of InhA alone. Furthermore, this study has 
identified three isoniazid analogues with apparent novel modes of action (27607, 33759, and 
40350). These three analogues will be useful tools in elucidating the nature of the secondary 
targets of isoniazid, and may have therapeutic use in the treatment of M. bovis and isoniazid 
resistant inhA mutant strains of M. tuberculosis.  
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6. General Discussion 
TB is the leading cause of morbidity and mortality by a bacterial pathogen, and there is a 
great need for the discovery of novel drugs that can shorten the treatment regimen, and 
effectively treat drug resistant cases, especially MDR-TB and XDR-TB (WHO, 2014). An 
important step in the drug discovery pathway is the identification of drug mode of action. 
Knowledge of drug mode of action enables rational modification of drugs to improve efficacy 
against both primary and secondary targets, and to decrease unwanted interactions or 
harmful side effects (Balganesh et al., 2008; Ioerger et al., 2013). To date, most studies 
investigating the modes of action of TB drugs have revolved around study of 
resistance-inducing mutations and altered transcription upon drug treatment, while little 
work had been done investigating mutations that induce hypersensitivity. Therefore, the aim 
of this thesis was to develop a high-throughput assay for identifying drug hypersensitive 
mutants of M. smegmatis mc2155 in order to study the genetic basis of the drug 
hypersensitivity and generate information on drug mode action.  
The two front-line anti-TB drugs isoniazid and rifampicin, along with bedaquiline, which is 
currently in phase III clinical trials, were selected for further investigation into their modes of 
action in this study. These drugs were selected because their primary targets are known and 
therefore the identification of mutations in genes already known to be involved in the drug 
mode or action or resistance mechanisms would validate our high-throughput screening 
assay for hypersensitivity mutations. Isoniazid is a prodrug that inhibits InhA, inhibiting 
mycolic acid biosynthesis (Banerjee et al., 1994). Isoniazid is activated by the 
catalase/peroxidase enzyme KatG, and reacts with NAD to form the INH-NAD adduct which 
binds to and inhibits InhA (Johnsson and Schultz, 1994; Rozwarski et al., 1998; Wilming and 
Johnsson, 1999; Zhang et al., 1992). Rifampicin inhibits transcription by binding to and 
inhibiting the β subunit of RNA polymerase (RpoB) (Levin and Hatfull, 1993; Maggi et al., 
1966; Wehrli et al., 1968). Bedaquiline inhibits the production of ATP by the ATP synthase, 
by binding to the C subunit of the F0 domain of the ATP synthase (Andries et al., 2005; Koul 
et al., 2007).  
To the best of my knowledge, one study utilising an assay to screen for mutations that 
induce hypersensitivity to rifampicin has been published, albeit using a different endpoint, 
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but no such studies have been published for isoniazid or bedaquiline. Therefore, it was 
expected that the assay for drug hypersensitivity used in this research would be able to 
identify genes not previously linked to isoniazid, rifampicin, or bedaquiline sensitivity. These 
genes may represent novel aspects of the known modes of action of these drugs, or 
completely novel modes of action. Both types of information can be used to improve our 
understanding of the complete modes of action of these drugs. 
 
6.1. Research summary 
6.1.1. Isoniazid 
The assay for hypersensitivity successfully identified mutants with significantly increased 
sensitivity to isoniazid. The sensitivities of the 12 most hypersensitive mutants were 
quantified by MIC and subsequently the Tn611 insertion sites were determined for these 
mutants. Three mutants were much more sensitive to isoniazid compared to the controls 
than the other hypersensitive mutant strains, with two of these mutants containing a Tn611 
insertion either within the nudC gene or in the adjacent gene MSMEI_1905. 
Complementation analysis suggested that the isoniazid hypersensitivity of both of these 
strains was due to a loss of function of nudC, whose protein product, NudC, is a protein 
recently identified in the detoxification of isoniazid. NudC hydrolyses the INH-NAD adduct 
that is the active form of isoniazid (Wang et al., 2011). As expected, given the role of NudC in 
detoxifying the INH-NAD adduct, the Tn::nudC mutant did not show any cross-sensitivity to 
either rifampicin or bedaquiline. Therefore these results strongly support a role for NudC in 
basal isoniazid resistance, as opposed to general multi-drug resistance. The isoniazid 
hypersensitive Tn::nudC mutant from the current study was identified prior to the 
publication of the results by Wang et al. (2011) and provides independent confirmation of 
the proposed role of NudC in basal isoniazid resistance in M. smegmatis mc2155 (Wang et 
al., 2011). 
The third isoniazid hypersensitive mutant that showed a large decrease in the MIC of 
isoniazid compared to the control had a Tn611 insertion within a gene (MSMEI_6092) likely 
to be involved in the oxidative stress response. This strain showed no cross-sensitivity to 
either rifampicin or bedaquiline, suggesting the mechanism of drug sensitisation is isoniazid 
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specific. Complementation of this strain was not performed due to toxicity of the 
complementation vector during plasmid subcloning in E. coli, and therefore it is not possible 
to say definitively whether loss of functional MSMEI_6092 is responsible for the isoniazid 
hypersensitivity of Tn::MSMEI_6092.  Interestingly, three other mutants with links to the 
oxidative stress response were identified in the assay for isoniazid hypersensitivity, although 
these mutants were not as sensitive as MSMEI_6092. These mutants had insertions within or 
adjacent to the ahpCD locus, and two genetic loci involved in sulfur metabolism, a process 
closely linked to the oxidative stress response (Dussurget and Smith, 1998). It has previously 
been demonstrated that mutations that retard the oxidative stress response lead to 
increased isoniazid sensitivity due to a compensatory increase in the expression of other 
oxidative stress response genes, including katG, resulting in increased activation of isoniazid 
(Sherman et al., 1996). It seems likely that this mechanism is responsible for the isoniazid 
hypersensitivity of mutants identified in this thesis with Tn611 insertions within or adjacent 
to genes linked to the oxidative stress response.  
Interestingly, only one isoniazid hypersensitive mutant that had a mutation in a gene with 
links to the mycolic acid biosynthesis pathway, which isoniazid inhibits, was identified. While 
it is possible that the transposon mutant collection generated in this thesis only contained 
this one mutant with an insertion in a mycolic acid biosynthesis genetic pathway, sequencing 
the insertion site of more mutants may have identified more hypersensitive mutants with 
insertions in genes related to mycolic acid biosynthesis. Strains with mutations in the mycolic 
acid biosynthesis pathway may have been less sensitive to isoniazid than the 12 mutants 
selected for further characterisation. Future investigations into the insertion sites of the 
other isoniazid hypersensitive mutants will reveal whether this was the case. The remaining 
sequenced isoniazid hypersensitive mutants had no clear links to the drug’s known mode of 
action, or known resistance mechanisms. These genes therefore represent novel aspects of 
the mode of action or resistance mechanisms of isoniazid, and further study into the nature 
of their interaction with isoniazid will improve our understanding of the complete isoniazid 
mode of action. 
140 
 
6.1.1.1. Identification of isoniazid analogues with novel modes of 
action 
The differential-sensitivity of the Tn::nudC mutant was determined for 14 isoniazid 
analogues active against M. smegmatis mc2155. All 14 analogues contained the core 
structure of isoniazid (Figure 5.1); the analogues that did not retain the core structure were 
found to be inactive against M. smegmatis. This indicates that these 14 analogues probably 
also retain the core mode of action of isoniazid, implicating the core structural component 
as an important part of the pharmacophore of the drug. The Tn::nudC mutant strain showed 
differential-sensitivity to six of the 14 isoniazid analogues, where the Tn::nudC strain was 
less sensitive to these analogues than expected. These six analogues were subsequently 
tested against an inhA and a nudC overexpression strain to investigate whether 
overexpression of these genes would lead to resistance to the analogues as it did for 
isoniazid. InhA is the primary target of isoniazid and its overexpression leads to isoniazid 
resistance. Three of these six analogues (37800, 141142, and 176757) appeared to still 
inhibit the growth of M. smegmatis mc2155 in an InhA-dependent manner despite the 
structural differences, as overexpression of InhA led to increased resistance to these three 
analogues. Additionally, these analogues appeared to inhibit growth via an INH-NAD adduct, 
as overexpression of NudC was able to increase resistance to these three analogues. These 
results, combined with the differential-sensitivity of Tn::nudC to these three analogues, 
suggests that while NudC can detoxify these analogues, it is not the only mechanism of 
detoxification as the Tn::nudC mutant showed little to no increase in sensitivity to these 
analogues.  
The remaining three analogues (27607, 33759, and 40350) inhibited the growth of 
M. smegmatis mc2155 in an InhA-independent manner as overexpression of InhA did not 
increase the resistance of M. smegmatis mc2155 to these analogues. Additionally, NudC 
appeared unable to detoxify these analogues as overexpression of nudC did not increase the 
resistance of M. smegmatis mc2155 to these analogues. Combined with the 
differential-sensitivity of Tn::nudC to these analogues, these results suggest that these 
analogues are not inhibiting the growth of M. smegmatis mc2155 by inhibition of InhA, and 
not working via the INH-NAD adduct. 
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A katG overexpression strain had increased sensitivity to all six analogues suggesting that 
KatG was able to metabolically activate all six isoniazid analogues. Combined with the 
previous observations, these results suggest that the three analogues 27607, 33759, and 
40350, which were inhibiting the growth of M. smegmatis mc2155 in an InhA-independent 
manner, were being activated by KatG to form growth-inhibitory metabolites other than the 
well characterised INH-NAD adduct. However, the Tn::nudC mutant still showed a slight 
increase in sensitivity to these analogues, suggesting at least some INH-NAD adduct may be 
being formed. Further studies of the growth inhibitory activity of these isoniazid analogues 
that are acting in an InhA-independent manner are warranted to determine their novel 
mechanisms of action, and to see where that mechanism of action overlaps with that of the 
parent compound.  
Preliminary testing of the sensitivity of M. tuberculosis H37Rv was performed for the six 
analogues that Tn::nudC showed differential-sensitivity to, and the MIC values compared to 
their activities in M. smegmatis mc2155. There were large differences in the relative 
activities of the analogues between the two species, including the three analogues that 
appeared to inhibit M. smegmatis mc2155 in an InhA-independent manner, with only the 
analogues 37800 and 141142 showing any activity in M. tuberculosis H37Rv. These results 
suggest that the target of the three inhA-independent analogues (27607, 33759, and 40350) 
may not be present in M. tuberculosis. Interestingly, it has been previously demonstrated 
that there are differences in the effect of isoniazid on M. smegmatis and M. tuberculosis, 
suggesting that the mode of action of isoniazid differs slightly between these two species 
(Mdluli et al., 1996). The NudC enzyme of M. tuberculosis H37Rv lacks INH-NAD hydrolysing 
activity, and it is predicted that the NudC of a large number of clinical isolates may also lack 
this hydrolysing activity (Wang et al., 2011). Despite these differences between strains, 
isoniazid analogues 27607, 33759, and 40350 will be useful in investigating the aspects of 
isoniazid’s mode of action outside of the inhibition of InhA. Additionally, these analogues 
may find use in the treatment of M. bovis, as the NudC enzyme of M. bovis BCG is able to 
hydrolyse the INH-NAD adduct, and may play a protective role in M. bovis against isoniazid 
(Wang et al., 2011). These analogues may also have potential therapeutic value in the 
treatment of isoniazid resistant inhA mutant strains of M. tuberculosis. 
142 
 
6.1.2. Rifampicin 
The assay for hypersensitivity successfully identified mutants with increased sensitivity to 
rifampicin. The Tn611 insertion sites were successfully determined for 11 of the 12 most 
sensitive mutants validated in the secondary assay, and the hypersensitivities of these 12 
mutants were quantified by MIC. Of these 12 mutants none showed any links to the known 
mode of action of rifampicin, and only three mutants had links to known rifampicin 
resistance mechanisms: Arr, an enzyme involved in a known rifampicin inactivation 
mechanism, PonA2, an enzyme involved in cell wall stability whose absence results in 
increased sensitivity to a range of lipophilic drugs including rifampicin, and the lipoprotein 
signal peptidase LspA. Two mutants had Tn611 insertions within two different multi-copy 
transposase genes, but which copies contained the Tn611 insertions, and therefore the 
genetic basis for the rifampicin hypersensitivity of these two mutants remains unknown. The 
remaining seven rifampicin hypersensitive mutants sequenced had insertions in genes with 
no clear links to the known mode of action of rifampicin or any of its known resistance 
mechanisms. These genes therefore represent novel mechanisms, and further study into the 
nature of their interaction with rifampicin will improve our understanding of the complete 
rifampicin mode of action. Of particular interest were two genes functionally related to the 
ESX-1 locus identified as containing Tn611 insertions in rifampicin hypersensitive mutants. 
The ESX-1 locus has not previously been implicated in the rifampicin mode of action or 
detoxification mechanism. These results therefore suggest a novel role for the ESX-1 locus in 
the rifampicin mode of action or detoxification pathways. 
Rifampicin inhibits the RNA polymerase β subunit (RpoB), inhibiting RNA transcription. 
Interestingly, none of the rifampicin hypersensitive mutants that were sequenced had 
mutations in genes that were known to be involved in transcription. This may suggest that 
these genes are essential in M. smegmatis mc2155, and therefore mutants of these genes 
would not have been present in the transposon mutant collection constructed in this thesis. 
Alternatively, sequencing of more of the rifampicin hypersensitive mutants may have 
revealed mutants with insertions in genes related to transcription. 
The two mutants most sensitive to rifampicin identified in Chapter Three were Tn::arr and 
Tn::MSMSEI_3093, which were eight- and four-fold more sensitive than the control strain, 
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respectively. Tn::MSMEI_3093 contained a Tn611 insertion in the pseudouridine synthase D 
gene, which modifies selected uridine residues of the rRNA. Tn::arr was not complemented 
in this thesis as its involvement in rifampicin resistance in M. smegmatis is already well 
characterised. Complementation was also not performed for Tn::MSMEI_3093 due to an 
inability to generate a control strain for complementation and therefore the exact 
mechanism for this strain’s rifampicin hypersensitivity remains unclear. However, it is 
possible that the rifampicin sensitivity may be due to altered transcription of the adjacent 
lipoprotein signal peptidase gene lspA rather than a loss of function of MSMEI_3093. 
Overexpression of lspA in M. tuberculosis has previously been shown to increase resistance 
to both rifampicin and isoniazid (Pathak, 2013). Interestingly, the transposon mutant 
Tn::MSMEI_3093 did not show cross-sensitivity to isoniazid in this thesis, suggesting that 
altered transcription of lspA may not be responsible for the rifampicin hypersensitivity of 
this strain. Alternatively, a loss of LspA function may cause increased rifampicin sensitivity 
but not increased isoniazid sensitivity. The two strains, Tn::arr and Tn::MSMEI_3093, were 
also examined for differential-sensitivity to rifapentine, an analogue of rifampicin. Both 
strains showed equal increases in sensitivity to rifapentine as they did to rifampicin, 
indicating that the role of these genes in the mode of action or resistance of rifampicin is 
conserved in rifapentine. Specifically, these results indicate that Arr can inactivate 
rifapentine, as well as its parent compound, rifampicin. 
 
6.1.3. Bedaquiline 
The assay for hypersensitivity successfully identified mutants with increased sensitivity to 
bedaquiline. The Tn611 insertion sites were determined for eight of the 12 most sensitive 
mutants validated in the secondary assay, and the hypersensitivity of these 12 mutants were 
quantified by MIC. Of the eight mutants that the insertion site was identified for, one had a 
Tn611 insertion in mmpL5, which encodes the transmembrane transporter MmpL5 which is 
known to be involved in bedaquiline detoxification (Andries et al., 2014; Hartkoorn et al., 
2014). An additional validated mutant had an insertion in atpB, a gene that encodes the A 
subunit of the F0 ATP synthase domain. Although this mutant was not one of the top 
bedaquiline sensitive strains, it was included in this thesis because atpB is related to the 
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known mode of action of bedaquiline. The work on bedaquiline was performed in 
collaboration with Professor Greg Cook’s research group at the University of Otago. The 
Tn::atpB mutant was identified in the primary assay for drug hypersensitivity, and was not 
one of the 12 most sensitive mutants further characterised in this thesis. However, a number 
of mutant strains that were identified in the primary screen of this thesis were sent to 
Professor Cook, who sequenced them and identified the Tn611 insertion site in the Tn::atpB 
mutant. Once identified it was decided to include Tn::atpB with the 12 most sensitive 
mutants for further characterisation.  
Neither the most bedaquiline hypersensitive mutant, which contained a Tn611 insertion in a 
glutamyl peptidase gene (MSMEI_3189), nor the Tn::atpB mutant showed cross-sensitivity to 
either isoniazid or rifampicin. This result for the Tn::atpB mutant was expected, as it is 
known that the ATP synthase is related to the specific target of bedaquiline. Although the 
mechanism of bedaquiline hypersensitivity of the Tn::MSMEI_3189 mutant is unclear, it 
appears to be specific to bedaquiline. 
 
6.2. Critical evaluation of methodology 
6.2.1. Limitation of using M. smegmatis mc2155 as the genetic model 
M. smegmatis mc2155 was chosen as a genetic model for investigating anti-TB drug modes 
of action, primarily due to the time benefits the species provides over the slow growing 
models M. bovis BCG and M. tuberculosis H37Ra. The fast growth rate of M. smegmatis 
increased the rate that the initial transposon mutants could be generated and then 
subsequently screened for drug hypersensitivity. This time benefit was offset, however, by 
the increased genetic differences between M. tuberculosis and the slow growing models 
such as M. bovis BCG. Therefore, any information on the mode of action generated from a 
study using M. smegmatis ultimately needs to be confirmed in M. tuberculosis. It has 
previously been proposed that one of the benefits of using M. smegmatis as a model is that 
it has a similar drug resistance profile as MDR-TB (Chaturvedi et al., 2007). However, the 
underlying genetic bases for these similar resistance phenotypes are very different. 
M. smegmatis contains drug detoxification mechanisms that M. tuberculosis does not have. 
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For example, both Arr and NudC, which were identified in this study, are mechanisms of 
drug detoxification present in M. smegmatis but not M. tuberculosis.  
The aim of this study was not to identify specific genes involved in the drug resistance 
phenotype, but rather to identify pathways that were sensitised to the drugs due to the 
presence of transposon insertions in their genes. This was achieved for isoniazid whereby 
multiple genes were identified that related to the oxidative stress response, and for 
rifampicin whereby two genes related to the ESX-1 locus were identified. However, the 
bedaquiline hypersensitive mutants did not reveal any such pattern of genes in a particular 
pathway. As discussed below, this may be a limitation of the number of mutants sequenced 
or the coverage of the library. An additional factor, however, is that the genome of M. 
smegmatis is not completely annotated, with numerous hypersensitive mutants identified in 
this study containing insertions in conserved, but hypothetical genes. This lack of annotation 
confounds the results as these genes with unknown function may be involved in the 
pathways of interest. Without better gene annotations it is not possible to determine from 
the literature if this is the case. The genomes of both M. tuberculosis and M. bovis are much 
better annotated and had the transposon mutant collection been constructed in one of 
these two species it would likely have been much easier to determine the role of any specific 
gene product. This situation is expected to improve with time as more of the genome of 
M. smegmatis mc2155 is annotated. 
 
6.2.2. Use of Tn611 for transposon mutagenesis 
One of the advantages of random transposon mutagenesis is that the nature of the mutation 
is consistently a loss of function (Guilhot et al., 1994). However, after determining the 
transposon insertion sites for the drug hypersensitive mutants identified in this study, it was 
apparent that Tn611 also exerts a significant polar effect on the surrounding genes. 
Specifically, the Tn611 insertion in MSMEI_1905 had a polar effect on the adjacent nudC 
gene. Additionally, a number of hypersensitive mutants were identified that had intergenic 
Tn611 insertions. Thus, mutants within the collection may have altered transcription of more 
than one genetic locus, with the potential for the hypersensitivity to be due to the combined 
effect, as opposed to due to loss of function of a single gene product. This altered 
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transcription could be down-regulation of adjacent genes or up-regulation driven by 
transposon internal promoters (Berg et al., 1980; Ciampi et al., 1982). To the best of my 
knowledge, little or no work has been done investigating the nature of the Tn611 insertion 
and its potential polar effects. Because most of the hypersensitive mutants identified in this 
study were not complemented, it is difficult to say with any certainty what the specific 
genetic basis for drug hypersensitivity was for all mutants other than the complemented 
Tn::nudC mutants.  
Another limitation with the Tn611 transposon is that to the best of my knowledge the 
sequence into which it inserts has not been characterised. Although this transposon has 
previously been reported to insert in a random manner, and appears to provide good 
genome coverage, no studies as to which genes it can insert into have been performed. 
Most studies utilising transposon mutants now use a phage based transposon (Himar1), both 
for mutagenesis of M. smegmatis and M. tuberculosis (Siegrist and Rubin, 2009). The 
sequence where this transposon can be inserted has been characterised and, at least for 
M. tuberculosis, the genes that this transposon can insert into have been determined (Griffin 
et al., 2011; Sassetti et al., 2001, 2003). To the best of my knowledge no such information 
exists for Tn611. The Tn611 transposon was used for this study as attempts to generate 
transposon mutants with another phage-based system were unsuccessful, and the plasmid 
based system of Tn611 mutagenesis was found to be much easier for generating mutants. 
However, in hindsight, utilisation of the phage-based transposon Himar1 would have been 
advantageous as it is much better characterised than Tn611. 
 
6.1.1. Transposon mutant collection coverage 
Transposon insertions inherently label the site of the genetic lesion responsible for the 
mutant phenotype, enabling rapid identification of the phenotype’s genetic basis. For this 
reason, random transposon mutagenesis is routinely employed for generating collections of 
random mutants of mycobacteria (both M. smegmatis and M. tuberculosis) for phenotypic 
screening. Another characteristic of transposon mutagenesis is the largely consistent nature 
of the mutations generated, in which insertion within a gene results in a loss of function 
mutation (Guilhot et al., 1994). However, this is also a major limitation of the approach in 
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that only genes that are non-essential for the conditions being used can sustain transposon 
insertions. Mutants with insertions in genes that are essential under normal growth 
conditions will not be present in a random transposon mutant collection; therefore, these 
essential genes cannot be queried in phenotypic screening. However, the advantage of being 
able to rapidly identify the site of the mutation makes transposon mutagenesis a valuable 
methodology. As mentioned above, gene essentiality may be the reason mutants were not 
identified in the isoniazid or rifampicin screens that had transposon insertions within or 
adjacent to genes involved in fatty acid biosynthesis and transcription, respectively. The 
calculations estimating mutant collection coverage (section 3.2.1) assumed that the 
proportion of genes essential in M. smegmatis mc2155 was the same as that for 
M. tuberculosis. An alternate method would have been to assume that the number of 
essential genes was consistent between the two species. The former option was selected as 
it would likely result in an underestimation of the number of essential genes, and it was 
decided this was preferable to an overestimation. This likely resulted in a slightly larger 
collection that had a higher genome coverage (and therefore more redundancy), which was 
preferable to a smaller collection with a lower genome coverage. The number of essential 
genes in M. smegmatis mc2155 may actually be smaller than that of M. tuberculosis since 
significant portions of the M. smegmatis mc2155 genome are duplicated. At least one gene 
that is essential in M. tuberculosis, atpD, is apparently non-essential in M. smegmatis 
mc2155 due to multiple gene copies (Tran and Cook, 2005). The gene atpB, which was found 
to play a role in bedaquiline hypersensitivity, is in the same genetic region as atpD and may 
also be duplicated in the genome of M. smegmatis mc2155. 
Another limitation of the transposon mutant collection is that collection’s size is related to 
the genomic coverage. As the transposition is random, the distribution of the insertion sites 
follows a normal distribution. It was predicted that the collection of 7680 mutants created in 
this thesis, which has approximately 1.1-fold genome coverage, would contain at least one 
transposon mutant for 73.2% of the non-essential genes. The implication of this is that 
26.8% of the non-essential M. smegmatis mc2155 genes are predicted to be excluded from 
the transposon mutant collection. These missing genes potentially include those related to 
the mode of action or resistance mechanisms of the drugs screened in this study, and may 
partially be responsible for the absence of mutants with insertions in pathways related to 
148 
 
the respective drugs modes of action. The size of the collection created in the current study 
was chosen for a relatively high level of coverage while keeping the collection small enough 
to allow high-throughput screening. Increasing the size of the collection, and therefore its 
coverage, would have reduced the impact the incompleteness of the mutant collection had 
on the results of the hypersensitivity assays, potentially increasing the number of mutants 
identified as hypersensitive to each drug.  
 
6.1.2. Quantifying mutant hypersensitivity 
Quantification of the drug sensitivity of mutants validated in the secondary assay revealed 
that these mutants showed approximately two-fold or less increases in MIC compared to the 
controls, with the exception of the three and two most sensitive mutants from the isoniazid 
and rifampicin assays, respectively. As the variation in MIC was relatively small between the 
majority of validated hypersensitive mutants and the control strains, only the most sensitive 
mutants from each drug’s assay were selected for complementation. Selection of only the 
most sensitive mutants allowed for clearer results in the complementation experiments as it 
was easier to determine if complementation was able to partially or completely restore WT 
sensitivity. Similarly, only the most sensitive mutants were selected for cross-sensitivity and 
differential-sensitivity testing. MICs are commonly used as the quantitative metric of drug 
sensitivity in the literature when discussing the sensitivity or resistance of mycobacteria to 
drugs and therefore were also used in this study. It was found in this thesis, however, that 
using MICs was not a very sensitive metric, with many of the dose-response assays showing 
variation close to the dilution factor used during serial dilution of the drugs (two-fold). This 
may have been mitigated by using smaller dilutions resulting in an improvement of the dose-
response assay variation. 
The recovery of mutants with only small changes in drug MIC may correlate with the 
essentiality of those genes. This is corroborated by the fact that no genes that are known to 
be directly involved in the known modes of action of isoniazid or rifampicin were identified. 
It may be the genes involved in the drug mode of action are essential, meaning that only 
mutations in genes that were less directly involved in drug mode of action were present in 
the collection. A strain containing a Tn611 insertion in atpB which is known to be involved in 
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the mode of action of bedaquiline was probably only recovered because of its duplication in 
the genome. Interestingly, a previous study of rifampicin hypersensitive transposon mutants 
of M. smegmatis mc2155 identified a Tn::arr mutant similar to the one isolated in the 
present study (Alexander et al., 2003). However, this previously described Tn::arr mutant 
showed a 16-fold increase in MIC, compared to the eight-fold increase in MIC observed in 
this study. The major difference between these two studies was the use of transposon Tn611 
in the present study and the Himar1 transposon in the study by Alexander et al. (2003) both 
transposons were delivered via temperature-sensitive delivery vectors; however, the 
non-permissive temperature for the Tn611 delivery vector was 41 °C compared to 37 °C for 
the Himar1 delivery vector (Siegrist and Rubin, 2009). Therefore, the rifampicin sensitivity of 
the Himar1 Tn::arr mutant was assessed at 37 °C, while all assays of Tn611 mutants were 
performed at 41 °C in our study. This higher temperature may also be responsible for the 
observed low level of sensitivity of the isolated drug hypersensitive mutants. This highlights 
another reason why the use of a Himar1-based transposon would have been advantageous 
over the use of Tn611.  
 
6.1.3. Transposon mutant controls 
In the primary assay for drug hypersensitivity, the sensitivity of the mutants was expressed 
relative to the median sensitivity of the transposon mutant libraries, as it was assumed that 
the majority of mutants would have no increased sensitivity to the drug of interest. For the 
lower throughput secondary assay, the sensitivity of the mutants was validated, with the 
mutants ordered from most to least sensitive according to their growth-inhibition. Before 
further phenotypic and genotypic characterisation of the mutants, the hypersensitivities of 
the mutant strains were quantified using the MIC of the relevant drug.  The selected control 
scheme was to use 10 mutant strains randomly selected from the mutant libraries, with the 
MICs of isoniazid, rifampicin, and bedaquiline averaged over the 10 strains. While WT 
M. smegmatis mc2155 or WT M. smegmatis mc2155 carrying a multi-copy plasmid with a 
kanamycin resistance gene were considered for the controls for this experiment, these 
strains would likely have had differing sensitivities to kanamycin compared with the 
transposon mutant strains.  It is possible that the presence of kanamycin was altering the 
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absolute sensitivity of the transposon mutants to the antibiotics, and therefore ideally the 
control should have the same level of kanamycin sensitivity as the transposon mutants. This 
condition was met by utilising random transposon mutant strains as the controls. It was 
expected that the chance of any one of the random transposon mutants selected as controls 
being hypersensitive or resistant to the drugs was low.  Averaging the MICs for each drug 
across all 10 strains would compensate for any one strain that showed an altered sensitivity. 
When testing the differential-sensitivity of the strains against various analogues, only one of 
the 10 mutant strains was used due to the logistics of the assay and the large number of 
analogues screened. This strain, D11, showed a similar MIC for all three original drugs 
compared to the other 9 random control strains and therefore it was assumed that D11 
would also show similar sensitivity to all the drug analogues. It would have been 
advantageous to have a WT control that had a single copy of extra-chromosomally encoded 
aph, the kanamycin resistance gene, so that no assumptions needed to be made about the 
requirement of any of the genes in the random transposon mutant controls for drug 
sensitivity or resistance.  
 
6.2. Future directions 
The work in this thesis has identified many novel genes that confer hypersensitivity and are 
potentially involved in the known modes of action or detoxification pathways of isoniazid, 
rifampicin, and bedaquiline. In addition, potential novel modes of action or detoxification 
pathways were identified, with numerous future directions for this research. 
 Completion of the sequencing and complementation of the isoniazid, rifampicin, and 
bedaquiline hypersensitive mutants identified in this study, as well as constructing 
knock-out mutants of genes containing Tn611 insertions. This would enable 
confirmation of the genetic basis for the hypersensitivity of these mutants. Better 
understanding of the genotypic basis would further improve our understanding of 
the complete modes of action of isoniazid, rifampicin, and bedaquiline facilitating 
rational drug design to improve drug treatment of TB. 
 Expansion of the transposon mutant collection beyond 1.1-fold genome coverage, 
and screening the additional mutants against isoniazid, rifampicin, and bedaquiline 
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would likely provide additional information on the mode of action of these drugs. 
Expansion of the library to three-fold coverage would mean that approximately 95% 
of the genes (versus 73.2% currently) predicted to be non-essential in M. smegmatis 
would be represented in the mutant collection. Further screening of isoniazid, 
rifampicin, and bedaquiline, would enable the identification of more novel genes in 
the modes of action or resistance mechanisms of these compounds, additional to 
those already identified in this thesis. 
 The drug hypersensitive phenotype of many of the mutants identified in this study 
may not directly be due to a loss of function of the gene containing the transposon, 
but rather as a result of a perturbation in the genetic networks interacting with the 
drug target. These genetic networks include genes that are functionally related to the 
target such as those encoding other components of the targets functional pathway, 
regulators of the components of the targets functional pathway, as well as genes 
encoding enzymes that provide functional redundancy for components of the target 
pathway. Genetic interaction studies would reveal how the genes identified as 
containing transposon insertions in the drug hypersensitive mutants are interacting 
with the drug target or innate resistance mechanisms. Genetic interaction studies 
can be performed by studying synthetic lethality, where two viable single mutants 
are combined to produce a non-viable double mutant (Joshi et al., 2006; Ooi et al., 
2006). This loss of viability indicates the two gene containing mutations have a 
genetic interaction. By generating collections of these double mutants a map of 
genetic interactions can be generated and used to identify functional relationships. 
Recent advances in the efficiency of generating targeted knock out mutations using 
allelic exchange in mycobacteria is making studies of genetic interactions more viable 
(Tufariello et al., 2014). This approach could be used to introduce secondary 
mutations into the transposon mutant collection in genes identified in this study as 
being involved in drug hypersensitivity to map their genetic interaction networks, 
and understand their functional relationship to the drug target or innate resistance 
mechanisms. 
 This study has demonstrated the power of screening for hypersensitivity in 
identifying genes related to the modes of action and resistance mechanisms of 
anti-mycobacterial compounds. Therefore, future research using the assay developed 
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in this thesis with novel anti-mycobacterial compounds would facilitate identification 
of their mode of action. Identification of the modes of action of novel anti-
mycobacterials would enable the prioritisation of compounds with novel modes of 
action. Additionally, knowledge of the novel compounds modes of action would 
allow for rational modifications to improve their efficacy against TB. This would 
facilitate the discovery of new drugs with novel modes of action, and ultimately lead 
to an improvement in treatment of TB including MDR-TB. 
 This study also identified three analogues of isoniazid that appear to inhibit the 
growth of M. smegmatis mc2155 independent of the known target or isoniazid, InhA. 
Future work to identify the primary targets of these analogues may identify a novel 
drugable target in mycobacteria. Investigation into the cross-sensitivity of the target 
of these three analogues to isoniazid, will determine whether the primary target of 
these analogues is a secondary target for isoniazid. The identification of a secondary 
target for isoniazid would enable rational design of co-treatment options to improve 
the efficacy of isoniazid therapy of TB. 
  
6.3. Conclusions 
The aim of this thesis was to generate information on anti-TB drug mode of action by 
identifying the genetic basis of drug hypersensitivity in mutants of M. smegmatis mc2155. 
The screening of a transposon mutant collection for isoniazid, rifampicin, and bedaquiline 
hypersensitive mutants confirmed a recently identified novel isoniazid resistance mechanism 
involving NudC detoxification, and highlighted a number of potentially new aspects of the 
modes of action of detoxification mechanisms for these drugs in M. smegmatis mc2155. 
Additionally, this thesis demonstrated that analogues of current anti-TB drugs with modified 
modes of action with potential therapeutic use can be identified by integrating genetic 
information from a screen for hypersensitivity with chemical derivatisation. Specific 
outcomes from this thesis were: 
 Novel genes that were related to the modes of action and resistance mechanisms of 
isoniazid, rifampicin, and bedaquiline were identified. This included genes related to 
the oxidative stress response that were identified in isoniazid hypersensitive 
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mutants; and of particular interest, two genes (espR and MSMEI_5621) related to 
ESX-1 that were identified as containing Tn611 insertions in rifampicin hypersensitive 
mutants. 
 NudC is responsible for detoxifying isoniazid, whereby a Tn::nudC mutant of 
M. smegmatis mc2155 is hypersensitive to isoniazid and overexpression of NudC in 
M. smegmatis mc2155 increases the MIC over 100-fold. This independently verifies 
the results of Wang et al. (2011) 
 The rifampicin ribosylating enzyme Arr, which can inactivate rifampicin, appears 
capable of also inactivating rifapentine, an analogue of rifampicin 
 The isoniazid analogues NSC27607, NSC33759, and NSC40350 appear to inhibit the 
growth of M. smegmatis mc2155 via a novel, InhA-independent, mode of action, with 
activity comparable to the parent drug in M. smegmatis mc2155. These analogues 
may have potential therapeutic use in the treatment of infections by M. bovis or 
isoniazid resistant inhA mutant strains of M. tuberculosis 
 Resazurin reduction is a valid surrogate for high-throughput screening of 
growth-inhibition of M. smegmatis mc2155 when paired with a secondary OD600 
based validation assay 
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8. Appendix 
8.1. Solutions 
All solutions with the exception of proteinase K were stored at room temperature. 
Proteinase K was stored at -20 °C.  
Tris-HCl (pH 7.5) 
121.1 g of Tris Base was dissolved in 900 mL deionised water, and the pH adjusted to 7.5 
with the addition of HCl. Once at the desired pH the volume was topped up to 1 L. 
0.5 M EDTA (pH 8.0) 
186.2g of EDTA was added to 900 mL deionised water, and the pH adjusted to 8.0 with the 
addition of NaOH. Once at the desired pH the volume was topped up to 1 L. 
TE Buffer 
A 10x stock of TE buffer was made up containing 100 mM Tris-HCl and 10 mM EDTA in 
deionised water and sterilised by autoclaving at 121 °C for 30 minutes on a liquid cycle. 
Working stocks of 1x TE buffer were made up using a 1/10 dilution of the 10x stock in 
deionised water and sterilised as above. 
TAE Buffer 
A 50x stock was made by dissolving 242 g Tris base in 1 L of deionised water containing 57.1 
mL glacial acetic acid and 50 mM EDTA. The solution was diluted to a 1x working stock in 
deionised water. 
CTAB 
10 g CTAB and 4 g NaCl were added to 100 mL deionised water. The solution was heated at 
65 °C in a water bath, with frequent agitation until dissolved. The CTAB solution was then 
stored at 4 °C.  
Proteinase K 
The proteinase K stock was made up by dissolving 1 mg of proteinase K powder (Sigma 
Aldrich) in 1mM Tris-HCl (pH 8.0) and 1.5 mM calcium acetate in deionised water. 
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Resazurin 
The resazurin stock solution was made up as a 0.3% (w/v) solution in ddH2O and stored at 
4 °C. A working solution of resazurin at a concentration of 0.03% (w/v) was made up by 
diluting the stock solution in ddH2O and filter sterilising before storing at 4 °C. 
 
8.2. Routine laboratory procedures 
Cleaning electroporation cuvettes 
Electroporation cuvettes were cleaned for reuse after each transformation. Cuvettes were 
soaked 12.5% bleach for 30 minutes with agitation, rinsed in ddH2O, soaked in 1 M HCl for 
30 minutes with agitation, rinsed in ddH2O, and then rinsed in 75% ethanol three times. 
Cuvettes were dried, and stored. Immediately prior to use cuvettes were sterilised with UV 
for 10 minutes in a laminar flow hood. 
 
Cleaning 384-pin RePads® 
RePads® were cleaned after each use. RePads® were soaked in 12.5% bleach overnight, and 
then soaked in a mixture of dishwashing detergent and water overnight. RePads® were then 
rinsed under tap water and scrubbed thoroughly wish a dish-brush, and then dried on the 
bench. RePads® were then dipped in 100% ethanol and left to dry in a laminar flow hood. 
Dry RePads® were stored in large zip-lock plastic bags. 
 
Cleaning metal 96-pin tool 
The pinning tool was dipped in 12.5% bleach (v/v) for one minute, then dipped in ddH2O for 
a further minute, before being dipped in 100% ethanol and flamed to sterilise between 
pinning each plate, and after use. 
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8.3. MSMEI and MSMEG annotations 
This study used the M. smegmatis mc2155 reference genome using the MSMEI annotations. 
The older MSMEG annotations are provided for each of the M. smegmatis mc2155 genes 
mentioned in this study. 
MSMEI 
annotation 
MSMEG 
annotation 
0062 0061 
0227 0234 
1186 1221 
1210 1245 
1211 1246 
1800 1842 
1801 1843 
1904 1946 
1905 1947 
2671 2738 
2672 2739 
3093 3175 
3189 3273 
3358 3437 
3380 3461 
3416 3496 
3684 3773 
4123 4221 
4267 4371 
4423 4536 
4424 4537 
4764 4889 
4765 4890 
4815 4942 
5136 5275 
5244 5392 
5460 5610 
5538 5688 
5554 5705 
5621 5775 
5828 5989 
6040 6201 
6092 6253 
6216 6384 
6263 6430 
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6264 6431 
6301 6473 
6730 6919 
 
8.4. Isoniazid analogues 
Drug (NSC) Structure 
Active against WT M. 
smegmatis mc2155 
(>75% Growth-
Inhibition at 
10mg∙mL-1) 
Differential 
Activity versus 
Tn::nudC 
Isoniazid 
(9659) 
 
Yes No 
647 
 
No n/a 
1483 
 
No n/a 
176 
 
2083 
 
No n/a 
3136 
 
No n/a 
6855 
 
Yes No 
18775 
 
No n/a 
177 
 
23449 
 
Yes No 
27607 
 
Yes Yes 
33759 
 
Yes Yes 
33760 
 
Yes No 
178 
 
33763 
 
Yes No 
36084 
 
No n/a 
36086 
 
Yes No 
37379 
 
Yes No 
179 
 
37800 
 
Yes Yes 
38340 
 
No n/a 
39298 
 
No n/a 
40350 
 
 
Yes Yes 
180 
 
54990 
 
No n/a 
59320 
 
Yes No 
61870 
 
No n/a 
69854 
 
No n/a 
181 
 
81850 
 
No n/a 
82353 
 
No n/a 
130848 
 
No n/a 
141142 
 
Yes Yes 
182 
 
176757 
 
Yes Yes 
274967 
 
No n/a 
322078 
 
Yes No 
359420 
 
No n/a 
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8.5. katG protein alignments 
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